Monte Carlo applications for local treatment healthcare usage simulations. by Mee, Thomas
  
Monte Carlo Applications for Local Treatment 
Healthcare Usage Simulations 
 
by 
 
 
Thomas Mee 
 
 
Submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
Faculty of Engineering and Physical Sciences 
University of Surrey 
 
June 2015 
 
© Thomas Mee 2015 
  
 i 
 
This thesis and the work to which it refers are the results of my own efforts. Any ideas, data, 
images or text resulting from the work of others (whether published or unpublished) are fully 
identified as such within the work and attributed to their originator in the text, bibliography or in 
footnotes. This thesis has not been submitted in whole or in part for any other academic degree or 
professional qualification.  I agree that the University has the right to submit my work to the 
plagiarism detection service TurnitinUK for originality checks.  Whether or not drafts have been 
so-assessed, the University reserves the right to require an electronic version of the final document 
(as submitted) for assessment as above.  
   
 ii 
Abstract 
Cancer is currently the second leading cause of death within the UK. In 2010, cancer caused 29% 
of all registered deaths, second only to circulatory disease. Cancer incidence is much higher in the 
elderly than in younger people, so cancer is considered a disease of the elderly. This combined 
with the fact that the population of England is getting both larger and older suggests that the 
number of incidences within England will keep on increasing year on year. However, there is an 
uneven spread of incidences throughout England, different regions have different cancer profiles 
depending on factors such as age profiles within the region or deprivation levels.  
There are three principal modalities for cancer treatment: radiotherapy, chemotherapy and 
surgery. These are used standalone or in conjunction with each other. This project will only look 
at the provision of radiotherapy. Currently 40% of all patients cured of cancer receive 
radiotherapy. However, a 2007 study comparing modelled demand and audited activity has 
indicated that England is currently under providing radiotherapy.  
The National Cancer Action Team commissioned The MALTHUS project in 2010 after the 2007 
study was criticised for being too hard to apply to regional areas, as it is a national model. 
MALTHUS builds on the 2007 study by creating a piece of demand prediction software that will be 
used to predict the number of radiotherapy fractions, the appropriate rate of radiotherapy 
required to be given to England, or within a health care boundary in England. This enables 
localised models and not just a single, countrywide average. A team of clinicians at 
Addenbrooke’s Hospital created the clinical decision trees used within MALTHUS and they gained 
general clinical consensus throughout England. MALTHUS will also utilise high quality incidence 
and population data to operate a novel Virtual Patient style of decision tree simulation, placing 
emphasis on the patient walking through the tree instead of the decision tree itself.  
The decision trees used in MALTHUS are different in design from those created by other research 
groups. The trees from two major research groups, CCORE and QCRI, use a program called 
TreeAge and are set up for a single decision with ultimately one of two terminal decisions, 
radiotherapy or no radiotherapy. The trees in MALTHUS are much more complex with more 
information within them and give the number of fractions, not just whether radiotherapy is given 
or not. The basis of them is a Virtual Patient construct where information passes between the 
tree and the Virtual Patients. It is the Virtual Patients themselves that have the information about 
the treatment stored and information gathered from all stages of the walkthrough, not just 
relying on the state of a terminal decision node. MALTHUS Pro also has the ability to offer a suite 
of statistical and sensitivity analysis options. In terms of tree size, there are 415 branches in 
CCORE’s trees, but around 2000 nodes in the MALTHUS trees. There are fewer trees from QCRI 
and so fewer branches.   
After the successful completion of model verification tests, a complete one way sensitivity 
analysis on the input data and clinical decision trees was undertaken, highlighting the effect that 
these parameters have on the outputs of the model. The most sensitive decision out of all cancers 
is colon cancer - palliative radiotherapy indications or no radiotherapy indications. For each 
percentage change in the decision the overall answer, for total amount of radiotherapy to be 
given to a region, changes approximately  -1.7% or +2%.  
Simulations have been completed on both the full Monte Carlo and fast Monte Carlo operating 
methods, both utilising Monte Carlo integrations, providing a full range of results including the 
appropriate rate of radiotherapy and number of fractions for every Primary Care Trust and Cancer 
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Network within England. Summary tables of these results once again showed how different 
regions within England are when it comes to the amount of radiotherapy that should be given. 
The largest difference being in prostate cancer with Hartlepool giving 845 fractions per 100,000 
population and Dorset giving 2346 fractions per 100,000 population. The application of 
deprivation indices show any potential links between the differences in the predicted number of 
fractions and levels of deprivation. Breast cancer shows a strong correlation to the more deprived 
while stomach shows a strong opposite correlation.  
MALTHUS has successfully achieved the original objectives of creating a robust, local radiotherapy 
utilisation model, using actual population and incidence data to be able to build a true 
representative cohort of patients and then be able to walk them through a clinical decision tree 
to predict the number of required fractions. MALTHUS not only works on a regional level and 
country level, but on any level that the input population and incidence data is available. 
Additionally the fast Monte Carlo results are applicable to any population/incidence data, 
including any future predictions in the data, adding in extra flexibility. 
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Glossary of Main Terms 
Access Rate – The actual amount of radiotherapy prescribed to a population 
ARR – Appropriate Rate of Radiotherapy, the modelled amount of prescribed radiotherapy  
ASR – Age Standardised Rate 
Average Fraction – The average number of fractions given per patient for a given cancer in a given 
region 
CBB – Criterion Based Benchmark 
CCORE – Collaboration for Cancer Outcomes, Research and Evaluation 
CNS – Central Nervous System 
CPU – Central processing unit 
CSV – Comma separated variable 
CN – Cancer Network, a network working to improve cancer services  
CV – Coefficient of variation 
EBEST – Epidemiological Based Estimate 
ESTRO – European Society for Radiotherapy and Oncology 
EU – European Union 
EUCAN – European Union Cancer database 
Fraction – A single dose of radiotherapy 
Fraction Burden – The number of fractions required for an incidence of a given cancer 
GLOBOCAN – Global Cancer database 
GUI – Graphical User Interface 
HL – Hodgkin’s Lymphoma 
Incidence – An occurrence of cancer 
MPI – Message Passing Interface 
NATCANSAT – National Clinical Analysis and Specialised Applications Team 
NCAT – National Cancer Action Team 
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NCIN – National Cancer Intelligence Network 
NHL – Non-Hodgkin’s Lymphoma 
NRAG – National Radiotherapy Action Group 
NRIG – National Radiotherapy Implementation Group 
ONS – Office for National Statistics 
PCT – Primary Care Trust, a previous health care division in England 
QCRI – Queen’s Cancer Research Institute 
QUARTS - Quantification of Radiation Therapy Infrastructure and Staffing Needs 
Relative ARR – The ARR of a cancer group relative to all cancers within a region 
RCR- Royal College of Radiologists 
RORU – Radiation Oncology Research Unit 
RTDS – National Radiotherapy Data Set 
Site Contribution – The number of incidences a cancer group contributes to the total incidence for 
a region  
TC – Tree Convertor program 
Total Fraction – The total number of fractions given in a simulation 
Trial - Single part of a simulation with fixed parameters, so a trial may consist of 2000 
walkthroughs. 
UKACR – United Kingdom Association of Cancer Registries 
XML – Extensible markup language 
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1 Introduction 
Cancer is currently the second biggest cause of death within the UK. In the UK in 2010, cancer 
caused 29% of all registered deaths. The only bigger cause of death than cancer was circulatory 
diseases [1]. In 2009 the number of cancer incidences increased by 0.77% in males and 1.9% in 
females from 2008 [2] [3].  
As can be seen in Figure 1-1 cancer incidence is much higher in the elderly than it is in younger 
people, so one can classify cancer as a disease of the elderly. The age band of 70-74 shows the 
highest number of incidences for men and aged 85 and over for women.  
Whilst cancer incidence is helpful to attribute risk to an individual, additional information about 
the population is required to determine the burden of cancer, which is important for planning 
cancer care. To take the population into account an Age-Specified Rates (ASR) can be used, which 
allow an understanding of the age specific incidence in the context of the population size. To 
calculate an ASR Equation 1-1 is used [3] :  
 𝐴𝑆𝑅𝑘 = (𝑟𝑘 𝑝𝑘⁄ ) ∗ 100,000 
𝐴𝑆𝑅𝑘 = 𝑎𝑔𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑟𝑎𝑡𝑒 𝑓𝑜𝑟 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 𝑘 
𝑟𝑘 = 𝑟𝑒𝑔𝑖𝑠𝑡𝑟𝑎𝑡𝑜𝑖𝑛𝑠 𝑖𝑛 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 𝑘 
𝑝𝑘 = 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 𝑘 
Equation 1-1 
   
 
Figure 1-2 shows ASRs for England broken down by gender. As can be seen in Figure 1-2 the ASR 
greatly increases in the older age ranges. This shows once again that the elderly are in fact much 
more likely to get cancer than the young are. 
The ASRs definitely show that cancer risk increases with age. This fact means that there must be 
consideration for the population of England and the future population predictions when 
generating predictions of future incidence rates of cancer. 
The population predictions shown in Figure 1-3 were generated by the Office of National Statistics 
(ONS) [4]. While the age groups are following a general trend of increasing and decreasing, over 
the years the population generally increases and gets older. The average age in 2010 is 37.8 
where as in 2035 it has risen to 42.3.  
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Figure 1-1. Cancer incidence rate in age bands for England in 2009, showing the difference 
between male and female. 
 
Figure 1-2. Age Specified Rates for England in 2009, showing the difference between male and 
female. 
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Figure 1-3. Population predictions up to 2034, in age bands, for ages above 50, showing how the 
population is aging.  
Combining the fact that the population of England is both increasing and getting older, with the 
greater number of incidences of cancer in the older age bands means that the overall incidences 
of cancer will keep on increasing year on year and so will the burden on resources. However, due 
to age-related comorbidities, elderly patients are potentially less likely to receive radical cancer 
treatment than younger patients are. This is where the idea of modelling for cancer treatment 
comes in, as it helps where the indications for treatment are not uniform. Modelling can take into 
account all treatment options and factors. 
It is clear from the projections that the amount of cancer care will have to increase year on year if 
England wishes to maintain an appropriate level of care in line with the developed nations. It is 
important to attempt to quantify the requirement for cancer services in the future in order to 
ensure appropriate allocation of resources and infrastructure. There have been times in the past 
where the nation’s cancer burden outstripped its treatment capacity. In some areas, this led to 
delays in starting potentially curative cancer treatments, with consequent detriment in cancer 
cure rates. As will be discussed below, previous attempts to try to avoid such situations from 
occurring again have utilised mathematical modelling. 
 
1.1 NHS Cancer Services and the Cancer Patient Pathway 
The National Health Service (NHS) in England is a free to access, state based health care system 
that was originally set up after the Second World War to support the health of the nation’s 
workforce. With changes in disease burden, it has evolved to provide comprehensive healthcare 
within a hierarchical structure of specialised services. Recently, cancer services within the NHS 
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had a specific federation structure consisting of Cancer Networks, the NHS itself was divided into 
a number of different sub-groups, called Primary Care Trusts (PCTs), to enable better local 
management and delivery of services provided by the NHS in England. Previously England 
consisted of 152 Primary Care Trusts. After the Health and Social Care Act in 2012, 211 Clinical 
Care Groups (CCGs) superseded the PCTs. At the beginning of this project, the NHS was still 
operating with PCTs and so PCTs will be used instead of the newer CCGs due to historic data being 
in PCT form.  
The creation of a “cancer pathway” occurs when a patient enters the NHS with a potential 
incidence and it leads the progression of the patient through the ideal steps from pre-diagnosis 
through all the stages of dealing with the cancer to follow up stages after treatment. The National 
Institute for Health and Care Excellence have created many different guideline pathways, for 
cancer and other clinical or health topics, these are viewable at https://pathways.nice.org.uk/ 
 
Usually a pathway will start with a screening detection of cancer in an outpatient setting. For 
many tumour types, the pathway starts with some form of surgical excision or biopsy happening 
before the patient sees an oncologist. From this point onwards, the pathway becomes varied and 
complex with patient and tumour factors, shown in Table 1-1.  
Tumour Factors [5] Patient Factors [5] 
Organ of origin Age 
Histological type Preference 
Degree of differentiation Co-morbidity (e.g. hypertension, diabetes, 
lung or kidney disease) 
Stage at presentation  
Loco-regional spread  
Distant metastases  
Tumour site  
Operability  
Pathological examination of the excised tissue  
 
Table 1-1. Tumour and patient factors that can affect the cancer pathway that a patient takes 
through the NHS. 
The fact that every patient with a suspected cancer diagnosis should generate a cancer pathway 
makes it an ideal point for collection of cancer incidence data. The cancer registration system 
collects this data. Cancer registries collect the cancer registrations and correlate them with other 
sources of information regarding the cancer diagnosis for each patient. Cancer registries have 
been collecting population based data for 40+ years now [6]. Their aims are to deliver timely, 
comparable and high quality cancer data [6], which enables them to be able to provide historical 
trend data on both incidence and survival. There are eight cancer registries in England and the UK 
Association of Cancer Registries (UKACR) governs them.  
 
The Office for National Statistics, who collate national databases, receives the cancer registration 
data from these registries. The national databases are then used in a number of national audits, 
such as within the National Cancer Intelligence Network, and a number of institutional audits, 
such as within Cancer Research UK centres. 
This high level of data collection greatly helps with any project requiring cancer, patient, 
incidence, cancer TNM staging or survival information. Cancer TNM staging is common 
nomenclature used to describe the extent of cancer within a patient. It takes into account the 
 5 
tumour size (T for tumour), whether it has spread to any lymph nodes (N for nodes) and if it has 
metastasised to any other parts of the body (M for metastasis). The cancer also has a 
classification of stage 1 – 4, with stage 1 being a small cancer and stage 4 being a larger, more 
infiltrative or metastatic cancer.  
The UKACR dataset is of extremely high quality and a curation team verifies the data items from 
multiple independent data sources. The UKACR also publish the levels of data completion of their 
datasets [7]. In the general demographics and diagnostics details (such as patient information, 
site of primary tumour, diagnosis date etc…) the only piece of information that did not hit the 
target was the diagnosis date, where the England average was 99.9% complete instead of the 
target 100% [7]. The only piece of information that did not hit 100% was the site of primary 
tumour growth. It did achieve the target data completion percentage but it still was only 96.9% 
complete [7], indicating that there will be some missed incidences in some tumour types.  The 
combination of a single health care system and the UKACR cancer registration mechanism results 
in excellent levels of cancer case ascertainment when compared to other developed nations. 
1.1.1 Variations in Incidence across England 
The fact that the information mentioned above does include postcode data means that 
separation of the data into different geolocations is possible, including NHS sub-divisions such as 
PCT or CCG. This enables comparisons of various factors between the different regions to see if 
there are patterns within the country. 
A good starting piece of information to compare across the country is incidence, while there are 
many factors that influence the incidence it does highlight variations within the country. As 
mentioned previously, age and incidence are related and age distributions are not consistent 
across the country. There are areas where people tend to go to retire, so have an age distribution 
that leans towards the elderly, and there are areas where younger people go to work so have a 
younger age distribution. This will have an impact on which cancers are more prevalent and have 
a higher incidence rate in a specific region 
Deprivation is another measurable factor of which a variation across England occurs. Deprivation 
has both a positive and negative correlation with specific cancer incidences. More deprived areas 
had a higher association with head and neck, stomach, liver, lung and cervical cancers, while 
malignant melanoma, female breast cancer and prostate cancer showed a stronger association 
with more affluent areas of England [8]. The largest reported difference was in lung cancer with a 
ratio of 2.5 to 1 between deprived and most affluent areas [8].  
Based on all cancer sites the ratio of incidences was 1.2 incidences in a more deprived region to 1 
incidence in a less deprived region [8]. To show the excess number of incidences in England if all 
deprivation quintiles had the same incidence rate as the least deprived quintile, a calculation was 
completed. The excess cases stood at 14,300 cases per year (based on data from 2000-2004) [8].  
It is clear that accurate prediction of cancer burden requires a complex, multifactorial model 
taking into account cancer incidence, age demographics and deprivation. Local factors, such as 
the ones just mentioned, have to be included when trying to predict or plan for future cancer care 
to account for variations across England. An England wide model may give a good base overview 
but may not be appropriate for a large number of regions within the country.  
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1.2 Radiotherapy and Radiotherapy Decision Making 
Radiotherapy is the usage of radiation, either externally or internally, in the treatment of a 
disease. Both methods directly or indirectly damage the DNA of cancerous cells, which kills them. 
Radiation directly damages DNA by ionizing one of the DNA’s bases or sugar-phosphate 
backbone. Indirect damage results from the radiation ionizing water within a cell and the 
products of the ionization of the water causing damage to the DNA. While the effects of the 
radiation damage nearby healthy tissue as well, they can usually repair themselves and grow 
normally [5].  
The administration of internal radiotherapy can be by injecting or swallowing a radioactive fluid, 
or by a process called brachytherapy, which is the placement of a piece of radioactive material 
near to a cancer. The administration of external radiotherapy uses a high-energy radiation beam 
to focus its energy onto the cancerous area. A machine called a linear accelerator, or linac for 
short, generates a high-energy radiation beam. A linac operates by utilising electromagnetic 
waves to accelerate particles that are charged. The produced beam deposits energy in matter 
that it passes through. The amount of energy that the beam deposits is called the dose, the 
measurement of dose is grays (with one gray equalling one joule of energy per kilogram of 
matter). However, the beam does not deposit its energy uniformly at all depths. At a certain, 
calculated, depth into the body the beam deposits its maximal dose, doing the maximal damage. 
Planners use information such as this to make sure the cancer receives the maximum amount of 
damage and the healthy tissue around the cancer does not [5].  
Radiotherapy is an effective anti-cancer treatment and it is utilised in three ways: as a 
replacement for surgery allowing preservation of function of the organs, as an adjunct to surgery 
to reduce local recurrence and as a palliative treatment for symptom control. There are also a few 
cases, such as in Lymphoma, where the usage of radiotherapy is as an adjunct to chemotherapy. 
Approximately 40% of patients cured of cancer receive radiotherapy [9]. Figure 1-4 shows an 
overview of the radiotherapy process within England.  
Several factors influence the decision on the usage of radiotherapy for a patient with cancer. The 
major treatment indications are for patients with breast, prostate, lung and head & neck cancers. 
Radiotherapy treatment decisions for these indications rely in the main on an established 
evidence base. These are typically clinical trials showing radiotherapy treatment is equivalent to 
surgery or that radiotherapy should be used adjunct to surgery. However, beyond the major 
treatment indications there are a whole range of indications where the degree of evidence is less 
certain. When the tumour is studied, the stage is calculated. It is these decisions combined with 
site specific decisions that are based on less certain evidence. The choice between radical and 
palliative treatment will also change the treatment plan. Radical treatment aims to eradicate the 
cancer while palliative treatment attempts to reduce the cancer symptoms. If the performance 
status of the patient is too high and the treatment is required to reduce pain and improve quality 
of life then palliative treatment is the option. A multi-disciplinary team consisting of radiologists, 
surgeons, oncologists and other healthcare professionals often looks at the factors as a group. 
Once the multi-disciplinary team has considered the general and tumour specific factors and a 
decision of radiotherapy has arisen for the treatment modality, then a radiation oncologist can 
plan the course of radiotherapy treatment. Normally there is a division of the total dose into a 
number of fractions, with the administration of the fractions spread over a number of weeks. This 
does depend on the type of treatment, as some palliative treatments only require a single 
fraction. Once the scheduled treatment has been finished then follow up consultations will 
 7 
normally occur and consideration given for further radiotherapy treatment if there is a recurrence 
of the tumour. 
The Appropriate Rate of Radiotherapy (ARR) offers a good overview of the level of radiotherapy 
provision that the country should be delivering. The ARR is simply a modelled percentage of 
patients with cancer who should receive radiotherapy. Other countries also use the ARR in 
reports on their healthcare systems. A comparison between the ARR and a recorded access rate 
will show if radiotherapy provisions are potentially lacking. The access rate is the actual 
percentage of patients who received radiotherapy through their treatment of their cancer. A 
2007 study in England calculated the ARR to understand the differences between modelled 
demand and audited activity [10] and Table 1-2 presents the results. 
Cancer Site ARR Access Rate 
Bladder 31 31 
Brain, meninges 
and CNS 61.3 63.7 
Breast 71.7 62.7 
Cervical 56.4 53.5 
Colon 0.7 5.2 
Corpus uteri 46.2 58.1 
Head and Neck 78.6 65.4 
Hodgkin 
Lymphoma 70.6 38.7 
Kidney 24.1 8.2 
Leukaemia 4 4.9 
Lung 65.9 49.7 
Melanoma 15.7 9.7 
Myeloma 33.1 24.4 
Non-Hodgkin 
lymphoma 54.3 29.3 
Oesophageal 53.7 51.2 
Ovarian 4 6.1 
Pancreatic 49.8 3.5 
Prostate 61.4 46.6 
Rectal 88.7 40.3 
Stomach 13.4 6.4 
Testicular 46 8 
Unknown 
Primary 50.2 19.8 
Total 50.7 36.8 
 
Table 1-2. Appropriate rates of radiotherapy, as modelled by Williams and Drinkwater and 
equivalent audited access rates for England in 2007 [10]. 
 
Table 1-2 shows the difference between the ARR and access rate, the modelled ARR for England 
was 50.7%, whereas the actual access rate was only 36.8%. This suggests that the current level of 
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radiotherapy provisions are not enough to cope with the current levels of cancer, let alone an 
increase in incidence. The ONS have calculated that the number of avoidable deaths (defined as 
preventable, amenable or both [11]) in England due to neoplasms for 0-74 years olds was 37,963 
in 2011 [11]. However, this figure is not down to radiotherapy alone, it is for all neoplasms 
regardless of specific treatments. The 2007 report was useful because it highlighted the 
difference between the calculated and actual access to radiotherapy in England. 
 
Prescription and delivery of treatment
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Figure 1-4. An overview of the radiotherapy process in England, detailing the inputs, processes 
and outputs. [5] 
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1.3 National Reports on the State of Cancer Treatment in the UK 
Pre 2000 there was no systematic planning for cancer services within the NHS and each treatment 
centre made its own plans and made them independent to any local demand calculations. The 
development of policies at a local level had little in the way of capacity planning. There was a 
strong effect felt in radiotherapy because the radiotherapy machines in the UK were operating 
beyond their scheduled life expectancy and there were not enough radiotherapy units to meet 
the required capacity. At this time patients had to wait for up to three months for curative 
radiotherapy treatment to begin, which was causing unnecessary deaths due to patients having 
to wait so long for radiotherapy that cure is compromised [12]. The Royal College of Radiologists 
(RCR) undertook an audit in 1997-2002 looking at the equipment, staffing and workload of 
radiotherapy services in England, highlighting the inadequate radiotherapy provisions within 
England [12]. 
The publication of the NHS Cancer Plan [13] occurred in 2000. It was a national programme that 
aimed to save more lives, increase the levels of treatment and support, tackle health inequalities 
and build the cancer services within the NHS to make sure the NHS would fall in line with other 
developed nations. The NHS Cancer Plan highlighted the facts that cancer patients in England 
have poorer survival prospects when compared to other European countries [13] and also that 
services across the country are patchy and a ‘postcode lottery’ exists based on the quality and 
type of treatment that a patient received [13]. A factor identified for the delays and variations in 
cancer care was decades of under-investment [13]. The creation of the Cancer Task Force, headed 
by Professor Sir Mike Richards, was an outcome of the Cancer Plan.  
The 2007 Cancer Reform Strategy [14] was a follow on to the NHS Cancer Plan. The Cancer 
Reform Strategy was a plan for the cancer services for the 5 years following the report. Amongst 
numerous actions to improve cancer outcomes the Cancer Reform Strategy highlights the need to 
ensure better treatment, including achieving a world class radiotherapy service based on local 
improvement from recommendations for improving radiotherapy capacity [14]. This also ties in 
with the high priority placed on reducing cancer inequalities, of which both variations in incidence 
and access to cancer services are major contributors to the inequalities. The basis of this is 
deprivation, race, age and gender to name a few variables [14]. The Cancer Reform Strategy also 
states that “Tools will be made available to PCTs to enable them to commission effectively and 
benchmark their performance, including national guidance, peer review data and a 
commissioning guide and toolkit” [14]. It also targeted a 31 day maximum wait for any cancer 
treatment, which acted as a driver to improved radiotherapy services and caused the formation 
of the National Cancer Intelligence Network (NCIN) and the National Cancer Action Team (NCAT). 
Within the NCAT the National Radiotherapy Advisory Group was made to advise on what the 
policies and procedures were needed to meet the targets. After the Cancer Reform Strategy 
NRAG turned into the National Radiotherapy Implementation Group (NRIG) to implement what 
NRAG had reported. 
In 2011 Improving Outcomes: A Strategy for Cancer [15] superseding the Cancer Reform Strategy. 
The report followed on from the previous two reports, noting how outcomes in England remained 
poor when compared to other European countries [15]. Once again this report highlights how 
there are still inequalities in cancer. 
Amidst the three major reports on cancer in England, the creation of NRAG, NCAT and NCIN was 
to help implement the major points that the reports highlighted about the inequality in access to 
radiotherapy and outcomes when compared to Europe. 
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Additional to the major NHS reports focussing on cancer the RCR released a document looking at 
the equipment, workload and staffing for radiotherapy in the UK from 1997-2002 [12]. Within the 
document, it, like the other reports, highlighted the fact that there was inadequate radiotherapy 
provision within the UK to meet the needs of the population.  It states that while it is generally 
accepted that approximately 50% of cancer patients may benefit from radiotherapy, in some 
regions only 22% were actually offered radiotherapy in 2002 [12]. Additionally it highlighted the 
unequal distribution of provisions. The National Cancer Plan targeted four linear accelerators per 
million population. However only 22 out of 57 radiotherapy centres achieved this target, with 
only 2 of the 22 being in the North of England [12]. The 2007 NRAG model was criticised due to it 
being a national model, therefore providing a poor fit locally in some parts of the country. It was 
also seen as being too aspirational with the targets it set being unattainable. This criticism set the 
scene for a new initiative to model radiotherapy demand at a local level.  
1.4 The Usage of Decision Trees 
Decision trees are not a new technique for decision analysis, one of the earliest records of 
decision tree usage was in the 1950’s [16]. As a decision tree is merely a technique to assist in 
decision making, they have a very wide range of applications. Some examples of their applications 
are in risk analysis [17], data mining [18], product decision [19], machine learning [20] and the 
detection on simulated leaks in rocket engines for NASA [21].    
The use of decision trees within the healthcare environment is not a new combination, or a 
combination that is exclusive to radiotherapy or demand prediction.  There are examples of 
decision trees being used in dentistry since the 1970’s [22], usage in cardiology [23] and 
Parkinson’s prediction symptoms [24] just to name a few. The basis of some research papers are 
solely decision trees and their use in medicine [25]. 
Even though the usages of decision trees has been ongoing for a number of years, and are well 
documented, the advancement of computer technology is allowing novel decision trees usage 
and applications to new scenarios and fields of study, or updating previous studies with novel 
decision tree applications [26].  
 
1.5 Aims and Objectives 
The previous section gives a description of the state of the healthcare services, with relation to 
radiotherapy, at the point where this project was conceived. In 2010, our research group was 
commissioned to develop MALTHUS as a radiotherapy demand modelling tool. 
The aim of the project as a whole was to provide a more accurate simulation of radiotherapy 
demand at the local level and the reason for doing so was the fact that the national level of model 
did not provide a good fit at local level. The MALTHUS project is an academically led project and 
this thesis forms an integral part of the project outputs.  Whilst NCAT commissioned and 
developed simple modelling tools, they lacked any formal statistical or sensitivity analysis. From 
our previous experience of simulations of this kind, we established that this was an important 
step in understanding how estimates of cancer incidence might affect the models’ predictions for 
radiotherapy demand. The demand predictions will not go as far as to say how many linear 
accelerators are required, because different centres across the country use different linear 
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accelerators from different suppliers. Therefore, the number of fractions will be the main output, 
allowing different regions to specify their own machines and machine capacity. 
The main aim of the MALTHUS PhD project is to address the hypothesis of the usage of formal 
Monte Carlo Methods to enhance the robustness of a discrete event simulation for radiotherapy 
demand prediction.  The PhD project will create a piece of decision tree software to evaluate the 
clinical treatment trees for cancer and output both national and local level results with detailed 
statistical analysis and a formal sensitivity analysis in an efficient manner.  
1.6 Contents of Thesis 
This thesis gives a description of how I formulated and tested a hypothesis, describes the model I 
created, and reports on the robustness of the sensitivity analysis and the additional features built 
within my model to enhance its use and adaptability.  
In total, there are nine chapters within this Thesis. The current chapter defines the clinical need 
for this work. Chapter 2 reviews other work on modelling radiotherapy demand that has occurred 
across the world, going from the original 2007 NRAG reports to the work in Australia and Canada. 
The MALTHUS project as a whole is presented in Chapter 3, including details on how the project is 
split into different work areas and specifically the different areas of the program that relate to 
this PhD, how they work and what MALTHUS can actually do. Verification tests of parts of the 
model follow in Chapter 4. 
Chapter 5 summarises and presents the results. Only some illustrative example PCTs and cancers 
are presented in some cases due to the sheer volume of results generated by MALTHUS. The rest 
of the results are in an electronic appendix on a CD attached to this thesis, with details and files in 
the printed appendix. 
The thesis is then finished with discussions, in Chapter 6, about assumptions that have been 
made during the PhD project, the key features of MALTHUS and an in depth discussion about the 
sensitivity analyses and other results. Some general discussions have also occurred on topics such 
as variations within the country and comparing MALTHUS to other models. Conclusions and 
recommendations follow in Chapter 7. The details of various publications, presentations and 
other things that have come out of MALTHUS to show its impact are in Chapter 8. 
1.7 Summary 
In this chapter, cancer has been identified as a disease of the elderly and that the population in 
England is aging, meaning that the demand for cancers services will increase year on year. It falls 
under the NHS’s remit to treat cancer patients and one of the modality of treatments is 
radiotherapy. Another factor to take into account is the fact that the spread of cancer incidences 
is not even across the country due to numerous factors. Previous national reports on the state of 
cancer treatment in the UK have demonstrated that there are inadequate radiotherapy provisions 
in England. Additionally, due to the uneven spread of incidences across England, previous 
modelling attempts of radiotherapy demand did not provide a good fit at local level because they 
only created a national model. This created a need for an accurate, local level, radiotherapy tool 
to predict demand to help future predictions. 
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The next chapter critically reviews the current literature from other research groups that have 
published their work looking at decision trees usage for radiotherapy demand prediction and a 
comparison given to what MALTHUS aims to achieve.  
  
 13 
2 Literature Review 
Following on from the identification of a need for a predictive radiotherapy model this section will 
critically review the literature from the original NRAG report and other research groups who have 
been attempting similar work. The study and comparison will look at the type of work they have 
undertaken, the configuration of their models and their data sources.  
2.1 2007 NRAG Report 
In 2007, a study was published on radiotherapy in England to understand the difference between 
modelled data and actual practice [10]. It was working with a model previously created by NRAG 
that evaluated at 22 different cancer sites. The NRAG model used a number of different sources 
from Canada, Australia and Scotland in its development [10]. The base data it used for the record 
of radiotherapy in England was from a weeklong snapshot of radiotherapy activity that happened 
in the week beginning 24th September 2007 [10].  
The analysis of this snapshot showed the prescription of fewer fractions to the patients than the 
modelling indicated [10]. Additionally, the observable radiotherapy access was lower than the 
modelled number (37% rather than 50%) [10]. Between the NRAG model and the amount of 
fractions actually delivered a 70% increase in radiotherapy fractions provided was required [10]. 
The difference in the modelled data and actual practice was not uniform across all cancer sites. 
For example only 7.1% of pancreatic cancer patients predicted to require radiotherapy actually 
received radiotherapy, in colon cancer this figure stands at 742% [10]. The analysis revealed some 
important differences between model and practice. These could highlight the fact that the NRAG 
models are incorrect for some cancers or that doctors are not providing radiotherapy in line with 
best practice.  
The first thing to note about this report is that the basis of the sources of data for the NRAG 
model is not England. The NRAG model [10] is based on Scottish Data [27] and the Scottish data 
was curated in 2006 [28]. A small group of clinical advisors adjusted the Scottish data to make it 
applicable to England [27], so this data did not gain consensus from a national group of clinicians.  
This could very easily lead to a divergence from accepted best practice in England. The 
appropriate rates of radiotherapy for England were an adjustment of the figures taken from the 
Scottish report, again leading to possible divergence from English best practice.  
When looking at overall quantities of radiotherapy given, based on incidence, there must be 
consideration for retreatment. Some patients will need to receive more radiotherapy after their 
main treatment, for example for radical re-treatment for local occurrence or palliative treatment 
for advanced diseases. Therefore, a retreatment factor needs to be generated and taken into 
account to apply to the initial figure for the quantity of radiotherapy. The 2007 report evaluated 
two different sources for this factor. The first source being an Australian figure of 25% and the 
other coming from the ESTRO-QUARTS report, quoting 25% too [27]. However, upon closer 
analysis of the ESTRO-QUARTS report [29] it can be determined that they cite their 25% re-
treatment figure from the same Australian source. Thus, a single piece of work accounts for both 
of the sources for the 25% figure. 
To make the re-treatment rate more accurate for England the 25% is scaled down to 13.1% 
because re-treated patients did not receive the same amount of fractions as the original 
treatment [27]. However, this estimate is still quite different to the recorded 4.9% from the 
snapshot of radiotherapy activity [10]. 
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Additionally the 2007 study does not take into account local variations in incidences (which can 
be attributed to life style, both current and past, and age distributions), practice and stage 
presentation. All of which could have an effect on the amount of radiotherapy required for that 
region. While the 2007 study does give an indication that England is under providing radiotherapy 
it does not indicate where about in the country this is happening,  how much each cancer is 
contributing to the under provision or what possible factors are contributing to this. Furthermore, 
by not making the model a localised model the under provision could actually be incorrect for 
certain regions, there may be regions where there is an over provision of radiotherapy for certain 
cancers. 
2.2 CCORE Modelling 
A series of papers explore the need for radiotherapy in Australia.  The Collaboration for Cancer 
Outcomes, Research and Evaluation (CCORE): Delaney, Jacob, Featherstone and Barton, wrote 
and published these between 2003 and 2005. The critical review is of the main summary paper 
[30]. 
The main aim of their work is to estimate the ideal proportion of new cases of cancer that should 
receive radiotherapy at least once during the course of their illness based on the best available 
evidence [30]. This was achieved by splitting the cancer sites into different groupings of breast 
carcinoma [31], lung carcinoma [32], melanoma [33], gastrointestinal [34], genitourinary [35], 
head and neck [36], gynaecological [37] [38], hematologic [39] [40], central nervous system, 
unknown and thyroid [41]. Each of the groups had a decision tree made for the cancers to 
determine the radiotherapy utilisation rate. By gathering all the rates together and combining 
them with the proportion of incidence over all cancers, it enabled the calculation of an overall 
utilisation rate.  
This project relied on external data and information to be able to compile the utilisation trees. 
The information was derived from both national and international institutions or specialist groups 
that published guidelines before 2003 [30]. The usage of other sources occurred when no 
guidelines existed or the guidelines were not adequate. Examples are reviews, trials, population 
based studies and single institution studies [30].  
The information utilised as the evidence for indications for radiotherapy was classified using Table 
2-1. 
 
Level of 
Evidence Description 
I Systematic review of all relevant randomized studies 
II At least 1 properly conducted randomized trial 
III Well designed controlled trials without randomization 
IV Case series 
 
Table 2-1. Classification of the different levels of evidence for indications for radiotherapy used 
by CCORE [30] 
As, in Table 2-1, the classification only covers the indications for radiotherapy another 
classification table was used to classify a hierarchy of epidemiologic data, . 
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The paper actually states “with only the highest level of evidence being used for each indication 
for radiotherapy” [30]. It also states, “The highest priority was given to Australian evidence-based 
clinical practice guidelines issued by national institutions such as NHMRC or the National Breast 
Cancer Centre. If these did not exist, then guidelines from other countries were used wherever 
possible” [30]. 
Quality of 
Source Source Type 
α Australian National Epidemiological data 
β Australian State Cancer Registry 
γ Epidemiological databases from other large international groups (e.g. SEER) 
δ Results from reports of a random sample from a population 
ε Comprehensive multiinstitution database 
ζ Comprehensive single-institution database 
θ Multiinstitution reports on selected groups 
λ Single-institution reports on selected groups of cases 
μ Expert opinion 
 
Table 2-2. Classification of the different hierarch of epidemiologic data as used by CCORE [30] 
These two statements suggest to the readers that only level I data (from Table 2-1) and that α, β 
and γ data (from ) would be used. However, upon further investigation this was not the case. The 
individual cancer site/group papers present the classification of the data. Table 2-3 and Table 2-4 
present the compiled classifications for lung, prostate, breast and head and neck. Table 2-3 states 
the actual number of pieces of evidence used in the different levels and the percentage of 
patients in that cancer group that the evidence is applicable to. 
Table 2-3 and Table 2-4 shows that the top level and high quality sources are not the main source 
of information for the data, especially in lung cancer where some of the sources are not even 
classified in the quality of source hierarchy. For example, one of the unclassified sources used for 
epidemiological data for Lung is a paper that isn’t reporting on lung cancer in general, it is looking 
at the influences of three chemotherapy drugs on the duration and quality of life for non-small 
cell lung cancer patients (Cullen MH, Billingham LJ, Woodroffe AD, et al. Mitomycin, ifosfamide 
and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J 
Clin Oncol 1999; 17:3188–94). However, most of the times of using unclassified epidemiological 
data more than one source has been used and Monte Carlo simulations can offer a spread of 
answers. This is also the case when there are different sources offering different answers. Monte 
Carlo simulations can account for multiple uncertainties. 
After the assembly of all the individual utilisation trees, the Monte Carlo simulations runs output 
an ARR figure of 52.3% [30] with 95% confidence limits of 51.7% and 53.1% [30]. From the 
confidence limits, the value of 52.3% seems to be quite accurate for Australia, while using data 
from a number of different countries.  
However, this 52.3% does not include re-treatments. A retreatment factor of 23% was taken from 
the New South Wales Health Department [42]. An estimation from a combination of the two 
figures was that every 1000 cancer patients required 643 courses of radiotherapy [30]. This figure 
is currently a lot higher than the figure of 440 patients per 1000 cancer patients receiving 
radiotherapy in the UK according to the National Radiotherapy Data Set (RTDS) report [43]. 
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Level of 
Evidence for 
Indications 
for 
Radiotherapy 
Lung Head and Neck Breast Prostate 
Number 
of pieces 
of 
evidence 
used 
% of 
patients the 
evidence is 
applicable to 
Number 
of pieces 
of 
evidence 
used 
% of 
patients the 
evidence is 
applicable to 
Number 
of pieces 
of 
evidence 
used 
% of 
patients the 
evidence is 
applicable to 
Number 
of pieces 
of 
evidence 
used 
% of 
patients the 
evidence is 
applicable to 
I 5 9% (3 
counts of 
<1%) 
0 0 2 4% 8 24% 
II 3 23% 0 0 3 71% (1 
count of 
<1%) 
0 0 
III 12 44% (3 
counts of 
<1%) 
11 60% 3 7% (1 
count of 
<1%) 
1 10% 
IV 2 <1% 10 12% (4 
counts of 
<1%) 
0 0 6 26% 
 
Table 2-3. Number of pieces of evidence for indications of radiotherapy, and their classification 
level used by CCORE for lung, head and neck, breast and prostate cancer and the percentage of 
patients the evidence is applicable to. 
  Cancer Site count of quality of source 
Quality of 
Source Lung[11] 
Head and 
Neck[15] Breast[10] Prostate[14] 
α 0 10 3 1 
β 0 4 1 0 
γ 3 0 0 7 
δ 0 0 0 0 
ε 15 1 3 6 
ζ 7 13 7 4 
θ 7 0 0 2 
λ 4 0 0 0 
μ 0 0 0 0 
Unclassified 15       
 
Table 2-4 Number of sources of epidemiological data used by CCORE for lung, head and neck, 
breast and prostate cancer.  
 
However, while the 52% ARR is an important figure it does not show the actual required amount 
of radiotherapy treatment, but instead how many courses of treatment should be given, to an 
Australian population. It also does not consider location specific factors which might lead to 
higher than normal levels of cancer and radiotherapy requirements or a lower than average 
demand. Also on the note of higher levels of cancer, there is no information on which specific 
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cancers require more radiotherapy, as this will have a major effect on how much radiotherapy is 
required. 
There is also the problem of the data sources. While using international databases can be very 
useful, a study would have to be undertaken to see if the cancer incidence, stage presentation 
and treatment options, to name a few, are the same in the country of the database and the 
country being studied. This could have a substantial effect on the number of fractions/likelihood 
of receiving radiotherapy especially if the root of the tree uses incorrect data. This is a source of 
error that Monte Carlo and sensitivity analysis would not pick up, as it would not show any 
uncertainty in the data.  
There are also some cases where the data used comes from a single institution. A single institute 
does not convey a national average. The institute may give a higher or lower probability for 
radiotherapy based on their own treatment preference, which could related to their site specific 
facilities. Additionally, the region the institute is in may have a tendency for its patients to present 
at a higher or lower stage, which would create inaccuracies towards the root of the tree again. 
The paper did mention a few limitations of the study. There was no consideration for other forms 
of radiotherapy, controversies in the recommended use of radiotherapy, the effect of patient 
choice considerations and rare indications for radiotherapy have not been included in the overall 
estimate. Nonetheless, the study result has been adopted as a benchmark figure in the literature. 
2.3 Canadian Healthcare System Model (QCRI) 
Queen’s Cancer Research Institute (QCRI) has worked on estimating the need for radiotherapy by 
using two different types of models [44]. A criterion based benchmarking model (CBB) and two 
epidemiological based estimate models (EBEST). CBB assumes optimal access to radiotherapy 
with no limiting factors such as treatment access or financial constraints, while EBEST does take 
into account factors such as detailed indications for radiotherapy and known case mix [44]. What 
QCRI were actually comparing was the 1 year and 5 year rates of radiotherapy to the different 
models. I will evaluate the EBEST model comparisons, as this is the type of model that will be 
used in the MALTHUS project. 
The comparison is between two EBEST models, which are a Canadian model, made by the 
Radiation Oncology Research Unit (RORU), and the Australian CCORE models. As the evaluation of 
the CCORE work is in section 2.2, it is best we consider the RORU model. An overview of the Lung 
model will be the example of the RORU models. 
The creation of the Lung model was by defining indications for radiotherapy, of which the basis 
was on a systematic review of the then available literature. An estimate of incidence for each 
indication was then made for the population of interest. These were the summed up to 
determine the total number of cases that should receive radiotherapy [45]. However, the fact 
that this model utilised North American clinical practice guidelines, where some of the practices 
are not accepted universally [45], leads to the possibility that the basis of parts of the decision 
tree are practice that is not actually adopted in certain regions that will use the model. A number 
of data sources contributed to the actual indications for radiotherapy. The most commonly used 
sources were national and regional oncology guidelines. In addition, QCRI utilised some sources 
from Canada, some American and some from the UK [45]. Thus, there is a mix of international 
data for the identification of indications for radiotherapy and this might not reflect the actual 
national practice or the best guidelines. 
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The actual complexity and the levels of evidence used in the RORU models are of a similar level to 
the CCORE models. There were not too many level I data sets used but instead a greater number 
of lower levels data sets. However, some of the data used for the epidemiology is not new data. 
There are sources dating back to 1986. Advances in practice may have occurred since then, 
leaving this data outdated and incorrect. 
Something that RORU included in their models, which CCORE did not, was to take into account 
patient preference. Patient preference is important in Canada due to the large distances between 
radiotherapy centres and so the amount of travel required by patients, for certain treatment 
options, can be significant enough to make a patient choose a different treatment option. 
Consequently, in some decisions where there might have been treatment options patient 
preferences were included in defining the indication for radiotherapy [45]. This could lower the 
overall demand for radiotherapy by taking into account things like a patient opting for different 
forms of treatment if there is not a radiotherapy centre nearby. 
RORU also included error estimates and sensitivity analysis in their models. Where there were 
more than one data sources of equal level the derivation of an estimate was from the largest 
sample in the main model [45]. A sensitivity analysis was completed and presented. The model 
ran simulations using the lowest and the highest values for the branch points where there were 
more than one estimate. A 95% confidence interval was calculated for the whole model by using 
+/- 1.96 standard error of the probability of receiving radiotherapy [45]. 
Table 2-5 presents the results from QCRI’s RORU comparisons. The RORU estimates are actually 
lower than CCOREs for lung and breast than that of prostate. 
 
 
EBEST 
Overall Average RT Rate RORU CCORE 
Lung 61% 75% 52.70% 
95% CI 
57.1%-
64.9% 
69.7%-
80.5% 50.7%-54.7% 
Breast 66% 83% 55.10% 
95% CI 
61.6%-
71.2% 
82.5%-
84.6% 53.3%-56.9% 
Prostate 61% 60% 42.50% 
95% CI 
55.6%-
66.8% 57%-67% 40.7%-44.3% 
 
Table 2-5. Lung, breast and prostate ARR estimation comparison between QCRI and CCORE 
models and the actual average rate observed in the British Columbia province [44] 
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2.4 Swedish Council on Technology Assessment in Health Care (SBU) 
In 2003, the Swedish Council on Technology Assessment in Health Care (SBU) released a series of 
papers updating their original work based on an overview of radiotherapy for cancer in Sweden, 
where they looked at the current practice against scientific literature. The critical review will be of 
the more recent papers, as they superseded the old reviews. Two summary papers are the basis 
of this review, one is based on the whole SBU project of the systematic overview of radiotherapy 
[46] and one is the review paper of the radiotherapy practices in Sweden compared to the 
scientific literature [47]. 
The scientific literature survey that was undertaken consisted of 934 different articles of which 
448 were considered to have high scientific value [47] and the survey of practice took part in all 
23 departments of oncology as well as three additional facilities that also provided radiotherapy 
in Sweden over a 12 week period in the autumn of 2001 [46]. The study consisted of 
approximately 4,500 patients receiving 5,500 treatments.  
The SBU project has slightly different targets compared to MALTHUS as it is mainly just comparing 
practice with scientific knowledge and not attempting to generate a theoretical target of 
prescribed radiotherapy.  
The study shows that, in 2001, 47% of patients in Sweden received radiotherapy [47], which is 
comparable to other reported radiotherapy levels from other countries. SBU concludes that the 
curative treatment given in Sweden is mainly in accordance to scientific literature and suggestions 
of overutilization from their previous report have declined [46]. However, underutilisation of 
palliative treatment was still a possibility in Sweden. 
The SBU does recognise that more than 50% of the increases in incidence since 1958 are due to 
the changing age structure of the population, as well as improved diagnostics, targeted screening 
and a general increase in certain types of cancer. This is in line with what other projects have 
realised with the changing age structure of their populations. Additionally they noted that the 
increase of incidence predicted from the previous report for 1990-2000 was greater than 
expected. An actual increase of 13% occurred instead of the predicted 10.5% increase. Combining 
several factors that have been calculated from the project, to maintain the currently level of 
treatment capacity in Sweden at least 65 accelerators would be required in 2010, Sweden had 59 
in 2001. 
 
2.5 ESTRO QUARTS Project 
The European Society for Radiotherapy and Oncology (ESTRO) Quantification of Radiation 
Therapy Infrastructure and Staffing Needs (QUARTS) project developed a model that established 
a direct and transparent link between epidemiological data and indications for RT based on best 
available evidence [29]. To create the model it used data from three systematic overviews, the 
Canadian model, a Swedish model and the CCORE model and for epidemiological data it used 
both EUCAN (a European Union cancer incidence, mortality and prevalence database) and 
GLOBOCAN (a worldwide cancer incidence, mortality and prevalence database). However, 
QUARTS does not simply estimate the ARR, it also estimates the number of linear accelerators per 
million population. As MALTHUS will not be looking into the number of linear accelerators, the 
methodology about this will not be discussed. 
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The project recognised that while cancer incidence is on the increase, cancer mortality is declining 
in many EU countries, so early detection and improved treatment is starting to have an effect on 
cancer survival. Therefore, adequate access to radiotherapy has to be a health care goal. 
However, across the EU, there are variations in provision of radiotherapy and even within 
countries (Sweden and the UK as examples) the variations still occur. It has also been recognised 
that another symptom of inadequate provision in some EU countries is the unacceptably long 
waiting times for radiotherapy, as stated by the RCR as well [12] this potentially has a detrimental 
effect on the treatment outcome. Long waiting times for radiotherapy indicates that a country 
does not have enough provisions to provide treatment before compromising the cure. Previously, 
to combat the radiotherapy shortages the basis of long term forecasts were crude assumptions 
and a notional 50% of patients requiring radiotherapy at some point in their treatment [29]. 
Research by Thomas et al. [48] looking into the excess capacity required to achieve waiting time 
target could be combined with HEROs linear accelerator calculations to give a more realistic linear 
accelerator per million target. Thomas et al. investigate the effects of random fluctuations in 
demand on the capacity required to achieve waiting time targets [48]. Various mathematical 
techniques are employed to calculate the results, but with the methodology well-described 
different countries could apply it for their own targets. 
The aim of the ESTRO QUARTS project was to provide healthcare planners and policy makers with 
objective estimates of infrastructure and staffing needs for radiotherapy, by basing estimates on 
clinical evidence of appropriate rates of radiotherapy [29].  
ESTRO QUARTS evaluated three main sources for evidence based radiotherapy indication, the 
Swedish Council on Technology Assessment in Health Care (SBU), the Canadian Division of Cancer 
Care and Epidemiology, Queen’s Cancer Research Institute (QCRI) and CCORE. ESTRO QUARTS 
chose the CCORE models to be the main source of evidence based radiotherapy utilisation rates 
due to the accessibility of its findings, methodology and comprehensive coverage [29]. QUARTS 
also used CCORE’s retreatment factor of 25%. Section 2.2 reviews the CCORE models.  
To produce the results of the linacs required per million population, QUARTS took the incidence 
data for 23 cancer sites off EUCAN/GLOBOCAN, multiplied them by the ARR for that cancer site 
and multiplied that by 1.25 to take into account the retreatment factor. Then a fraction number 
weighting factor was applied to take into account the different treatment complexities. The 
number of linacs required for each of the 25 EU countries resulted from a conversion of the 
number of weighted fractions.  
The QUARTS project also undertook some sense checking of the CCORE estimates against the 
current practice within the EU. A comparison of the 95% confidence intervals of the CCORE 
estimates against the 2001 Swedish audit of radiotherapy activity in Sweden acted as the sense 
check. There are some quite substantial differences between the two sets of results. Hodgkin’s 
disease, brain and nervous system, bladder, pancreas and stomach all showed a greater than 50% 
lower radiotherapy utilisation in Sweden compared to CCORE. As a general note fewer sites over 
prescribe radiotherapy in Sweden compared to CCORE, however QUARTS did not perform a 
detailed analysis of this as the difference were beyond the scope of the project [29].  
There was no thorough sensitivity analysis attempted on the QUARTS project. However, they 
stated that the QUARTS estimates are rather robust with respect to the difference between the 
QCRI and CCORE estimates and the application of the weighting factor. Based on the fact that if 
they accepted the lower QCRI ARRs for colorectal, breast, lung and prostate cancer and taking out 
their weighting factor for treatment complexity then the average number of megavoltage 
treatment units required for the EU countries would drop from 5.9 per million to 5.2 per million. 
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The drop is 5.9 per million to 5.3 per million when keeping the weighting factors in the model 
[29].  This is merely stating that the QUARTS weighting factors have not overly adjusted the 
original differences between QCRI and CCORE. This does not prove robustness of the QUARTS 
model for use in the EU, especially as the CCORE model was shown to be different to the SBU 
audit.  
The paper did state that the usage of datasets from southern and central Europe for validation 
would strengthen QUARTS, showing recognition of the limits of using a Swedish audit and 
Australian model. The main limitation of QUARTS using the CCORE model is that the basis of 
CCORE is Australian data, so they have to assume that the cancer profiles, treatments and stage 
presentation are the same in both Australia and the EU. This is quite an unrealistic assumption as 
it is known that cancer types and stage presentation varies within a country, let alone across 
different continents. 
In terms of England, the QUARTS project suggests that the targets set out in the NHS Cancer Plan 
are far too low, giving a target of around 6.2 linacs per million whereas the NHS Cancer Plan gave 
a target to 4.2 linacs per million in 2004. When comparing the number of current linacs vs the 
required number for the radiotherapy capacity estimations, England comes out relatively low 
down in a comparison with other countries, with Lithuania, Hungary and Slovakia all achieving a 
better actual vs required radiotherapy capacity [29]. This backs up the RCR’s statement that 
previous investment in radiotherapy in England has only resulted in a standstill in provisions 
instead of an improvement against demand and that further investment is required to bring 
England to the forefront of radiotherapy in the EU. 
 
2.6 Decision Tree Software 
A review of the currently available decision tree software was undertaken to assess the 
capabilities of these applications. The most capable piece of software on the market is TreeAge, 
the software used by CCORE. TreeAge offers a very good suite of features, such as sensitivity 
analysis, Monte Carlo, markov chain analysis amongst others. A sensitivity analysis looks at the 
effect that a models parameters has on the output. Monte Carlo methods utilise random 
sampling or random numbers to evaluate models that are too complex to generate an analytical 
solution. Markov chain analysis is a tree style structure that relies on states until an exit condition 
is met, used in healthcare often with exit conditions such as alive, cured or dead. However, 
TreeAge only offers a generic walkthrough, in that each cancer patient is handled in the same way 
by the software. This is significantly different to how the MALTHUS project wants to run. A 
“Virtual Patient” system will replace the generic walkthrough of the tree to give an accurate 
representation of England’s population, essentially eliminating the generic walkthroughs of 
decision trees and replacing it with a much more complex, adjustable tree walkthrough system. 
While TreeAge can run multiple different types of simulations on a decision tree, it is only 
configured to run a simulation on a single tree. MALTHUS will  need to operate running 
simulations over a number of trees, automatically collating the results of numerous trees at the 
end as in MALTHUS a ‘simulation’ could involve 23 different clinical decision trees.  
The TreeAge interface has, while useful for developers, the appearance of being complex, which 
will not be useful for users who only wish to run a single simulation. In addition, the insertion of 
new nodes or modification to existing trees also may not be intuitive if the user does not have a 
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background in computers (the manual for the latest version of TreeAge spans over 600 pages). 
The idea of MALTHUS is the reduction of these problems and the interface will be very simple to 
use, even eliminating the need to look at the trees and such if a simulation is required. 
Another problem with using a third party piece of software is that the software is required to 
make any local changes to the tree, which requires a licence fee for every copy of the program. 
While a program may be suitable for part of the job, it can easily become impractical when you 
require hundreds of licences for all users who want to make minor changes to the trees or 
simulations based on their local data. This is a core requirement for MALTHUS and with custom 
software, this will not be an issue as there will not be any licensing costs. 
A simple computational speed comparison was undertaken to compare the simulation speed of 
TreeAge against Fortran. The same tree was encoded in both and a fixed number of runs was 
completed, with TreeAge using all four cores on a computer and Fortran only using a single core 
on the same computer. TreeAge achieved approximately 55,000 walkthroughs per second while 
Fortran achieved almost 220,000 walkthrough per second on a quarter of the computer 
processing power. On a small simulation the differences between the two will be negligible, 
however on large simulations, such as full Monte Carlo simulations over numerous regions, the 
fact that Fortran operates at almost four times the speed of TreeAge gives it a great advantage 
and could save hours of simulation time. There is also the possibility that in the future of the 
implementation of the Fortran code over multiple cores, which would give it an even greater 
speed advantage over TreeAge. 
2.7 Comparison of CCORE, QCRI and the MALTHUS Plans 
To be able to compare other research groups work to MALTHUS a brief overview of the areas of 
MALTHUS that are to be compared must be given at this stage. 
MALTHUS will use decision trees that do not rely on a two state output, radiotherapy or no 
radiotherapy. The MALTHUS trees will contain information on the amount of prescribed 
radiotherapy, enabling a fraction burden to be calculated. It does this via a Virtual Patient 
construct, the Virtual Patients themselves that carry information gathered from all stages of the 
walkthrough and do not just rely on the final state of the terminal node reached. The nodes 
within the trees take information from the Virtual Patient to make decisions and feed information 
back to the Virtual Patient after any calculations. 
The MALTHUS tree nodes can even adjust any parameter within the node based on 
predetermined conditions that can react to information held within the Virtual Patients. 
Therefore, the clinical decision trees can react appropriately to different factors such as age or 
deprivation, adjusting the treatment probabilities or number of fractions on the fly.  
The sensitivity analysis in MALTHUS operates by adjusting every single node within all trees to 
determine the effect on the output every decision has. Tornado diagrams are then produce to 
show the effect different nodes have on the average number of fractions prescribed. A tornado 
diagram is a modified bar chart often used in sensitivity analysis to display the sensitivity of a 
parameter. The structure of them places the most sensitive parameter, giving the greatest 
variation in output and therefore the biggest bars, at the top with the least sensitive at the 
bottom, giving the rough shape of a tornado. While this will lead to a greater computational load, 
it reduces the possibility of not identifying an area of a tree that has a great effect on the output. 
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QCRI used a probability tree diagram, constructed in TreeAge and integrated the probabilities of 
the branches into two categories of indications for radiotherapy or no indications for 
radiotherapy. This is a very basic static way to make the calculations. While this method is not 
incorrect it only offers a basic answer and does not include full regional differences or number of 
fractions like MALTHUS will do.  
CCORE used TreeAge to construct the trees and to complete the sensitivity analysis and Monte 
Carlo simulations on the trees. This is more complex than QCRI, however, there are still only two 
outputs, indications for radiotherapy and no indications for radiotherapy. The sensitivity analysis 
completed by CCORE only looked at the nodes with multiple different data sources, as there was 
a disagreement between the sources for the decision probability. TreeAge then automatically 
performs a one way sensitivity analysis to construct tornado diagrams to show the effect of the 
different sources on the ARR. TreeAge then also performs a Monte Carlo simulation to show the 
combined effects of the uncertainty in some of the estimated uncertainty in the decisions to give 
the ARR with a 95% confidence interval. 
In terms of tree size, there are 415 branches in the CCORE trees, but over 2000 nodes in the 
MALTHUS trees. There are fewer trees from QCRI and so fewer branches. 
2.8 Summary 
This section has looked at the NRAG report, CCORE's models and QCRI’s models. The design of 
them is not to work at a regional level to enable the generation of local results from the same 
model to provide more tailored outputs. The basis of the models are a basic decision tree 
structure and operating mode, which does not include patient generator at the front end of the 
models, which creates a more complex model that is better for local level simulations. They also 
do not have the level of statistical robustness that is required for the type of local simulations 
that MALTHUS will be running. MALTHUS will require a full sensitivity analysis to show precisely 
where important variations may occur within the clinical decision trees, which is important to 
identify in case a highlighted decision is one that changes from region to region.  
Additionally while TreeAge appears to be a very capable piece of decision tree software it does 
not offer the front end patient generation with multiple tree simulations that is a core 
requirement for the MALTHUS project to be a success. This combined with the facts highlighted in 
the paragraph before about the previous models justifies the creation of the MALTHUS PhD 
project to generate a new, novel piece of software that can run local level simulations offering full 
statistical and sensitivity analysis on predicted fraction burdens.  
In the next chapter the operation of the MALTHUS program will be broken down, detailing how 
the different sections of it work and the various operating modes that MALTHUS can operate 
under, including the sensitivity analysis and the different Monte Carlo methods.   
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3 The MALTHUS Project, Program Methodology, Design and 
Implementation 
The objective of the project is to generate a decision tree program that is able to accurately 
recreate population and incident cohorts from real, high level regional data and walk them 
through clinical decision trees. This will generate an overview of the amount of radiotherapy that 
a region within England, or England itself, should be delivering.  
This chapter will explain the model and the individual sections that make up the model, along 
with the different operating modes of the program. This should give good overall knowledge of 
how MALTHUS works to help understand the results and discussion further on.  
3.1 The MALTHUS Project 
As mentioned before the MALTHUS project extends beyond the scope of this PhD. There are a 
few components to the whole project. There is the construction and validation of the clinical 
decision trees, the data acquisition and sorting for the population and incidence data and the 
actual MALTHUS programs.  
The overall MATLHUS project has created two different programs, MALTHUS Workbench and 
MALTHUS Pro. MALTHUS Dashboard, a simple web interface, display results from previously run 
simulations only.  
Dr Jena created MALTHUS Workbench and it acts as an easy to use, lightweight version of 
MALTHUS Pro that is currently available to the clinical community. The creation of a lightweight 
version of MALTHUS was for ease of use, as it does not offer the full statistical calculations and 
sensitivity analysis that MALTHUS Pro offers. A user friendly graphical user interface written in 
Delphi is the basis for Workbench, so users without any programming experience can use the 
program. This enabled the NHS to use MALTHUS Workbench before the completion of MALTHUS 
Pro and before the full sensitivity analysis was completed. 
MALTHUS works with 23 different cancer sites, with 22 being the most common cancers and a 
final ‘others’ group that will contain all incidence that have not been included in the 22 sites. The 
23 sites and their corresponding ICD-10 codes are: 
 Bladder – C67 
 Breast – C60-D05 
 Cervix – C53 
 CNS – C70-72 
 Colon – C18-19 
 Endometrium – C54 
 Head and Neck – C00-14+C30-32 
 Hodgkin’s Lymphoma – C81 
 Kidney – C64 
 Leukaemia – C91-95 
 Lung – C33-34 
 Melanoma – C43 
 Myeloma – C90 
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 Non-Hodgkin’s Lymphoma – C82-85 
 Oesophagus – C15 
 Others 
 Ovarian – C56-57 
 Pancreas – C25 
 Prostate – C61 
 Rectal – C20 
 Sarcoma –C49 
 Stomach – C16 
 Testis – C62 
 
This is not fully comprehensive list of all cancers treated with radiotherapy, however it was 
determined to be the most suitable list, by the clinicians at Addenbrooke’s, with relation to the 
information available to create the clinical decision trees. Historically some tumours were not 
registerable, benign brain tumours for example, and so comprehensive incidence data is not 
necessarily available. Additionally it was considered inefficient to create a clinical decision tree for 
every different type of cancer, especially when some have very low incidences and so the ‘others’ 
group was formed for every cancer incidence that is not in one of the main groups. 
3.2 Clinical Decision Trees and Input Data 
Every cancer site has a separate clinical decision tree that has been compiled ab-initio by a team 
of clinicians at Addenbrooke’s hospital.  The trees contain information on the type of cancer, 
what stage it is likely to be and various other pieces of information that would affect a clinician’s 
decision on how much, if any, radiotherapy to prescribe. They were compiled by reviewing the 
evidence base for indications of radiotherapy for a cancer site using national and international 
guidelines, meta-analysis, systematic reviews and key clinical trials. The English cancer registry 
datasets contained the stage presentation data [49]. For some of the trees there are two options 
for the basis of the decision probability, evidence based or pragmatic trees. The pragmatic trees 
utilise every decision that is available while the evidence based trees will cut off some decision 
routes because there is a strong evidence base for a certain decision. For example with breast 
conserving surgery, stage 1 breast cancer there are three radiotherapy options: 15 fractions, 16 
fractions or 25 fractions. Due to the outcome of the MALTHUS user group meeting 15 fractions is 
set as the most likely option and so when using evidence based trees the probability of the16 and 
25 fraction options is zero, with 100% of patients going to the 15 fraction option. With the 
pragmatic tree, all three options are included in the decision. 
A patients’ performance status is another factor that can affect the decision of a patients 
prescribed treatment. However, in general, there was insufficient data to accurately encode this 
within the clinical decision trees and Virtual Patient generator (the Virtual Patient generator is 
explained in section 3.3.3) to allow every Virtual Patient to have a performance status. Where 
data was available, the clinical decision tree had it encoded in a more general form such as ‘fit for 
curative therapy’ or ‘not fit for curative therapy’. 
The complexity of the information within the trees varies from cancer to cancer.  For some 
cancers, indications for radiotherapy are rare. For example, the colon cancer decision tree is 
simply palliative radiotherapy indications or no radiotherapy indications. In counterpoint, the 
number of contributing decisions or factors in the treatment for the head and neck cancer group 
means that its decision tree contains 529 nodes. The total number of decision nodes within all 
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trees is 1987. In general the clinical decision trees are structured in a way that the first set of 
decisions relate to the actual cancer type (if it is a category where numerous cancers are covered, 
i.e. head and neck, which includes eight different type of cancers) followed by the stage 
presentation. After the stage presentation, the clinical decision trees go into site specific 
decisions such as surgery decision or actual suitability for radiotherapy. Figure 3-1 shows part of a 
clinical decision tree in MALTHUS Workbench. Figure 3-2 shows the same clinical decision tree 
but in MALTHUS Pro form. As can be seen in Figure 3-2 the MALTHUS Pro decision tree format 
does not hold the actual decision information and is not designed to be read by a user as it has 
been optimised for reading data into an array within the Fortran program. Each row of numbers 
represents a single node and its contained information, with each column representing a different 
piece of information such as node number, decision probability and number of fractions. 
As a validation for the trees, there was a MALTHUS user group meeting where clinicians and 
medical professionals from around the country attended and the major trees were analysed and 
discussed to make sure that they do represent the correct current practice. With some 
modifications, all of the trees passed general clinical consensus and achieved clinical validation 
for England.   
The source of the input data for the project, the population and incidence data was via personal 
correspondence with Sean McPhail, a Senior Information Analyst within the NCIN. The separation 
of the population data was by PCT/CN and 5 year age bands with the top end age band being 85+ 
and sent to the project in an Excel spreadsheet, the source of the data was the ONS. The 
incidence data was provided in Excel too, separated by the MALTHUS ICD-10 groups, PCT/CN, sex 
and age bands. The grouping of the incidence data was in 5 year age bands except for the first age 
band that was 0-24 and the final age band that was 85+. The larger age band of 0-24 is due to the 
smaller number of incidences in young people, the data had to be in such a way that a cancer 
with fewer incidences could not become patient identifiable and if the data had been broken 
down more at a young age there was a risk that this was possible. The age band of 85+ was given 
a maximum age of 100 due to the small number of people who are aged over 100. In general, this 
will not affect the validity of the results, as the overall calculations will not ignore any age or 
incidence data. The only time it may affect results is if a paediatric centre is running simulations 
due to the often used years 0-16 age band, however within MALTHUS there is scope for a custom 
dataset to be used that contains a specific centres incidence and population data that is not 
available to the project due to the patient identification issue. In both sets of data, for ease of use 
a split of the age bands into single years occurs within MALTHUS Pro, it does this by dividing the 
number of incidences within the age band by the number of years in the age band.  
The population and incidence data used for this project are from the years 2007-2009 and were 
the most up to date three-year period data that was available. Towards the end of the project it 
was enquired into to get more up to date data however due to the switch from PCT to CCG and a 
new computer system which holds all of the incidence data in the central servers, this was not 
possible. Once more up to date data comes available, it will be input into MALTHUS. 
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Figure 3-1. Example of a clinical decision tree displayed in the Delphi produced MALTHUS 
workbench 
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1.00   0.55   0.00   2.00   0.00   0.00   0.00 
2.00   0.85   0.00   3.00   1.00   0.00   1.00 
3.00   0.20   0.00   4.00   2.00   0.00   1.00 
4.00   0.85   0.00   5.00   3.00   0.00   1.00 
5.00   0.00   0.00   0.00   4.00   0.00   1.00 
6.00   0.50   0.00   7.00   4.00   0.00   0.00 
7.00   0.00   0.00   0.00   6.00   0.00   1.00 
 8.00   0.00   0.00   0.00   6.00  15.00   0.00 
30.00 0.03   0.00   9.00   3.00   0.00   0.00 
   9.00   0.96   0.00  10.00  30.00  10.00   1.00 
 10.00   0.00   0.00   0.00   9.00   0.00   1.00 
11.00   0.00   0.00   0.00   9.00   0.00   0.00 
  12.00   0.96   0.00  13.00  30.00   0.00   0.00 
 13.00   0.00   0.00   0.00  12.00   0.00   1.00 
  14.00   0.05   0.00  15.00  12.00   0.00   0.00 
  15.00   0.00   0.00   0.00  14.00  20.00   1.00 
 16.00   0.00   0.00   0.00  14.00   0.00   0.00 
 29.00   0.67   0.00  17.00   2.00   0.00   0.00 
  17.00   0.30   0.00  18.00  29.00   0.00   1.00 
  18.00   0.00   0.00   0.00  17.00  15.00   1.00 
  31.00   0.03   0.00  19.00  17.00   0.00   0.00 
  19.00   0.00   0.00   0.00  31.00  20.00   1.00 
  20.00   0.95   0.00  21.00  31.00   0.00   0.00 
  21.00   0.00   0.00   0.00  20.00   0.00   1.00 
  22.00   0.00   0.00   0.00  20.00  20.00   0.00 
  23.00   0.95   0.00  24.00  29.00   0.00   0.00 
 24.00   0.00   0.00   0.00  23.00   0.00   1.00 
  25.00   0.00   0.00   0.00  23.00  20.00   0.00 
 26.00   0.98   0.00  27.00   1.00   0.00   0.00 
 27.00   0.00   0.00   0.00  26.00   0.00   1.00 
  28.00   0.00   0.00   0.00  26.00  20.00   0.00 
Figure 3-2. MALTHUS Pro Clinical Decision Tree Example showing: node number, probability of 
upper branch, probability of lower branch, upper branch node number, parent branch node 
number, number of fractions given, upper branch indicator (1 if node is an upper branch node) 
3.3 Program Design 
A decision tree structure is the basis for the core of the program. A decision tree is essentially a 
structured algorithm based around probabilities and occurrences. In this project, the decision 
trees will include clinical decisions, information about the decision, resource usage and the 
decision’s possible outcomes.  
From the initial planning, a few main sections to the program came to light. The patient 
generator, the tree builder/ walkthrough and the data collection/analysis. The first two sections 
are what really distinguish this program from others are currently available and used in other 
work reviewed earlier. 
Figure 3-3 shows the core structure of the program for a simulation, as this is only the core 
structure the program may change it depending on the selection of the operating mode.  
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Early on in the project a decision on how the program would operate with the decision trees was 
finalised, as once coded it would be difficult to go back and adjust it without affecting the rest of 
the coding. The main initial consideration was whether to use binary decision trees or ones that 
are more complex. The choice of binary trees was taken due to the lower complexity of coding 
required to write the program and to make it easier for the program to actually compile and 
debug the decision trees. Being a binary decision tree every node, unless it is a terminal node, will 
have a single parent and two children. An upper branch or lower branch connects two child nodes 
to their parent node. The names upper branch and lower branch are simply given names used to 
identify the different branches coming out of a node. If trees that are more complex were to be 
used a more complex system of pointers would have to be used to link the nodes of the tree 
together. Consequently, it would require a much more complex method of how the program 
builds it trees, as more verification checks would have to take place to ensure the connection of 
all pointers is correct. An incorrectly connected or unconnected pointer could go unnoticed and 
could cause the program to output incorrect results.  
Another major decision taken was to define the structure of the decision nodes. Each decision 
node would have to contain a certain amount of information for the program to make decisions. 
The basic information in each node is: 
 Node number 
 Decision probability to the upper branch 
 Whether the current node is linked via an upper or lower branch from its parent 
 Number of fractions received from arriving at node 
 A counter for the number of times the node was visited 
There are also a few pointers associated with each node. A pointer is a programming variable that 
points to a memory address where information is stored, it can be imagined with an arrow 
connecting two pieces of information on a piece of paper that lie amongst other pieces of 
information in a random fashion. In this case, the program uses pointers to know where another 
relevant node is.  Each pointer only represents a direction of travel for the tree program that lets 
the program pass from node to node when either completing a simulation or building a tree. A 
pointer is not a piece of information that adds to the output. The pointers from each node are: 
 To its parent node 
 To its sibling node 
 To its child nodes via: 
o Its upper branch decision route 
o Its lower branch decision route 
 
The pointers either connected to another node, or nullified if the node is a terminal node at the 
time of building the decision tree. 
As this is bespoke software built from scratch the scale of the nodes is not limited. With further 
development, the node structure can contain more data. In addition, the complexity of the nodes 
can be increased, and the increase occurs in example simulations, to make the nodes self 
adjusting to different pieces of information extracted from the Virtual Patient. 
The selection of the operating mode happens after the start of the program. The different modes 
will allow the program to run on single or multiple PCT, single or multiple cancers, sensitivity 
analyses or Monte Carlo methods. 
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Figure 3-3. Basic operation flow chart for MALTHUS Pro showing the different areas of the 
program and the links between them. 
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The programming language of choice for MALTHUS was Fortran for a couple of reasons. While 
Fortran has been around for many years, it is still one of the most computationally efficient 
languages for numerical work and is still the de facto language to test the number crunching 
abilities of supercomputers. The fact that it has been around many years also leads to there being 
a wealth of knowledge and legacy code readily available, including a whole suite of code that has 
been developed over the years by Professor Norman Kirkby for computational biology, statistical 
analysis and Fortran input/output operations.  
One minor issue that arose from using Fortran as the main programming language for MALTHUS 
is that, as standard, Fortran only utilises a single thread on a computer’s processor. This leaves 
plenty of available computing power unused on the computer that is running a MALTHUS 
simulation. After most of the MALTHUS Pro code had been written it was attempted to get 
Fortran working with parallel programming (parallel programming means utilising more than one 
thread to run simultaneous calculations), unsuccessfully. Fortran does have a couple of parallel 
programming options built into it: MPI, coarray and OpenMP.  
Message Passing Interface (MPI) is the most complicated method and is mainly utilised by cluster-
based systems with multiple computer nodes that have distributed memory systems, rather than 
the architecture of a home computer. Consequently, MPI was ruled out as it would have been 
impractical to try to implement. 
Coarray Fortran, when run, creates multiple copies of itself that each run different tasks that the 
program as a whole was given to run initially. While this initially appeared easy to implement into 
MALTHUS (and simple test coarray programs worked) the complexity and number of different 
parts of MALTHUS Pro that are linked together to enable a single set of calculations to be 
completed meant that information was being lost between the different copies causing the 
program to fail. 
A similar situation occurred when trying to implement OpenMP. OpenMP doesn’t create multiple 
copies of itself like coarray does, but instead when a set of calculations is required to be 
completed it splits the required calculations into a different number of predetermined threads 
and runs the threads simultaneously. So multithreading only occurs when large calculations are to 
be completed. However, while this was probably the closest out of the three methods to being 
successful, there were problems when it came to combining the results of the numerous threads. 
Results were being lost or while attempting to combine the results the program was just crashing.  
With the complexity of the interlinking sections of MALTHUS Pro and running it on a single 
computer, OpenMP is the best choice, however the timeframe constraints of the PhD did not 
allow for further attempts at getting MALTHUS Pro working with parallel processing. However, it 
is possible to exploit multiple CPU cores on a pc manually by running a number of independent 
simulations on the same computer with each simulation working on different tumour types. This 
divides the workload that MALTHUS has to undertake and can reduce calculation time, but has to 
be set up by hand. 
3.3.1 The XML Clinical Tree Reader and Bifurcator 
The clinical decision trees are originally stored in XML format for visual representation in the 
MALTHUS WorkBench program, enabling the user to modify them easily. However, XML is a 
verbose language and not the most efficient for fast reading into the program. Therefore, a Tree 
Converter program (TC) was created to read the XML files, bifurcate them when necessary and 
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store them in a text file for the Fortran program to use. It serves as the front end of MALTHUS Pro 
when required. Figure 3-4 shows the basic layout of the converter. 
Opens tree XML file
Reads in whole tree 
into linked list of 
custom node type 
containing:
Node number
Probability
Variance
Treatment
Parent
Walks through and 
inspects tree for 
number of child 
nodes
Inserts new node 
acting as 
intermediate parent 
node, splitting up 
child nodes/
bifurcating the tree
If 2+ child nodes
Repeats until
only 2 child
nodes 
Moves onto next 
node
If 2 child nodes or end node
When 2 child nodes 
per parent achieved
Writes new Fortran 
Tree File
When all nodes are inspected
 
Figure 3-4 Operation flow chart of the tree converter showing how the clinical decision trees 
are bifurcated. 
The TC extracts all the required information from the XML tree files and stores it in memory. It 
then works through the tree node by node recording how many child nodes each parent has. 
Where a parent has more than two child nodes it inserts a new node and automatically re-
calculates all the relevant probabilities. Figure 3-5 shows an example of the process, with 
probabilities.  
After the tree has been fully bifurcated, or even if no bifurcation was required, the program then 
organises the nodes into an order such that no child node appears before its parent node.  
Once the conversion of the tree into Fortran format is complete, it saves the file to a .Txt format 
in the program directory. Saving the files means the conversion of a tree only happens once. They 
only have to be re-converted when a change to any original XML clinical decision tree occurs. 
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An example of the XML tree files and the resultant Fortran tree file can be found in Appendix 1. 
Parent Node
Child Node 1
33%
Child Node 2
33%
Child Node 3
33%
Parent Node
Child Node 1
33%
New Parent Node
66%
Child Node 3Child Node 2
50% 50%
Bifurcation Process
 
Figure 3-5 Detailed flow chart example of how the bifurcation process divides the nodes 
probability when inserting new parent nodes.. 
3.3.2 The CSV Data Reader 
The core data for the patient generator is stored in comma-separated values (CSV) files. A CSV file 
is a common, simple data storage format that many programs use. While its name is comma-
separated the data does not specifically use commas for separation, however MALTHUS will just 
be using commas for its files. This keeps it simple for MALTUHS pro, Workbench and Excel to all 
use. 
The CSV data reader works in a simple methodical way shown in Figure 3-6. 
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Figure 3-6. Step by step operation flow chart of how the CSV reader operates. 
The CSV reader operates in such a way that it extracts the data in the header row to get the age 
bands for that column in the data table. It then processes the data in the relevant column by 
dividing the extracted data by the number of years in the age band to give the data in individual 
years. The program allocates the age bands at run time, as long as the first row of the data file 
defines the age bands.  
The population data and incidence data do not have to have corresponding age bands. The 
program gets round this by moving all the data into single year age bands so it can be matched 
easily and the probabilities are worked out for both the population and incidence.  
 
3.3.3 The Virtual Patient Generator 
The Virtual Patient generator itself consists of two parts, the population generator and the cancer 
incidence generator. These two combined generate the cohort of Virtual Patients for the 
program. As standard, the patient generator generates the same number of population as the 
region it is simulating. 
3.3.3.1 The Population Generator 
The population generator uses the actual population statistics of England for 2007-2009, from the 
Office of National Statistics and the NCIN, broken down into age bands, PCT and sex, so the 
program will be able to recreate the regions of England accurately to enable more precise results 
for regional/national simulations. The population data is stored externally to the program and 
imported when needed. By keeping it external to the program, it allows updates and 
modifications without having to adjust the program code. To import the population data the 
program uses the CSV data reader. 
Once the program has loaded the data, it generates the sex of the person by looking at the male 
to female ratio for the region, for example, 0.49, which is 49% are males and 51% are females, 
and draws a random number. If that random number falls below the male to female ratio number 
then the person generated is male, vice versa for female. 
Once the sex has been determined, the model uses the acceptance rejection method to generate 
the age of a person. This is where a simple test to see if random numbers fall (between 0 and 1) 
within the limits required. The program generates a random number and multiplies this by 100 to 
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get an age (i.e. random number of 0.2486…. would be multiplied by 100 and rounded to 25) it 
then generates another random number. The program will then look at the population data for 
the selected region and, for example, if the probability for a 25 year old male in Newcastle PCT  is 
0.01947 then it checks to see if the random number is less than 0.01947. If it is then the age 
generated is lower than the probability the person is accepted. If not then the age is rejected and 
a new age is generated and tested until the generation of a valid person. This process repeats 
until the program generates the required number of people for the PCT. Due to using the 
probabilities for each age band, the generated distribution of ages is approximately the same as 
the original input population data as it is re-creating the data. 
This process utilises a pseudo-random number generator that takes the seed (start point) off the 
CPU clock cycle and so even though it is a pseudo-random number generator it retains enough 
randomness due to the varying starting position. The pseudo-random number generator in the 
Intel Fortran Compiler XE13.1 has a period of 1018 [50]. However, for validation purposes a fixed 
starting seed is assigned to the pseudo-random number generator to enable accurate 
reproducibility of the pseudo-random number sequence. 
The patient generator works with the acceptance/rejection method, even though it is 
computationally intensive, because it is the most robust technique for ensuring that the virtual 
population generated by the program matches the region in question. 
3.3.3.2 The Cancer Incidence Generator   
The Cancer Incidence Generator works in essentially the same way as the population generator. It 
uses cancer incidence data supplied by the NCIN, broken down by cancer site, sex, age band and 
PCT. This data comes to the project via personal correspondence with a NCIN senior analyst in 
data files. The incidence data is from the years 2007-2009 and was the latest release when 
programming, so the most up to date data was used at the time of programming and running 
simulations. 
As with the population data, the program uses the CSV data reader to import the incidence data. 
The data is then converted to a probability that a person of a given age and sex and in a given PCT 
is likely to have a given cancer. The incidence data is stored external to the program for the same 
reasons as the population data. 
When the Cancer Incidence Generator receives a Virtual Patient, it uses the same form of 
acceptance/rejection test to see if the Virtual Patient has a type of cancer.  If it does, the program 
stores the patient in a cancer bin and gathers all patients with that type of cancer in the same bin. 
There is a different bin for different types of cancer (if numerous types of cancer are included in 
the simulation). If a Virtual Patient is deemed to not have a cancer then the Virtual Patient is 
deleted to keep the computer’s resources free. 
 
3.3.4 The Tree Builder, Walkthrough Module and Data Collection and Analysis 
Once the program has run the patient generator and determined how many Virtual Patients have 
certain types of cancer it runs them through the clinical decision trees. This is performed on a 
cancer by cancer simulation rather than patient by patient. By doing it this way, it reduces 
computational time, as the construction of the trees only happens once per PCT, instead of 
building a clinical decision tree every time a patient with a different cancer is selected. The tree 
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data is stored externally to the program in individual files so the program does not have to store 
the built trees within the program. Storing it this way enables easy editing of the tree files 
without having to enter the main program code. It also allows the XML clinical tree reader to 
generate output files into working form without entering the program code.  
When the program or user has selected which cancer should be utilised, the simulation calls up 
the required decision tree file, reads the data and constructs the tree using pointers. Every node 
contains all the data mentioned previously. Figure 3-7 shows the method for writing the tree. The 
way the program writes the tree, the nodes have to be in an order within the data file so that a 
child node does not appear before its parent node. If a child node does appear before its parent 
then the building of the tree will fail as the builder will not be able to link a node to its parent 
node and the program will not be able to navigate through the tree properly. However when the 
tree is converted to Fortran format from XML the nodes are automatically organised in such a 
way that this should never happen. This also adds in an integrity test because if the XML 
convertor has not worked properly the tree should not build and will generate an error. This 
method of building a tree is based upon original work and code from a pointer example by 
Metcalf and Reid [51]. The method is a single pass method, rather than a multi pass method, for 
simplicity and because the bifurcator sorts the nodes, a multi pass is not required. 
After the program has built the tree, it calls up the first Virtual Patient for the tree and starts at 
the root node. Figure 3-8 gives an overview of the tree walkthrough process. The program reads 
the data in the node that the Virtual Patient is currently at and undertakes the processing 
required for the decision. If there are radiotherapy fractions given on the node, the Virtual 
Patient adds the amount to its total. The Virtual Patient carries the amount of fractions received 
with it as it traverses through the tree, this is part of the program’s self-reporting nature. Other 
parts of the self-reporting are that when a node is visited it activates a counter within the node to 
mark the fact that the node was visited, the Virtual Patient also records the node number it is on 
so the route through the tree can be traced. The probability of the route taken is also read here. 
To determine the actual route the program uses the random number generator again to call a 
random number and if the random number is lower than the probability read from the node the 
Virtual Patient moves onto the next node on the “upper branch” route, if not then it moves to the 
lower branch route. 
When the Virtual Patient has reached an end point in the tree, the program records the number 
of fractions the Virtual Patient received in total for the summary statistics. The Virtual Patient 
then goes back to the start of the tree to complete another walkthrough. This is completed a 
number of times that can be set by the user. Initially this is set at 2000, however the actual 
number of optimum walkthroughs required is currently subject to an addition piece of work to 
generate a formula, described in section 3.3.6. This formula will undergo extra testing before 
implementation into MALTHUS, replacing the user adjustable figure of 2000 to allow the program 
to auto adjust the figure depending on the tree and accuracy of results required.  
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Figure 3-7. Detailed operation flow chart of the how the tree builder constructs the clinical 
decision trees within MALTHUS Pro. 
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Figure 3-8. Detailed operation flow chart of how the tree walkthrough process operates within 
MALTHUS Pro. 
As the trees are binary and they do not loop back upon themselves there is actually a definitive, 
individual route for every end node. It is this fact that enables the Fast Monte Carlo operating 
mode where not every patient has to walk through the tree and the calculations only have to be 
completed once per tree, as the results will not change (section 3.4.7).   
The statistics module then calculates the Virtual Patient’s statistics.  
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The statistics module can calculate the following for the Virtual Patient (depending on operating 
mode): 
 Mean number of fractions 
 Median number of fractions 
 Mode number of fractions 
 The variance in the number of fractions 
 The standard deviation of the number of fractions 
 95% confidence interval of the mean 
 ARR 
 Kurtosis of the distribution of the number of fractions 
 Skewness of the distribution of the number of fractions 
The calculations, mentioned above, are all standard mathematical calculations to provide the user 
with relevant data about the spread of the Virtual Patient’s results. In addition, it allows the 
calculation of the overall statistics of the cancer to contain enough information to give the user 
details of the spread of results for the entire cancer on top of the spread for a single Virtual 
Patient with the cancer.  
For calculating the median and the mode, MALTHUS bins the number of fractions and then sorts 
through the bins to determine which bin contains the middle value for the median and which bin 
contains the maximum number of data for the mode.   
The 95% confidence interval uses a t value of 1.962. 1.962 was chosen as the standard for all 
calculations within MALTHUS as 1.962 is the value for N=1000, the only other greater value given 
in T tables is for N=∞ which gives a T value of 1.960. N=1000 was chosen as there will typically be 
2000 walkthroughs for each Virtual Patient and 2000 is closer to 1000 than it is to ∞. 
Kurtosis and skewness have been included to assist in the analysis of the results. Both kurtosis 
and skewness help describe the shape of a distribution. Kurtosis indicates the peakedness of the 
distribution, a kurtosis value of three indicates a normal distribution. The higher the value of 
kurtosis, above three, the more the data gathers around the mean and lower values indicates a 
wider spread of data. Skewness indicates if the distribution skews to one side of the mean. If the 
skewness is zero then a distribution is a normal distribution with a negative value indicating a tail 
of data towards the side below the mean and a positive value indicating the opposite. 
Kurtosis is calculated by: 
 
𝑘𝑢𝑟𝑡𝑜𝑠𝑖𝑠 =
∑ (𝑌𝑖 − ?̅?)
4𝑁
𝑖=1
(𝑁 − 1)𝑠4
 
Equation 3-1 
 
Skewness is calculated by: 
 
𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 =
∑ (𝑌𝑖 − ?̅?)
3𝑁
𝑖=1
(𝑁 − 1)𝑠3
 
 
Equation 3-2 
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With: 
𝑁 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑡𝑎 𝑝𝑜𝑖𝑛𝑡𝑠 
𝑌 = 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑑𝑎𝑡𝑎𝑝𝑜𝑖𝑛𝑡 𝑖 
?̅? = 𝑡ℎ𝑒 𝑚𝑒𝑎𝑛 
𝑠 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎 
The statistics calculations use a combination of the Fortran common library statistic module [52] 
and a custom MALTHUS statistics module. This process is fully customisable and can be 
programmed and updated to calculate any extra statistics required in the future. Two statistics 
modules are used to utilize the legacy code within the common library where possible, but to also 
enable easy coding and addition of new calculations where this would not be possible, or it would 
be very time consuming, in the legacy code. Additionally if there are any discrepancies between 
the two modules the output can easily be switched from one module to the other, to enable 
continuous working of the program while concurrently investigating the errors and updating the 
code.  
After the statistics have been calculated they are stored in a temporary location in a “Virtual 
Patient medical record” within the program and the next Virtual Patient is selected for the same 
cancer to start the tree walkthrough. This continues until all of the Virtual Patients for the type of 
cancer selected have completed their walkthroughs of the tree. 
Once all of the Virtual Patients for the type of cancer selected have finished, the program writes 
the Virtual Patient records that were stored temporarily, to separate files on the user’s computer 
if required. The newly created Virtual Patient medical record contains their patient number, age, 
sex, statistics, the trial numbers, fractions given and the number of times each node is visited. 
These are written after all of the tree walkthroughs have been completed due to the extra load 
on the computers system resources required for writing all of the files. Writing them all 
afterwards allows the program to run much more efficiently. 
After the program writes the Virtual Patient medical records for that cancer type, the statistics 
module calculates the overall statistics for the cancer and then writes a cancer summary file 
alongside the Virtual Patient medical records. It also adds some data to another temporary data 
store to enable the writing of a whole PCT summary file at the end. The cancer summary file 
includes: 
 Number of Virtual Patients with that cancer 
 Walkthroughs per Virtual Patient 
 Mean  number of fractions given 
 Standard deviation of the mean number of fractions 
 ARR 
 The number of times each number of fractions are given 
After the completion of the cancer summary file, that is all the calculations and simulations done 
for the selected cancer type and the program moves onto the next cancer. 
After the calculation of all of the selected cancers for the PCT, the program writes a PCT summary 
file. This file is a basic overview of the results from each cancer to save having to go into each 
cancer separately. It includes: 
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 Cancer site, incidences of that cancer and total fractions for that cancer 
 Total fractions within the PCT 
 Fractions per age band 
3.3.5 The .Tom Reader 
Ultimately MALTHUS Pro will be integrated into the Delphi based MALTHUS workbench and for 
that the nicknamed “.Tom” format files have been created. These files are essentially 
configuration files that MALTHUS Pro reads in to prevent there being any user input into 
MALTHUS Pro. This is because Delphi is Graphical User Interface (GUI) based programming 
language and creates a more user friendly front end of the program. However as Delphi is GUI 
based it is a much slower language for computational purposes   
The .Tom files are actually .Txt files with a simple XML like syntax. They contain variable 
information, check values, data and encompassing statements. Figure 3-9 shows an example 
.Tom file. 
<No of PCT = 1 >  
 2 
 <End> 
 <No of Patients = 1 > 
 1 
 <End> 
 <No of Cancers = 1 > 
 10 
 <End> 
Figure 3-9. Example of the XML style .Tom file layout for data transfer between MALTHUS 
workbench and MALTHUS Pro. 
It is a clearly structured format that states what data it is about to present, the number of data 
points expected and when that data section is terminated.  
 
The current data contained is the PCT number, which is easily changeable to a Cancer Network 
number, the population proportion of that PCT and which cancer sites the program is to use.  
Figure 3-10 shows the basic overview and operation of the .Tom file reader 
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Figure 3-10. Operation flowchart of how the .Tom file reader within MALTHUS Pro. 
3.3.6 Coefficient of Variation 
A piece of work to look at the optimal number of walkthroughs of a decision tree commenced 
towards the end of the project. There is not any guidance or previous work completed on this as 
the number of walkthroughs depends on the size, complexity and precision required. It was due 
to this that it was realised a small decision tree of under 10 nodes , for example, would probably 
need many fewer walkthroughs than a decision tree of over 500 nodes. An inadvertent bonus 
factor in MALTHUS was the decision to use bifurcated decision tree, so a single node only has two 
outputs (or zero if it is a terminal node). This helps with the complexity of the trees, or complexity 
of nodes to be precise, as there is not a worry of a whether a formula would apply to a tree where 
some nodes have five, six or seven outputs. Additionally as the nodes within MALTHUS currently 
do not self-adjust this reduces the complexity of the trees again. Due to this, the only factor 
contributing to tree complexity is the number of nodes within the tree. 
All of the factors reducing the complexity of the trees makes any relationship generated to 
estimate the optimal number of walkthroughs not applicable to trees that are more complex. It 
would be a relationship for bifurcated, static decision trees only. Nonetheless, this has the 
opportunity to increase computational efficiency or increase the accuracy of the output of 
MALTHUS.  
To be able to generate a relationship between the number of nodes, incidence numbers and 
accuracy, a common factor in a variety of MALTHUS simulations is required. Standard deviation is 
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the de facto method of measuring the variation in a set of data. However, simply using the 
standard deviation does not give an accurate comparison point between different data sets due 
to the fact the size of the standard deviation relates to the magnitude of the output. In theory, a 
standard deviation of 1,000 could be from a more accurate output of a model than a standard 
deviation of 10, so a reference point is required to quantify the standard deviation. The natural 
figure for this is the mean.  
One ideal relationship between the standard deviation and mean is the coefficient of variation 
(CV).  
 
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑉𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 (𝐶𝑉) =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
 
Equation 3-3 
 
 
The CV is a dimensionless number that enables the comparison of outputs of different models to 
show which lie closer to the actual values. Effectively the different trees with different incidences 
will act as the different models in this situation.  
Every dataset from the full Monte Carlo results has its CV calculated and then compared to see if 
there are any relationships between the CV, the number of nodes and the number of Virtual 
Patients generated. The reason for using the number of Virtual Patients generated is that this 
number is what currently controls the number of walkthroughs, as the program is set to complete 
2,000 trials of 2,000 walkthroughs per Virtual Patient.  
3.4 Program Operating Modes 
Within the program, there are a number of different operating modes covering a number of 
simulation types, testing routines and verification/fixed simulations. There is a brief overview of 
the main operating modes in this subsection, with the results from those modes shown in future 
sections. The different modes are: 
 Random number check 
 Data store test 
 Virtual Patient test – incidence based 
 Virtual Patient test – population based 
 Population test – PCT based 
 Fixed incidence test 
 Node modifier test 
 Sensitivity analysis – Tree 
 Sensitivity analysis – Patient Generator 
 PCT simulation 
 Monte Carlo run 
 Fast Monte Carlo run 
The model verification and the results sections contain the results of the tests, analysis and main 
runs. 
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3.4.1 Virtual Patient and Population Generator Tests 
The population generator test simply uses the population generator acceptance/rejection test to 
generate a population cohort separated by age and export it in .txt file format to allow 
comparison with the actual age distribution of the selected PCT for verification. This gives 
increased confidence in the model’s ability to produce accurate, representative population 
cohorts. 
The two Virtual Patient tests combine the population generator and the incidence generator. One 
test calculates the number of population required to hit a specified number of incidences, the 
other calculates the number of incidences within a specified population. The latter is used for 
verification purposes to show that the program is generating the correct number of incidences 
within the PCTs. 
3.4.2 Fixed Incidence Test 
The fixed incidence test tests the actual tree walkthrough, without the population and incidence 
generator. This enables verification of the tree walkthrough procedures by being able to compare 
the results it outputs to expected results generated by MALTHUS Workbench. 
The program generates a single generic patient for each cancer, sex dependant cancers have the 
correct sex patient so that they will not be accidentally missed. The program automatically 
adjusts for a single patient. The patients complete their walkthroughs in their respective clinical 
decision trees to generate a number of fractions that to allow checking and validation. 
The fixed incidence test adds in another level of confidence to the model as it allows the users to 
see that it correctly calculates the number of fractions, thus giving confidence when using custom 
decision trees. 
3.4.3 Node Modifier Test 
One of the main reasons for writing custom tree software was to enable reactive nodes, nodes 
that change its own properties depending on the Virtual Patient that hits the node. Currently the 
main clinical decision trees do not require that property, however this was included anyway in 
mind of future expansion. 
The node modifier works by the program detecting a certain parameter of the Virtual Patient that 
has entered a node and changing a parameter of the node depending on the detected parameter 
of the Virtual Patient. 
The node can react to can be any of the Virtual Patient’s parameters. For example, a node could 
adjust any of its parameters if the Virtual Patient is over, or under a certain age, or depending on 
the sex of the Virtual Patient. For example the node could adjust the number of fractions given 
could change or the decision probability. 
To demonstrate this capability of the program a simple trial was set up for the Leukaemia 
decision tree. The selection of this tree was because it only has a single decision node, selecting 
between radiotherapy treatment and no radiotherapy treatment. 
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Modification of the decision tree file created an enhanced decision tree file, containing more 
information than a standard one. The information is stored under a simple number indicator and 
parameter information. For example in a specific column a 1 instead of a 0 would represent an 
age trigger parameter, the next number being a 70 specifies that Virtual Patient of age 70 or 
above would get the decision probability adjusted. The third parameter was set to 0.5 indicating 
that if the Virtual Patient is 70 or above they would have a 50% chance of receiving radiotherapy 
as opposed to the original 5% decision probability. If there are no modifications required then 
everything to do with the node modifier parameters are set to 0. The extra information in this 
example is: 
 What “trigger parameter” the node has to look out for 
 The age that the node modifier will trigger at 
 The new decision percentage if the node modifier is triggered 
For the capability test the simple modifier of if the age of the Virtual Patient age is above 70 then 
probability of radiotherapy is changed from 5% to 50%. In the Leukaemia decision tree, this 
should be easy to verify by taking a patient older than 70 and one younger than 70 and looking at 
the number of times they receive radiotherapy over 2000 trials. The modification code looks for 
the modification parameters in the enhanced node and if the trigger parameter is detected it 
looks at the Virtual Patient for the relevant information. If the result is positive, in this example if 
the Virtual Patient is 70 or older, then it checks what the new decision percentage should be. 
Figure 3-11 shows and example of this process.  
While in the example, it only works on the Virtual Patient age this can be fully expanded to work 
on any parameter and for any probability. For example, it could look to see if the Virtual Patient is 
specifically male and over the age of 75 and then it might change the decision probability to 90%. 
It also does not have to be the decision percentage that is the changing factor, the number of 
fractions could also be adjusted. 
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Figure 3-11. Example of how the self adjusting nodes operate. 
3.4.4 Sensitivity Analysis 
Due to the nature of this model and the numerous different data inputs and decisions throughout 
the simulations, it was imperative that a sensitivity analysis was included within the program. A 
sensitivity analysis looks at what causes the uncertainty of an answer. In addition, it allows the 
identification of areas with the greatest influence on the output. There are a couple of types of 
sensitivity analysis that are applicable to the model, a one way sensitivity analysis and a multiway 
sensitivity analysis. 
A one way sensitivity analysis works by changing a single parameter of the model (a single 
decision node for example) by a certain amount and then the change in the outcome is recorded 
[53]. This will show the overall effect on the outcome a single point has. For the project, this will 
show the areas of the trees that require the most robust input data and areas that do not need 
such high level data and if there are any age bands that would significantly affect number of 
fractions required within an area. 
A multiway sensitivity analysis adjusts more than one parameter at the same time, showing how 
a number of changes would affect the output [25]. With the current clinical decision trees, a 
multiway sensitivity analysis is not required, but there are definitely situations where a multiway 
sensitivity analysis would be important to undertake. A multiway sensitivity analysis would be 
important if there were multiple sources of conflicting information for a single, or multiple, 
clinical decisions, to show the combined effect of the multiple sources over the entire clinical 
decision tree. In this situation, the multiway sensitivity analysis would work by changing the 
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node/s with multiple sources to one of the sources’ value and then changing the rest of the nodes 
within the clinical decision tree, one by one. The repetition of this process happens by changing 
the node/s with multiple sources to the other input values and changing the rest of the nodes 
again. A best case/worst case scenario could be generated from the range of results of which is 
outputted. 
Another situation that could require a multiway sensitivity analysis in the program is to see how 
sensitive the model is to change in treatment consensus or method. If a new treatment comes 
into play that affects a number of different nodes at once then the simultaneous adjustment of all 
relevant nodes would occur to see the variation of the output. 
A best case/worst case scenario could also be generated if there is a couple of treatment options 
throughout the tree based on the same clinical decision or same reasoning for a given number of 
fractions prescribed. A multiway analysis would go through and look at the outcomes if all areas 
prescribe the maximum number of fractions, or the minimum number and the overall changes in 
the outcomes recorded.  
As the clinical decision trees do not have multiple sources for a single decision and due to the 
number of variables within the model, 2015 variables from the decision trees and 
population/incidence data, a multiway sensitivity analysis was not undertaken as it would require 
a large amount of computational time. Only a one way sensitivity analysis was completed on the 
trees, patient generator and incidence numbers. 
3.4.4.1 Tree Sensitivity Analysis  
The program contains the capability for the tree sensitivity analysis to enable the completion of a 
sensitivity analysis on any tree within the program. It will also work on any new tree or user 
customised tree that is input into the program. This involved modifying both the tree 
walkthrough procedure and the results gathering procedure  
As the required results are only based on the tree then patient generator section of the program 
is not used, instead the program uses a single random patient, as the trees are currently not 
reactive to the Virtual Patient.  
To make the sensitivity analysis results reproducible the random number generator is set to start 
from a specific point every time a simulation starts.  It does this to keep the base case the same 
every time, thus enabling the output to show exactly the effect changing the node has compared 
to the base case answer. If the program selects the random number generator seed the way it 
normally is then the variations in the answer could be due to different paths walked and not due 
to modifying a node.  
The number of walkthroughs each trial completes also had to be decided. While the number of 
walkthroughs should depend on the complexity of the tree, the complexities of the trees change 
tree by tree (some trees have three nodes going up to the Head and Neck tree with 530 nodes). 
The higher the number of walkthroughs the more accurate the results would be. However, it is 
not practical to allow the simulations to keep running for a very high number of walkthroughs. 
The selection of 1 million walkthroughs was to make sure that the number of walkthroughs would 
not be a contributing factor to any anomalies in the results, especially in the larger trees, after the 
identification of some minor variations in trials with 100,000 walkthroughs. 
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Every single node in all of the tree diagrams (with a decision probability attached to it, i.e. not the 
root nodes) had their decision probability adjusted by +/- 10, 5 and 1%. The results were 
outputted into a .txt file and excel was used to display the results and to generate tornado 
diagrams. The results are also presented in % fraction change per % decision change. This was 
achieved by simply dividing the percentage that the number of fractions changed by (adjusted 
number of fractions / base case number of fractions), by the amount the decision was changed 
by. This gives the percentage that the fractions change with a 1% decision change, by 1% decision 
change this means a decision going from 50% to 51% or 49%, not 50% to 50.5% or 49.5%. 
3.4.4.2 Patient Generator Sensitivity Analysis 
The patient generator sensitivity analysis is a much simpler sensitivity analysis compared to the 
tree version. The separation of the patient generator from the tree walkthrough is possible and 
the data manipulated outside of the Fortran program by using Microsoft Excel. The output of the 
change in incidence can then have the standard fraction burden applied to get the total change in 
fraction burden within that PCT. 
The sensitivity analysis has to examine both data sources: the population figures and the 
incidence figures.  
There are two main ways to look at these, firstly completing a sensitivity analysis on the 
population figures while keeping the rate of incidence the same, and secondly completing a 
sensitivity analysis on the incidence and ignoring the population figures.  
In theory, completing a sensitivity analysis on the population figures while keeping the rate of 
incidence the same is actually the same as just adjusting the incidence figures. For example, 10% 
incidence rate in 100 people equals 10 incidences, increase the population by 10% give you 110 
people, which with the incidence rate of 10% gives you 11 incidences. If you increase the original 
10 incidences by 10%, you get 11 incidences without having to change the population number.  
However if you let the rate of cancer incidences change with the population numbers then the 
simulation will come out with twice the effect that was required, for example a 10% increase in 
population and 10% increase in incidence rate would actually yield a 21% change in output 
instead of the desired 10% change.    
Therefore, the sensitivity analysis on the patient generator will only be undertaken on the 
incidence figures and will increase or decrease them directly and see what the overall outcome is. 
This will cover both the population and then incidence figures in one as the derivation of the 
output could be from changes in population or changes in incidence rate.  
By using Excel, a number of tables were generated using the four example PCTs and going 
through incidence age band by age band, increasing and decreasing the figure by 10%. The total 
number of incidences, with an increase or decrease of an age band, was calculated and then 
presented as a percentage of the base case to show the overall difference within that cancer 
group. 
3.4.5 PCT Simulation 
The PCT simulation mode works using the patient generator, incidence generator, tree 
walkthrough and data analysis sections of the program. It is the main basic operating mode of the 
program that completes a single full simulation on any number of PCTs and cancers required. 
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However as it only does a single simulation on the PCT/cancer site, it is not as accurate as a full 
Monte Carlo run.  
Please see section 3.3.3, 3.3.3.2 and 3.3.4 for the methodology and the resulting output. 
3.4.6 Full Monte Carlo  
The basis of the full Monte Carlo method section of the program is around an expansion of the 
PCT Simulation. It re-runs the PCT simulation a given number of times and takes averages of the 
results, giving a more accurate answer. Thus, the methodology for the full Monte Carlo is the 
same as the PCT Simulation (section 3.4.5), but the process repeats a number of times and the 
results are aggregated. It is classed as a Monte Carlo method as it uses sampling from a uniform 
distribution (the random number generator) to approximate the solution to the decision tree. 
It makes the answer more accurate in two ways, firstly there are many more walkthroughs of the 
trees, so the average number of fractions given will be much more accurate as the distribution of 
answer should be tighter around the mean. However, the main effect is the multiple iterations of 
the patient generator that gives the higher accuracy of incidence numbers. This is especially true 
of the smaller PCTs and the rare cancer types.  
Figure 3-12 shows the two sections that are Monte Carlo integrations.  
The coding of the full Monte Carlo simulation is only slightly different to the normal walkthrough 
and data analysis. The difference is to allow the completion of the simulations efficiently and 
avoid the need to write out to a file after every simulation as it does for the PCT simulation mode. 
Currently it outputs: 
 Number of Virtual Patients for that cancer site within the PCT 
 Mean number of fractions for that cancer site 
 The ARR 
 Total number of fractions for that cancer site within the PCT 
These are stored in arrays and then after the completion of that cancer site within the PCT the 
data analysis section completes the normal calculations on the output and writes the results to a 
text file (please see Appendix 1 for example output file of the Monte Carlo Methods simulation 
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Figure 3-12. Operation flow chart showing the Monte Carlo sections within MALTHUS Pro. 
3.4.7 Fast Monte Carlo 
The creation of the fast Monte Carlo was to exploit the fact that currently the clinical decision 
trees do not contain reactive nodes, where a node automatically adjusts one of its parameters 
based on information within a Virtual Patient. Thus, the trees are effectively blind to any Virtual 
Patient parameters meaning that it only needs a single ‘generic’ Virtual Patient to run the 
simulation and then the results from that single patient is applied to the number of incidences 
taken directly from the incidence data provided by the NCIN. The application of the results can 
also extends to any form of population and incidence prediction. It operates the same as the PCT 
simulation (section 3.4.5) with the exception of that it only generates a single, sex valid, Virtual 
Patient. Due to the usage of only a single Virtual Patient, the number of walkthroughs has been 
increased.  
This makes this mode of operation faster than the full Monte Carlo as it takes out the need to run 
the patient generator every time. For example, the full Monte Carlo completed for breast cancer 
in Surrey takes around 12 hours, whereas the fast Monte Carlo takes approximately 33 seconds 
on the same computer. Additionally after the completion of the fast Monte Carlo on all of the 
difference cancers, another run is not necessary until the clinical decision trees change.   
3.5 Summary 
In this chapter, the inner workings of MALTHUS program have been explained in order to better 
understand the results of the program and how they were generated. The description of the 
operating modes was to show the range of analyses that MALTHUS can perform. 
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To verify that MALTHUS works correctly some verification tests were completed on certain 
sections of the program and the results are presented in the next chapter.  
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4 Model Verification 
This section presents the results of the model verification tests to demonstrate that the program 
operates correctly and that the results it outputs can be trusted. To say that the whole program 
works correctly only requires the verification of a few sections: the Virtual Patient generator, the 
tree walkthrough and its results and the node modifier. Everything that MALTHUS does is a 
combination of these things. 
For the verification purposes a few example PCTs are used: Newcastle, Hartlepool, Surrey and 
Cornwall. The four PCTs have different population sizes (and hence difference numbers of 
incidences) from the smallest PCT in England, Hartlepool with a population of 90,752, to the 
second largest, Surrey with a population of 1,089,562. Newcastle and Cornwall are in between 
with populations of approximately 280,000 and 531,000 respectively.  
4.1 Population and Virtual Patient Generator 
4.1.1 Population Generator 
To demonstrate that the method explained in section 3.3.3.1 works correctly, the test, explained 
in section 3.4.1, of running the population generator and outputting the results straight to .txt file 
for import in excel was undertaken. The example PCTs were used for a single run through. 
PCT 
Actual 
Population 
Population 
Produced Accuracy 
Hartlepool 90751.33 90752 99.47% 
Newcastle 279232 279232 99.27% 
Cornwall 531118 531118 99.32% 
Surrey 1089562 1089562 99.27% 
 
Table 4-1. Results from and accuracy of the patient generator for Hartlepool, Newcastle, 
Cornwall and Surrey. 
 
Table 4-1 shows the results from the tests. Accuracy is the accuracy of the population being in the 
correct age band, taken from population produced for an age band divided by the actual 
population in the age band. The usage of accuracy in this situation, instead of uncertainty, is 
because the inputs to the population generator are known values. If the population generator 
operated by a set of algorithms that attempted to generate PCT populations without initially 
knowing the number of persons in each age band, then uncertainty calculations would be essential. 
However, the patient generator is merely attempting to replicate the known data into Virtual 
Patient form, from ONS values that the program reads in and so accuracy is the appropriate 
method of validation. 
As previously mentioned the population data averaged over 3 years. This would explain why for 
Hartlepool the actual population quotes 1/3 of a person.  
Chart 4-1 shows the actual results generated for Surrey PCT in chart form. The generated 
population is visibly close to the actual population, backing up the 99.27% accuracy. The standard 
deviation of the accuracy is 2.54% again showing that the accuracy is close to the mean. 
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Chart 4-1. Population generator results for Surrey PCT showing the generated results against 
the actual figures. 
4.1.2 Virtual Patient Generator 
This verification test uses the example PCTs along with three selected cancers. Breast, Cervix and 
Colon cancer offer a large, small and medium amount of incidences as well as giving single sex 
and mixed sex cancer sites. 
The tests were run 1000 times and an average taken. This is because the patient generator works 
on very small percentages, the percentage likely hood of getting a specific cancer within a specific 
PCT within a specific age band for a specific sex. Therefore, 1000 runs proved to be adequate and 
are lower than the standard Monte Carlo number of runs. The lower number also saves on 
computational time. Furthermore, with any probabilistic model such as this, the higher the 
number of runs performed, the more accurate the results become. Therefore, the attainment of 
an acceptable accuracy in only 1000 runs when it comes to a full Monte Carlo methods simulation 
it should provide an even tighter accuracy. 
 
Table 4-2 presents the results of the test. The average accuracy over the 12 tests is 99.6%. 
  % of incidence generated 
PCT Breast Cervix Colon 
Hartlepool 100 100 99.08 
Newcastle 99.5 96.9 100.2 
Cornwall 99.9 100.4 99.2 
Surrey 99.6 100.8 99.6 
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Table 4-2. Virtual patient generator test results showing the percentage of actual incidences 
generated by MALTHUS Pro.  
In percentage terms, the worst result was for cervical cancer in Newcastle with only a 96.9% 
accuracy. However, this translates into missing only 0.4 Virtual Patients (generating 12.6 instead 
of 13). This error is small and so it is clinically acceptable.  
In terms of actual number of Virtual Patients, the worst result was breast cancer in Surrey. The 
0.4% it missed accounts for 4.2 Virtual Patients.  
4.2 Tree Walkthrough 
A fixed incidence test, explained in section 3.4.2, offers verification to the tree walkthrough 
procedures.  
Because the trees are not dependent on the selected population this verification test only 
requires a single PCT, in this instance the random choice was Newcastle PCT. The same three 
cancers used in the previous example, breast, cervix and colon, are used again for the same 
reason, to give a spread of the number of incidences. 
To make sure that the same number of incidences were used in MALTHUS Pro and Workbench 
the incidences were manually entered into a separate file, which the program reads in directly 
when it is running the Fixed Incidence test.  
For this verification test, the number of walkthroughs for each patient was set to 100,000. The 
reasoning for this is that the more walkthroughs that are completed, the more accurate the 
answer will be. A simple assessment was performed to evaluate the variation in the results with 
an increasing number of walkthroughs and at 100,000 walkthroughs, the results settled down. 
This directly connects to the complexity of the trees and so the 100,000 was determined on the 
breast cancer decision tree as it was the most complex in this verification test. Please see 
Appendix 1 for more information on this.  
Table 4-3 presents the results from the verification test. 
  
Workbench Pro 
Fractions Per VP Fractions Per VP 
Breast 2778 14.39378 2776 14.38342 
Cervix 147 11.30769 149 11.46154 
Colon 69 0.496403 69 0.496403 
 
Table 4-3. Comparison of fractions from MALTHUS Pro against MALTHUS workbench for breast, 
cervix and colon cancer for verification of the tree walkthrough procedures. 
Between MALTHUS Pro and workbench there are only very minor differences of predicted 
fraction burden 0.07% for breast, 1.36% for cervix and 0% for colon. These minor differences 
could be down to simple things like how the random number generator works differently in each 
program, or how the bifurcation process generates more nodes for the tree. Either way on the 
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overall scale of the answer the differences of 2 or 0 fractions is minor and is acceptable at this 
stage. 
4.3 Node Modifier 
For the node modifier test a very simple tree was modified to provide a clear outcome to prove 
that the self-adjusting nodes work correctly. 
The tree used was Leukaemia because this only contains a single clinical decision, namely 
radiotherapy indications or no radiotherapy indications. The modifications made meant that if a 
Virtual Patient with an age of 70 or above traversed the tree then the node would adjust its 
decision percentage from a 5% chance of receiving radiotherapy to 50% chance of receiving 
radiotherapy. Section 3.4.3 explains the methodology in detail. 
If this operated correctly then in the Virtual Patient records one would expect to see patients 
aged 70 or above with approximately 50% of the runs receive radiotherapy and under the age of 
70 only receiving radiotherapy approximately 5% of the runs. 
  
Runs Receiving 
RT 
Runs Not 
Receiving RT RT % 
Age 61 93 1907 4.7 
Age 74 981 1019 49.1 
 
Table 4-4 Self adjusting node verification test results demonstrating the difference with the self 
adjusting nodes activated or deactivated. 
The results in Table 4-4 prove that the self adjusting node was behaving correctly. While the 
results are slightly off it must be noted that this was done over a single simulation and when a full 
Monte Carlo simulation is undertaken the percentage prediction will become more accurate with 
the increased number of runs. 
While this is only a very simple proof of concept it has the ability to expand and take into account 
any/multiple parameters that the model uses on as many or few nodes required. 
4.4 Summary 
All of the verification tests came out with positive results showing that MALTHUS is able to 
generate correct cohorts of patients, walk them through the tree and get out viable results. With 
the verification complete, it adds validation to the general results the program outputs as it 
verifies that the core components work correctly. The next chapter presents the results 
generated from the sensitivity analysis and Monte Carlo runs. 
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5 Results 
This chapter presents the results from the sensitivity analysis, Monte Carlo runs and the fast 
Monte Carlo. The sensitivity analysis results will be from both the patient generator and the 
clinical decision trees, with the clinical decision trees sensitivity analysis operating from a fixed 
random number generator seed to enable reproducibility and so that any sensitivities discovered 
are purely due to node changes and not random number differences. The Full Monte Carlo runs 
will be completed on only four PCTs to show a spread of four different sized PCTs. The fast Monte 
Carlo only uses a single patient as the nodes in the clinical decision trees are not reactive to any 
patient factors, and the results applied to incidence data for all PCTs and CNs.  
The majority of the results will be on the attached CD (Appendix 1) due to the size and volume. 
Summary tables have been created where appropriate and are either in this section or in the 
printed appendix. The results here will show what the program and related analysis techniques 
can produce. The basis of the results in this section is the pragmatic trees, which covers every 
node in the decision trees. 
 
5.1 Sensitivity analysis 
The next two sub-sections present a selection of the two sensitivity analyses undertaken. The 
complete patient generator sensitivity analysis consists of 184 separate charts and so only four 
are presented. Equally, with the decision tree sensitivity analysis every single node in all 23 trees 
was adjusted two ways, three times and so the results tables are very large, as are the overall 
summary tables. Therefore the majority of the results for the sensitivity analysis will be on the 
attached CD (Appendix 1) with only examples and summary tables shown here.  
5.1.1 Patient Generator Sensitivity Analysis 
As mentioned before, the one-way patient generator sensitivity analysis is performed externally 
to the Fortran program, in Microsoft Excel, using macro programming and the core incidence 
files. The sensitivity analysis has been set up so it can be completed on any PCT/CN for all cancer 
sites. The sensitivity is done via a +/- 10% adjustment on each age band and then the 
increased/decreased incidence added in to the total cancer site incidence to see the overall 
change. These overall changes can be added up to give results for bigger groups, for example the 
over 75's is often used to show the elderly patient cohort In MALTHUS this would consist of the 
three age bands of 75-79, 80-84 and 85+ but simply added up and with no further simulation 
gives the answer for over 75's. 
The sensitivity analysis was completed on the four example PCTs. Only the female breast results 
from the four PCTs are shown here. The choice of breast cancer is because it is one of the most 
prevalent cancers, and as mentioned previously the four example PCTs give a range of population 
sizes from across the country. The rest are located in Appendix 1. 
As the input is simply the raw incidence data, the outputs, shown in Chart 5-1 - Chart 5-4, follow 
the pattern of the inputs with the largest increases in incidences coming from the age bands with 
the most incidences to start with. The largest increase over female breast cancer from the four 
PCTs is age 60-64 in Cornwall with a 10% increase in the age band giving a 1.59% increase in 
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incidence. As expected, the charts show a linear response to the changes to the input and this is 
the case through all of the patient generator sensitivity analysis results on the CD. 
The four charts are different, showing the difference in age profiles and incidence profiles within 
each PCT, reinforcing the need for regional or tailored planning and not just a central average 
English model. 
 
Chart 5-1. +/-10 % patient generator sensitivity analysis results for Hartlepool female breast 
cancer incidence separated, by age band. 
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Chart 5-2. +/-10 % patient generator sensitivity analysis results for Surrey female breast cancer 
incidence separated, by age band. 
 
Chart 5-3 +/-10 % patient generator sensitivity analysis results for Newcastle female breast 
cancer incidence, separated by age band. 
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Chart 5-4. +/-10 % patient generator sensitivity analysis results for Cornwall female breast 
cancer incidence, separated by age band. 
5.1.2 Decision Tree Sensitivity Analysis 
The one-way tree sensitivity analysis was completed on every cancer site with a single, sex 
appropriate, Virtual Patient walked through the clinical decision tree 1,000,000 times. 
Individually, every node had an adjustment of +/- 1%, 5% and 10% applied to it. 
From the data the actual sensitivity of each node was calculated by using the +/-10% results. The 
amount the output (average fractions per person) changed by is divided by the actual change in 
decision to give change in fractions per person per 1% decision increase/decrease (note this is not 
decision change it is 1% increase/decrease so a 50% decision would go to 51% or 49% not 50.5% 
or 49.5%). Please refer to section 3.4.4.1 for the full methodology. 
The creation of a summary table for the decision tree sensitivity analysis is due to there being 
1987 nodes (excluding the root node of each tree) in total. The summary table contains the five 
most sensitive nodes for each cancer site. It also contains data on how much each cancer site 
contributes to the overall cancer fraction burden so the percentage change in number of fractions 
for a given site can be applied to the overall figure for every site. This allows for an overall 
comparison as a 20% change in the number of fractions of a cancer that is associated with a low 
radiotherapy burden will not change the overall number of fractions as much as a 5% change in a 
cancer that utilises more radiotherapy. 
For the results, tornado diagrams have been produced for every cancer site, these have been 
limited to the most sensitive 40 nodes if there are a greater number of nodes in a tree, to keep 
the size of the tornado diagrams to a readable level. Table 5-1 to Table 5-8 presents the summary 
tables of the five most sensitive nodes within the tree. The core sensitivity analysis data is 
available in the Appendix 1.  
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The summary tables contain a number of pieces of information. The table is broken down into the 
cancer site with only the most sensitive nodes shown.  The node number is the node identifier in 
the Fortran code and this is paired up with the node description and sibling node description to 
enable identification of the actual decision without having to look it up in MALTHUS Workbench. 
The percentage change of fractions given is the percentage change per 1% increase or decrease 
of the decision percentage (50% decision changes to 51% or 49%). The percentage cancer group 
contributes to the overall fraction burden is calculated from the core incidence files so it is the 
most accurate ratio to use in MALTHUS. The percentage overall change of number of fractions is 
the percentage change of fractions multiplied by the percentage cancer group contribution. 
Linearity has also been included to show where the clinical decision trees do not change 
proportionally with an equal positive and negative sensitivity test. A linearity of zero shows a 
balanced model around the decision in question. The greater the value of linearity the greater the 
unbalance is in the change in output. 
The last two columns show the overall sensitivity that the decision nodes has on the whole model 
and not just the cancer site it lies within. The 10 largest increases and 10 largest decreases in the 
percentage overall change have been highlighted to show what has the greatest influence over 
the whole model.  
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Table 5-1. Tree sensitivity analysis summary results for bladder, breast and cervix cancer, showing the most sensitive nodes and the effect they have on 
both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red highlighting 
indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions per 
% decrease 
Bladder 33 
s2 - good PS - Cystectomy 
and neoadjuvant 
chemotherapy ChemoRad - pat pref -1.27 1.26 75 0.004 1.37 -0.017 0.017 
  39 
s2 - good PS - ChemoRad  
pat pref 
Cystectomy and 
neoadjuvant 
chemotherapy 1.25 -1.27 25 0.008 1.37 0.017 -0.017 
  2 Stage 1  S2/3/4 -1.15 1.14 43 0.004 1.37 -0.016 0.016 
  124 NN (Stage 2/3/4) S1 1.15 -1.14 57 0.004 1.37 0.016 -0.016 
  34 
S2 - Good PS - Cyst & 
enoadjuvant chemo - No 
Adjuvant RT Aduvant RT -0.87 0.91 98 0.022 1.37 -0.012 0.012 
Breast 10 S1 - Mast BCS -0.37 0.37 23 0.000 28.78 -0.106 0.106 
  30 S1 - BCS Mast 0.37 -0.37 77 0.000 28.78 0.106 -0.106 
  67 s2 - BCS  Mast 0.34 -0.34 53 0.000 28.78 0.098 -0.098 
  49 s2 - Mastectomy  BCS -0.34 0.34 47 0.000 28.78 -0.098 0.098 
  3 DCIS - Mast BCS -0.17 0.17 31 0.000 28.78 -0.049 0.049 
Cervix 2 FIGO I  FIGOII/III/IV -1.19 1.19 63 0.000 1.46 -0.017 0.017 
  69 NN (FIGO III/IV) FIGO II 1.19 -1.20 37 0.004 1.46 0.017 -0.018 
  11 Figo I - IB - IBI[T1b1] IB2[T1b2] -0.60 0.60 60 0.000 1.46 -0.009 0.009 
  16 Figo I - IB - IB2[T1b2] IBI[T1b1] 0.60 -0.60 40 0.000 1.46 0.009 -0.009 
  3 Figo I - Figo IA Figo - IB -0.57 0.57 43 0.000 1.46 -0.008 0.008 
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Table 5-2. Tree sensitivity analysis summary results for CNS, colon and endometrium cancer, showing the most sensitive nodes and the effect they have 
on both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red 
highlighting indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions per 
% decrease 
CNS 41 
NN(Meningioma - Grade 
1 Simp 4/Grade 2/ Grade 
3) G1 Simp2 or 3 resec  1.13 -1.13 25 0.000 2.05 0.023 -0.023 
  19 
Menig - G1 Simp2 or 3 
resec  
Grade 1 simp 4 / 
grade 2 / grade 3 -1.13 1.14 75 0.004 2.05 -0.023 0.023 
  38 
NN(Meningioma or 
Vestibular scwannoma) Low Grade Glioma -1.06 1.08 89 0.009 2.05 -0.022 0.022 
  8 
Low Grade Glioma and 
other low grade tumours 
NN(Meningioma or 
Vestibular 
scwannoma) 1.07 -1.06 11 0.005 2.05 0.022 -0.022 
  37 
NN(Low Grade Glioma, 
Meningioma, Vestibular 
schwannoma) 
High Grade Glioma & 
other high grade 
tumours -0.73 0.75 71 0.014 2.05 -0.015 0.015 
Colon 3 No RT Palliative RT -19.00 19.97 95 0.025 0.53 -0.101 0.106 
  2 Palliative RT No RT 19.89 -20.07 5 0.005 0.53 0.105 -0.106 
Endometrium 4 
s1-surgery-low/int risk, 
no EBRT or VB only  high risk -2.33 2.34 75 0.002 2.06 -0.048 0.048 
  5 s1-surgery-high risk 
low/int risk, no EBRT 
or VB only 2.33 -2.33 25 0.000 2.06 0.048 -0.048 
  9 S1 - Medically inoperable Surgery 1.91 -1.88 5 0.008 2.06 0.039 -0.039 
  3 S1 -Surgery Medically Inoperable -1.81 1.88 95 0.019 2.06 -0.037 0.039 
  44 NN(S2/3/4) S1 0.38 -0.40 23 0.026 2.06 0.008 -0.008 
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Table 5-3. Tree sensitivity analysis summary results for head and neck cancer, showing the most sensitive nodes and the effect they have on both the 
average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red highlighting indicates 
a top 10 most sensitive node. 
Site Node No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
H&N 73 
Oropharynx/Unknown Primary 
HNC - Stage IVC Stage III-IVB -0.27 0.28 4 0.018 8.77 -0.024 0.025 
  33 
Oropharynx/Unknown Primary 
HNC - Stage III-IVB Stage IVC 0.27 -0.28 96 0.018 8.77 0.024 -0.025 
  66 
Oropharynx/unknown primary 
hnc - Stage III/IVB - Not Fit for 
curative therapy 
Fit for 
curative 
therapy -0.26 0.26 5 0.000 8.77 -0.023 0.023 
  59 
Oropharynx/Unknown primary 
HNC - Stage III-IVB - Fit for 
curative therapy - Disease 
unsuitable for curative therapy 
Disease 
suitable for 
curative 
therapy -0.26 0.25 5 0.020 8.77 -0.023 0.022 
  34 
Oropharynx/unknown primary 
hnc - Stage III/IVB - Fit for 
curative therapy Not fit 0.25 -0.25 95 0.000 8.77 0.022 -0.022 
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Table 5-4. Tree sensitivity analysis summary results for HL, leukaemia, lung and melanoma cancer, showing the most sensitive nodes and the effect they 
have on both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red 
highlighting indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
HL 37 Not fit for aggressive therapy 
Fit for agg 
therap -0.70 0.69 5 0.007 0.56 -0.004 0.004 
  2 Fit for aggressive therapy 
not fit for agg 
therap 0.64 -0.67 95 0.023 0.56 0.004 -0.004 
  24 fit - stage 3 and 4 stage 1 and 2 -0.77 0.76 50 0.007 0.56 -0.004 0.004 
  3 fit - stage 1 and 2 stage 3 and 4 0.76 -0.77 50 0.007 0.56 0.004 -0.004 
  30 
Fir for aggressive therapy - S III & 
IV and SI & II with B symptoma - 
ABVD 6-8 cycles 
Escalated 
BEACOPP 6-8 
cycles 0.53 -0.53 50 0.000 0.56 0.003 -0.003 
Kidney 3 No RT Palliative RT -10.00 10.00 90 0.000 0.23 -0.023 0.023 
  2 Palliative RT No RT 10.04 -9.97 10 0.003 0.23 0.023 -0.023 
Leukaemia 3 No RT RT -19.00 19.97 95 0.025 0.08 -0.015 0.016 
  2 RT No RT 19.89 -20.07 5 0.005 0.08 0.016 -0.016 
Lung 65 NSCLC - Stage 3a NN(S3b/4) 1.28 -1.31 13 0.012 13.3 0.170 -0.174 
  157 NN (NSCLC -Stage 3b or 4) Stage 3a -1.31 1.27 87 0.016 13.3 -0.174 0.169 
  87 NSCLC - Stage 3b Stage 4 0.98 -1.01 28 0.015 13.3 0.130 -0.134 
  98 NSCLC - Stage 4 Stage 3b -1.00 0.98 72 0.010 13.3 -0.133 0.130 
  88 NSCLC Stage 3b - Good PS Poor PS 0.59 -0.60 0.5 0.008 13.3 0.078 -0.080 
Melanoma 3 S1 - Surgery 
Medically 
Inoperable -7.03 7.11 99 0.006 1.25 -0.088 0.089 
  4 S1 Medically Inoperable Surgery 7.01 -7.11 1 0.007 1.25 0.088 -0.089 
  2 Stage I Stage II/III/IV -2.71 2.71 67 0.000 1.25 -0.034 0.034 
  31 Stage II/III/IV Stage I 2.70 -2.71 33 0.002 1.25 0.034 -0.034 
  8 Stage II Stage III/IV -2.01 2.00 61 0.002 1.25 -0.025 0.025 
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Table 5-5. Tree sensitivity analysis summary results for myeloma, NHL and oesophagus cancer, showing the most sensitive nodes and the effect they 
have on both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red 
highlighting indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
Myeloma 3 No RT 
Symptomatic bone 
disease -3.99 4.01 75 0.002 0.13 -0.005 0.005 
  2 Symptomatic bone disease No RT 4.01 -3.99 25 0.002 0.13 0.005 -0.005 
NHL 4 
Follicular B Cells & other 
low grade - Stage 3/4 S1/2 -1.44 1.44 80 0.000 1.64 -0.024 0.024 
  3 
Follicular B Cells & other 
low grade - Stage I/II RT S III/IV 1.43 -1.43 20 0.000 1.64 0.023 -0.023 
  20 
Diffuse & Large B Cell - 
Stage 3/4 R-CHOP - PET 
positive at completion 
End of treatment PET 
negative - No RT 1.37 -1.37 20 0.000 1.64 0.022 -0.022 
  18 
Diffuse & Large B Cell - 
Stage 3/4 R-CHOP S1/2 -1.36 1.36 80 0.000 1.64 -0.022 0.022 
  15 
Diffuse & Large B Cell - 
Stage I/II R-CHOP S III/IV R-CHOP 1.35 -1.36 20 0.004 1.64 0.022 -0.022 
Oesophagus 41 
Stage III - Suitable for 
radical treatment - Chemo 
and Surgery chemoradiotherapy -1.31 1.30 75 0.004 1.45 -0.019 0.019 
  36 
Stage III - Suitable for 
radical treatment - 
Chemoradiotherapy Chemo and surgery 1.29 -1.32 25 0.011 1.45 0.019 -0.019 
  62 NN (S3/4) S2 -1.23 1.21 79 0.008 1.45 -0.018 0.018 
  12 Stage II NN(SIII/IV) 1.21 -1.22 21 0.004 1.45 0.018 -0.018 
  15 
Stage II - Surgery - Adjuvant 
RT No aduvant RT 0.82 -0.83 35 0.006 1.45 0.012 -0.012 
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Table 5-6. Tree sensitivity analysis summary results others, ovarian, pancreas and prostate cancer, showing the most sensitive nodes and the effect they 
have on both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red 
highlighting indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
Others 3 No RT RT -4.99 5.01 80 0.002 2.74 -0.137 0.137 
  2 RT No RT 4.98 -5.03 20 0.005 2.74 0.136 -0.138 
Ovarian 3 No RT RT -15.67 16.65 94 0.030 0.12 -0.019 0.020 
  2 RT No RT 16.54 -16.66 6 0.004 0.12 0.020 -0.020 
Pancreas 43 
Stage III unresectable - 
NN(Palliative RT/Stenting) Chemo-RT -2.08 2.10 80 0.005 0.82 -0.017 0.017 
  23 Stage III - Chemo_RT 
NN(Palliative 
RT/Stenting) 2.10 -2.09 20 0.002 0.82 0.017 -0.017 
  20 
Stage II - Non-resectable - Chemo-
RT 
Stenting/BSC no 
RT 1.67 -1.68 20 0.003 0.82 0.014 -0.014 
  21 
Stage II - Non-resectable -
Stenting/BSC no RT Chemo_RT -1.67 1.68 80 0.003 0.82 -0.014 0.014 
  29 Stage IV Stage III -1.50 1.51 0.71 0.003 0.82 -0.012 0.012 
Prostate 269 Metastatic Disease High Risk T3-4 -0.60 0.60 33 0.000 27.7 -0.166 0.166 
  197 High Risk T3-4 
metastatic 
disease 0.60 -0.60 67 0.000 27.7 0.166 -0.166 
  249 
High Risk T3-4 - Unfit for radical 
treatments 
Fit for radical 
treatments -0.53 0.53 22 0.000 27.7 -0.147 0.147 
  198 
High Risk T3-4 - Fit for radical 
treatments 
unfit for radical 
treatments 0.53 -0.53 78 0.000 27.7 0.147 -0.147 
  327 
NN( High Risk T3-4 - Fit for radical 
treatments - Hormones 
alone/Surgery-found to be T3 with 
pos margins) 
Hormones & 
Radiotherapy -0.41 0.40 20 0.012 27.7 -0.114 0.111 
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Table 5-7. Tree sensitivity analysis summary results for rectum, sarcoma and stomach cancer, showing the most sensitive nodes and the effect they have 
on both the average number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red 
highlighting indicates a top 10 most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
Rectum 2 Stage 1  
NN(Stage 
II/III/IV) -1.22 1.25 25 0.012 4.18 -0.051 0.052 
  75 NN(Stage II/III/IV) S1 1.23 -1.22 75 0.004 4.18 0.051 -0.051 
  13 Stage II NN Stage(III/IV) 0.79 -0.79 33 0.000 4.18 0.033 -0.033 
  76 NN(Stage III/IV) Stage II -0.79 0.79 67 0.000 4.18 -0.033 0.033 
  46 Stage III - Preoperative RT Surgery 0.75 -0.75 50 0.000 4.18 0.031 -0.031 
Sarcoma 27 NN (Stage II/III/IV) SI 1.08 -1.07 79 0.005 0.65 0.007 -0.007 
  2 Stage I 
NN (Stage 
II/III/IV) -1.07 1.08 21 0.005 0.65 -0.007 0.007 
  21 Stage IV SIII -0.73 0.73 65 0.000 0.65 -0.005 0.005 
  16 Stage III SIV 0.73 -0.72 35 0.007 0.65 0.005 -0.005 
  4 SI - RT No RT 0.62 -0.62 95 0.000 0.65 0.004 -0.004 
Stomach 5 
Local Disease - Surgery - Adjuvant 
RT No RT 23.19 -22.79 2 0.009 0.09 0.021 -0.021 
  4 Local - Surgery - No RT Adjuvant RT -22.56 22.98 98 0.009 0.09 -0.020 0.021 
  30 
Metastatic disease- Symptomatic 
- Metastatic symptoms - No RT RT -3.70 3.09 90 0.090 0.09 -0.003 0.003 
  26 
Metastatic disease - Symptomatic 
- Metastatic symptoms - RT No RT 3.04 -3.06 10 0.003 0.09 0.003 -0.003 
  12 
Local disease - No Surgery - 
Palliative intent - Palliative 
radiotherapy BSC 2.43 -2.48 5 0.010 0.09 0.002 -0.002 
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Table 5-8 Tree sensitivity analysis summary results for testis cancer, showing the most sensitive nodes and the effect they have on both the average 
number of fractions for the cancer site and the overall number of fractions when considering all cancer sites together. Red highlighting indicates a top 10 
most sensitive node. 
Site 
Node 
No Node description 
Sibling node 
description 
% change 
of 
fractions 
given per 
% 
increase 
% change 
of 
fractions 
given per 
% 
decrease 
Original 
decision 
% linearity 
% cancer 
group 
contributes 
to overall 
incidences 
% overall 
change of 
number of 
fractions 
per % 
increase 
% overall 
change of 
number of 
fractions 
per % 
decrease 
Testis 28 
Teratoma - Occasional RT 
indications 
Majority will not 
receive RT 12.08 12.01 2 0.003 0.06 0.007 0.007 
  27 
Teratoma - Majority will not 
receive RT 
Occasional RT 
indications -11.77 12.03 98 0.011 0.06 -0.007 0.007 
  9 
Seminoma - S1 - Para-aortic 
RT 
Carboplatin single 
cycle 4.90 -5.01 3 0.011 0.06 0.003 -0.003 
  12 
Seminoma - S1 - Carboplatin 
single cycle Para-aortic RT -4.82 4.97 97 0.015 0.06 -0.003 0.003 
  3 Seminoma - Stage I 
NN(Stage II / Stage 
IIC - IV) -2.65 2.66 85 0.002 0.06 -0.002 0.002 
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For the node and sibling node description where it has NN at the start of the description it 
signifies the creation of an intermediate, which is a Fortran inserted node to bifurcate the tree.   
This table will be further discussed in the discussion chapter. 
5.2 Coefficient of Variation 
To enable the most accurate calculation of a relationship between the coefficient of variation (CV) 
and the optimal number of walkthroughs required, the calculations utilise all of the full Monte 
Carlo simulation results from 23 clinical decision trees and four PCTs. For each simulation the 
number of nodes, number of Virtual Patients, standard deviation and mean was collected in Excel 
and the CV was calculated. 
The amount of data from the full Monte Carlo allowed the generation of charts for the different 
number of nodes, plotting the CV against the number of Virtual Patients. Figure 5-1 is the 
generated chart for clinical decision trees with 45 nodes. Due to the natural curve that appeared 
on each chart, Excel’s trend line function was used to overlay a power trend line and generate an 
equation for the trend line in the form of Equation 5-1. It was noticed how similar the power 
trend line equations were so another chart was created plotting all of the node groups on a single 
chart. From this chart, it was easy to see that the number of Virtual Patients, therefore the 
number of walkthroughs, had the greatest influence over the CV rather than the number of nodes 
having the greatest influence. Therefore, the CV and the number of Virtual Patients should be the 
focus of the relationship, rather than the CV and the number of nodes within a tree. 
                                                  𝑦 = 𝑚𝑥𝑐 
𝑦 = 𝐶𝑉 
𝑚 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
𝑥 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑟𝑡𝑢𝑎𝑙 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
𝑐 = 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡 
Equation 5-1 
 
 
The trend line equations were gathered to attempt to find the relationship between the trend 
lines and the number of nodes and it was noted that the coefficient of the power trend line was 
decreasing with an increasing number of nodes. Figure 5-2 shows the chart of the coefficient 
against the number of nodes, and this generated an approximate power function, giving Equation 
5-2.  
                                                     𝑦 = 1.295𝑥−0.05 Equation 5-2 
 
𝑦 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
𝑥 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑑𝑒𝑠 
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Figure 5-1 The coefficient of variation plotted for a range of number of Virtual Patients, for a 
clinical decision tree containing 45 nodes. 
 
Figure 5-2 The coefficient of the CV vs number of Virtual Patients trend line against the number 
of nodes in the corresponding decision trees, plotted with a trend line. 
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The fact that the exponent was also changing on the power trend line from the different number 
of nodes plots, needs to be taken into account.  Figure 5-3 plots the exponent against the 
coefficient and shows a negative, linear relationship and provides Equation 5-3 . 
 
Figure 5-3 The exponent of the CV vs number of Virtual Patients trend line against the 
coefficient of the CV vs number of Virtual Patients trend line, plotted with a trend line. 
                                                  𝑦 = −0.2084𝑥 − 0.2899 
 
Equation 5-3 
 
𝑦 = 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡 
𝑥 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 
The information gathered was studied to develop an overall relationship. The basis of the 
relationship was the original power trend line equation form, as given in Equation 5-1. Equation 
5-4 was generated by substituting the coefficient equation and exponent equation into the power 
equation form. 
 𝐶𝑉 = (1.295 ∗ 𝑁−0.05) ∗ 𝑉𝑃(−0.2084(1.295∗𝑁
−0.05)−0.2899) 
 
Equation 5-4 
 
𝑁 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑑𝑒𝑠 
𝑉𝑃 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑟𝑡𝑢𝑎𝑙 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
𝐶𝑉 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛  
However, as the output that is required is the number of Virtual Patients, for a specified CV, 
Equation 5-5 is the result of rearranging Equation 5-4 to make the Virtual Patients the subject of 
the formula. 
y = -0.2084x - 0.2899
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𝑉𝑃 = √
𝐶𝑉
1.295 ∗ 𝑁−0.05
(−0.2084(1.295 ∗ 𝑁−0.05) − 0.2899)
 
 
Equation 5-5 
 
 
Equation 5-5 allows the calculation of the theoretical number of Virtual Patients required to give 
a CV of a specified value for a tree with a known number of nodes. The final stage to adapt this 
into a workable form is to relate the theoretical number of Virtual Patients to the actual number 
of Virtual Patients that MALTHUS generates. The fact that the original full Monte Carlo 
simulations used 2,000 trials of 2,000 walkthroughs for each Virtual Patient makes the adaptation 
simple. If it is assumed that 2,000 trials is going to remain static in MALTHUS then a ratio between 
the theoretical number of Virtual Patients and the generated number of Virtual Patients needs to 
be applied to the 2,000 walkthroughs, giving Equation 5-6. 
 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑉𝑃
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑉𝑃
∗ 2000 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑊𝑎𝑙𝑘𝑡ℎ𝑟𝑜𝑢𝑔ℎ𝑠 
Equation 5-6 
 
 
Equation 5-7 has all terms substituted into the formula. 
 
2000 √
𝐶𝑉
1.295∗𝑁−0.05
(−0.2084(1.295 ∗ 𝑁−0.05) − 0.2899)
𝐺𝑉𝑃
= 𝑊𝑇 
 
Equation 5-7 
 
 
𝐶𝑉 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 
𝑁 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑑𝑒𝑠 𝑖𝑛 𝑑𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑡𝑟𝑒𝑒 
𝐺𝑉𝑃 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑣𝑖𝑟𝑡𝑢𝑎𝑙 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
𝑊𝑇 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑎𝑙𝑘𝑡ℎ𝑟𝑜𝑢𝑔ℎ𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 
The results and relationships generated out of the results will be discussed in the discussion 
section. 
 
5.3 Full Monte Carlo  
The full Monte Carlo, as described in section 3.4.6, was completed on the four example PCTs for 
all of the cancer sites. The full Monte Carlo fully uses the Virtual Patient generator, utilising both 
the input population data and incidence data to make cohorts of Virtual Patients. Excel imports 
the results, which the Fortran outputs in .txt form, via a macro that automatically sorts the results 
and makes total fraction histograms with cumulative frequency percentage plotted as well. The 
bladder results are shown here as an example, the rest can be found in Appendix 1. 
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The simulation was run 2000 times with 2000 walkthroughs for each cancer site within a PCT to 
make sure that the simulation was run enough times to give an accurate result. The results files 
contain the following: 
 average number of Virtual Patients generated  
 the mean number of fractions per patient 
 median and mode number of fractions for the 2000 runs of the PCT 
 the variance and standard deviation of the number of fractions for the PCT 
 the ARR 
 the average total number of fractions and the 95% confidence limits 
 kurtosis and skewness of the total number of fractions 
 the individual run results 
The total number of fractions is the average of the total number of fractions from all of the runs 
combined, with the total number of fractions of a single run calculated by multiplying the mean 
number of fractions by the number of patients. The basis of the 95% confidence limits is the mean 
number of fractions per patient, this is why the value is so small compared to the spread of the 
total fractions in the histograms (such as Chart 5-5). The total fraction histograms include the 
variability in the number of incidences generated, whereas the mean number of fractions is going 
to remain roughly the same as it is on a per patient basis. Table 5-9 shows a summary of the 
information generated. However, as can be seen, the information is similar in each PCT, just 
scaled to the number of Virtual Patients, because these trees are not Virtual Patient reactive. 
The 95% coverage in Table 5-9 is the number of fractions required to take into account 95% of all 
of the runs. This is taken from the histogram cumulative frequency information in the results 
output. 
The histograms produced use the total number of fractions information to show the spread of 
possible outcomes for each cancer site with the cumulative percentage indicating the number of 
fractions required to cover a given percentage of outcomes.  The kurtoses for the four PCTs 
results are all close to three and the skewness close to zero, which indicates that the results are 
approximately normally distributed.  
Another factor for comparison is the coefficient of variation. It is the standard deviation divided 
by the mean, resulting in a dimensionless number that enables the comparison of the levels of 
variance within different datasets. A value of zero would show that all of the data points within a 
data set lay around the mean. Whereas a value of one would show that the data points are 
scattered away from the mean. A low coefficient of variation is much more favourable.  
As expected for the full Monte Carlo the coefficient of variation varies from PCT to PCT and 
cancer to cancer. This is due to the number of walkthroughs that is completed and whether this 
number is suitable for a given decision tree. The greater the number of walkthroughs completed 
(a larger number of incidences gives a greater number of walkthroughs) the lower the coefficient 
of variation, but the more complex the decision tree the higher the coefficient of variation is, as 
more walkthroughs are required to get the full spectrum of results. 
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Bladder Cancer  
PCT 
Newcastle Hartlepool Cornwall Surrey 
Number of Virtual 
Patients 39.6 19.23 105.23 180.16 
PCT Fractions Summary 
Mean Fractions per 
patient 3.37 3.36 3.36 3.37 
Median Fractions 132 64 353 605 
Mode Fractions 131 60 333 597 
Variance 461 225 1151 2075 
Standard Deviation 21.46 15.02 33.94 45.55 
Total Number of 
Fractions (mean total 
number of fractions of 
all runs completed) 132.79 64.17 353.53 605.62 
95% Confidence Limits 
(based on the Mean 
Fractions) 
131.8-
133.7 63.5 - 64.8 
352.0-
335.0 
603.6-
607.6 
Kurtosis 3.08 3.04 3.17 3.07 
Skewness 0.18 0.16 0.11 0.09 
ARR 23.18% 23.17% 23.17% 23.17% 
95% Coverage 168 89 409 680 
Coefficient of Variation 0.16 0.23 0.10 0.08 
 
Table 5-9 Example bladder cancer summary results from full Monte Carlo runs for Newcastle, 
Hartlepool, Cornwall and Surrey, demonstrating some of the generated information. 
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Chart 5-5. Histogram of the total number of fractions for bladder cancer in Surrey PCT, 
calculated from a Full Monte Carlo run, including cumulative percentage.  
 
Chart 5-6. Histogram of the total number of fractions for bladder cancer in Hartlepool PCT, 
calculated from a Full Monte Carlo run, including cumulative percentage.  
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Chart 5-7. Histogram of the total number of fractions for bladder cancer in Newcastle PCT, 
calculated from a Full Monte Carlo run, including cumulative percentage.  
 
Chart 5-8. Histogram of the total number of fractions for bladder cancer in Cornwall PCT, 
calculated from a Full Monte Carlo run, including cumulative percentage.  
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5.4 Overall (fast MC) 
As the trees currently are not reactive to the Virtual Patients, a “fast Monte Carlo” calculation can 
be undertaken. This involves the generation of only a single Virtual Patient, instead of a whole 
cohort of Virtual Patients, but it still goes through the same number of generations and runs as 
the full Monte Carlo. 
The combination of the average fraction and ARR with the incidence data for England and all PCTs 
and CNs occurs in an Excel spreadsheet controlled via a macro that automatically extracts the 
incidence data from the raw incidence files. The result is a basic Monte Carlo completed on every 
PCT and CN within the country in a vastly quicker time, in the order of 50 times faster for PCTs on 
equal computer processing power, than by using the standard Monte Carlo technique used in 
section 5.3. 
The output table splits up the results by PCT and cancer site. As well as containing the number of 
incidences, average fraction given per patient, ARR and total fractions given to that cancer site it 
also gives the site contribution percent. This is the amount the incidence for that site accounts for 
in the total incidences across all sites. Also given is the relative ARR, which is simply the cancer 
site’s ARR multiplied by the site contribution to give the cancer site’s contribution to the overall 
ARR for the PCT/CN/whole of England. 
Table 5-10 shows the overall results for England for all cancer sites. The ARR for the whole 
country is calculated to be just below 40% and a total number of fractions of 2.074 million 
fractions. This equates to approximately 40,000 fractions per million population, without 
retreatment and based on the pragmatic trees. The tables containing all PCTs and CNs are in 
Appendix 1, these tables also contain all of the incidence data. 
These fast Monte Carlo results tables in the appendix also highlight the difference in incidence 
between the PCTs and CNs showing how each different region should be planning their resources 
based on individual models rather than the average for the whole country.  
To highlight the differences between the PCTs Table 5-11 shows the maximum and minimum 
percentage a cancer site contributes to the overall incidence within a PCT, this is a simple 
calculation of dividing the cancers incidence by the total incidence of all cancers with a given 
region. It also contains the various PCTs rank of deprivation. The deprivation shown is the rank of 
the average of Lower Super Output Areas (LSOA) ranks. This is a population weighted average of 
the combined deprivation ranks for the LSOAs in a PCT [54]. The fractions per 100,000 population 
are the results from the fast Monte Carlo calculations. While this is by no means an exhaustive 
comparison with deprivation of PCTs, it shows if the extremes of contributions to PCT incidences 
occur at different ends of the deprivation scale. In the following, PCTs are ranked numerically 
according to the level of deprivation. Please note therefore that on the scale used, one is the 
most deprived and 151 the least deprived. 
Breast cancer is a good example of a negative correlation with deprivation. The maximum 
contribution occurred in the 149th ranked PCT and the minimum occurred within the fourth 
ranked PCT. Stomach shows the opposite correlation with the maximum occurring within the 
23rd ranked PCT and the minimum occurring within the 149th ranked PCT. 
The head and neck cancer comparison shows the variations in cancer profiles between regions. 
The maximum and minimum contributions to PCT incidences are at 5.13% and 2.15% while the 
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fractions per 100,000 are 357 and 327 respectively. The fact that the fractions per 100,000 are 
similar shows that the incidence of head and neck cancer per 100,000 is similar in both PCTs but 
North Lincolnshire has a much higher overall number of incidences per 100,000 than Tower 
Hamlets and so the contribution of incidences of head and neck in North Lincolnshire is actually 
much lower.  
Please refer to the glossary of main terms for the definitions of the terms in the table. 
PCT   Bladder Breast Cervix CNS Colon Endometrium 
England 
Incidence 8847.333 45085.33 2536.66667 4187.333 23403.33 6190 
Av.Frac 3.36 14.41 11.51 10.82 0.5 6.52 
ARR 23.43% 76.09% 47.32% 45.50% 5.00% 28.72% 
Total Frac 29727.04 649679.72 29197.0333 45306.95 11701.67 40358.8 
Site Contribution 3.31% 16.85% 0.95% 1.56% 8.74% 2.31% 
Relative ARR 0.775% 12.818% 0.449% 0.712% 0.437% 0.664% 
  H&N HL Kidney Leukaemia Lung Melanoma 
England 
Incidence 7700.333 1487.333 6401 6820.333 33478 9693.333333 
Av.Frac 22.62 8.33 0.8 0.25 8.19 0.52 
ARR 80.85% 58.67% 10.00% 5.00% 61.24% 2.60% 
Total Frac 174181.5 12389.49 5120.8 1705.083 274184.8 5040.533333 
Site Contribution 2.88% 0.56% 2.39% 2.55% 12.51% 3.62% 
Relative ARR 2.33% 0.33% 0.24% 0.13% 7.66% 0.09% 
  Myeloma NHL Oseophagus Others Ovary Pancreas 
England 
Incidence 3905.333 9850.333 6734.66667 27505.33 5504 6922 
Av.Frac 0.75 2.68 4.75 2.2 0.48 2.63 
ARR 25.00% 19.83% 29.67% 20.00% 6.04% 14.85% 
Total Frac 2929 26398.89 31989.6667 60511.73 2641.92 18204.86 
Site Contribution 1.46% 3.68% 2.52% 10.28% 2.06% 2.59% 
Relative ARR 0.36% 0.73% 0.75% 2.06% 0.12% 0.38% 
  Prostate Rectum Sarcoma Stomach Testis Overall 
England 
Incidence 32966 8988.333 1273.33333 6338.333 1807 267625 
Av.Frac 16.39 10.34 12.39 0.3 0.75   
ARR 53.56% 48.37% 48.14% 4.74% 4.89%   
Total Frac 540312.7 92939.37 15776.6 1901.5 1355.25 2073554.933 
Site Contribution 12.32% 3.36% 0.48% 2.37% 0.68% 100.00% 
Relative ARR 6.60% 1.62% 0.23% 0.11% 0.03% 39.63% 
 
Table 5-10. Fast Monte Carlo results for England, showing incidence, average fraction per 
incidence, ARR, total number of fractions, site contribution and relative ARR for each cancer 
site and the overall incidence, total number of fractions and ARR. 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-11 Maximum and minimum cancer site incidence contribution to the total number of incidences within a PCT and the fractions per 100,000 for 
the cancer site, with the PCT rank of deprivation.  
Cancer 
Maximum 
Contribution to 
PCT Incidences PCT 
Rank of 
Deprivation 
[54] 
Fractions per 
100,000 
Minimum 
Contribution to 
PCT Incidences PCT 
Rank of 
Deprivation 
[54] 
Fractions per 
100,000 
Bladder 4.53% Salford 25 95.31 1.89% 
Heart of Birmingham 
Teaching 2 21.88 
Breast 21.08% 
Richmond & 
Twickenham 149 1374.27 13.07% Tower Hamlets 4 525.27 
Cervix 2.27% Central Lancashire 94 167.64 0.45% Shropshire, Havering 105,109 32.50, 31.40 
CNS 2.05% Hounslow 68 80.52 0.99% Stoke on Trent 23 60.54 
Colon 10.57% Cumbria 89 40.17 6.07% Southwark 24 4.52 
Endometrium 3.32% Harrow 114 96.29 1.37% North Tyneside 86 62.58 
H&N 5.13% Tower Hamlets 4 357.27 2.15% North Lincolnshire 87 327.50 
HL 1.38% Newcastle 50 21.85 0.19% Hartlepool 30 9.17 
Kidney 3.32% Middlesbrough 26 15.56 1.49% Greenwich Teaching 19 5.44 
Leukaemia 3.51% Berkshire West 146 3.70 1.40% Gateshead 36 2.08 
Lung 19.57% Newcastle 50 949.75 8.69% Wiltshire 139 467.29 
Melanoma 5.82% Oxfordshire 140 107.26 0.81% Newham 1 8.85 
Myeloma 2.52% Brent Teaching 22 13.21 0.82% Hastings and Rother 51 7.47 
NHL 5.37% Barnet 104 87.74 2.39% Middlesbrough 26 48.56 
Oesophagus 3.57% Ashton Leigh & Wigan 65 95.30 1.31% Haringey Teaching 12 22.89 
Others 13.71% Tower Hamlets 4 87.24 8.72% 
Great Yarmouth & 
Waveney 67 131.82 
Ovary 3.08% Milton Keynes 127 7.43 1.19% Middlesbrough 26 3.67 
Pancreas 3.46% Gateshead 36 40.98 1.77% Bassetlaw 66 27.87 
Prostate 16.43% Dorset 121 2346.15 7.40% Hartlepool 30 845.16 
Rectum 4.27% Sunderland Teaching 42 270.78 1.83% Harrow 114 75.54 
Sarcoma 0.94% Westminster 56 35.59 0.17% Camden 46 7.36 
Stomach 4.01% Stoke on Trent 23 10.17 1.09% 
Richmond and 
Twickenham 149 1.21 
Testis 1.43% Wandsworth 74 3.78 0.29% Isle of Wight 78 1.43 
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5.5 Summary 
The results shown in this chapter illustrate how changes within age bands affect the number of 
incidences and how changing the decisions within the tree can affect the overall radiotherapy 
demand. This is important, as it is a known fact that the population distribution is changing and 
that the impact of clinical decisions is not going to be the same in every region. The Monte Carlo 
results show the capabilities of the program and the fast Monte Carlo provides a wealth of 
information about the different PCTs within England and their differences. The implications of 
these results will be discussed in depth in the next chapter.  
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6 Discussion 
This section contains the discussion of the program, its inputs and the results it has generated. It 
covers topics such as the assumptions made while creating the program, the significance of the 
results and if they were expected or unexpected, possible links to deprivation and comparing the 
program and results against the work of others such as CCORE, QCRI and NRAG. 
6.1 The MALTHUS Program 
Having written MALTHUS ab-initio there were a few assumptions and decisions with regard to 
how it generated patients, how it handled the clinical decision trees, what Monte Carlo methods 
to use, how it ran the simulations and would the fast Monte Carlo be either accurate or suitable. 
A couple of key, novel features also emerged with the creation of MALTHUS 
6.1.1 MALTHUS Assumptions 
The method chosen for the patient generator was to use an acceptance/rejection test based on 
original input data on the population and incidence. While the majority of the simulations use the 
patient generator, it was not always used to its full capabilities. For example, it only generates a 
single patient for some simulations, such as in the fast Monte Carlo, in a trade-off between speed 
and precision. In other testing simulations trading reproducibility with precision, it was unused 
when a specific cohort of pre-determined patients is required. However, for the full Monte Carlo 
runs it was used to generate all the patients.  
The acceptance/rejection method itself is a robust method that can accurately recreate the input 
data, or any density function, as long as the generation of enough points occurs. It is the best 
option for MALTHUS as the probability density functions of the populations and incidences are 
different for every region. They will also differ when taking into account forwards prediction and 
so factors will be applied to the population or incidences for simulation of future years. In section 
4.1.1 the input density functions and simulated output show that this method is effective.  
The age and incidence data comes into the program from NCIN in grouped age bands, e.g. ages 
60-64 and is then split into individual age bands, so the data is only actually an average. As it is an 
average, it is the same across all ages within an age band. Therefore, in the program for ages 60-
64 it actually has the same number of population or incidence for ages 60, 61, 62, 63 and 64, 
which is not actually true.  An advantage of using the acceptance/rejection test over just using the 
averaged input data split into individual age bands is that the acceptance/rejection test will 
introduce fluctuations into the data, which has the effect of smoothing out the discrete age bands 
slightly. While the patient generator will not have as much of an effect running a base case 
without reactive nodes (hence the fast Monte Carlo mode) it has been fully implemented with the 
idea that the clinical decision trees will not always be un-reactive to the patients. When trees 
become reactive to age, the changing patient cohort will have a bearing on the output and this is 
something to take into account when preparing data for the model.  
The only minor downside to how this works currently is when the acceptance/rejection test 
detects that a patient has a cancer it then exits, it doesn't go on to determine if a patient has 
more than one type of cancer. However, the input data does not specify this covariance and it is 
known that at the population level, second cancer incidence represents a small part of the overall 
cancer burden. 
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Early on in the project, it was decided that MALTHUS would run on bifurcated trees where there 
are only two outcomes to each decision. This makes the generation of the program and the tree 
walk through simpler and faster. While it does mean that there are more nodes in the bifurcated 
Fortran trees compared to the original XML decision trees, the additional computational time 
caused by this would be negligible. This way also keeps the node structure simpler and the actual 
Fortran tree files easier to check and validate.  
The main nature of Monte Carlo methods is the fact that it completes numerous runs based on 
some random sampling. However, the number of runs required to give an accurate output is not a 
fixed amount and it will vary depending on the complexity of the underlying model. Thus, the 
number of runs had to be determined for our model. Owing to the fact that the number of nodes 
in a decision tree can range from three to 500+ the number of runs would be tailored around the 
larger trees. Although this means that on a smaller tree the number of runs would be excessive, 
the additional computation burden is relatively low.  
As mentioned in section 4.2 a few tests were performed to determine the number of runs of 
100,000 as a suitable number of walkthroughs when performing a single patient walkthrough of a 
tree. However, when undertaking a full Monte Carlo methods run it generates a number of 
cohorts of patients to walk through the tree. Thus, the actual number of walkthroughs done per 
Virtual Patient can be lower as the number of Virtual Patients is greater and so in total there is a 
lot more than 100,000 walkthroughs of the tree. As standard, the program is set to walkthrough 
the tree 2000 times and completes 2000 simulations. This equates to 4,000,000 walkthroughs per 
incidence.  
While 4,000,000 may seem like quite a large number of walkthroughs, it is required to give the 
full Monte Carlo the maximum range of outputs for a comprehensive analysis on all of the 
treatment options. However, this does mean that in a large PCT (Surrey for example) simulating a 
high incidence cancer (breast for example) it can take over 10 hours on a moderately powerful 
laptop (3GHz processor). Nonetheless, the extra time required for computation is worth the 
benefit of the more complex results output. 
Along with the full comprehensive Monte Carlo methods, the creation of the fast Monte Carlo 
takes into account the fact that the current trees are not reactive to the Virtual Patients. The 
creation of this method was so that all that has to be run is a full Monte Carlo methods 
simulation, with a single Virtual Patient per cancer site, once. This gives 4,000,000 walkthroughs 
of each tree, which is more than adequate compared to the 100,000 required. Once this has been 
performed, the average fractions and ARR can be applied to any incidences to give an answer of 
how many fractions a PCT or CN requires and how they will be split up between the cancer sites. 
It can be broken down into age bands too if the incidence data is stratified by age.  
This is much faster than re-running the whole simulation every time a different PCT or CN is 
wanted to be simulated. However, this method would not be valid when the trees become Virtual 
Patient reactive as then each region may give slightly different treatment due to the differences 
in age profiles.  For now, it has given the results for every PCT and every CN. When updates to the 
incidence data arrive, the results can be scaled according to the new incidence values, which will 
save having to run a new simulation.  
6.1.2 Key Features of the Model 
The two most important, novel features within MALTHUS are the Virtual Patients and the reactive 
nodes.  
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The Virtual Patients’ architecture gives the model the flexibility and adaptability that is required 
for a modern, comprehensive, predictive health care model. The reactive nodes give the program 
the ability to be able to adjust the decision trees ad hoc depending on what Virtual Patient or 
more precisely, what parameter of the Virtual Patient could influence a doctor’s decision about 
treatment.  
The Virtual Patients themselves hold information based on the input data, such as age, sex and 
cancer type and the program uses the Virtual Patient data to traverse the correct decision tree. 
The Virtual Patient collects all the data itself as it completes its walkthroughs. This is a step away 
from programs such as TreeAge, where the tree gathers and calculates the data. This has the 
effect of creating a tree based simulation rather than a patient based simulation.  
As the program was written ab initio, it is easily expandable to allow extra parameters to be 
added into the Virtual Patients and the nodes, enabling the program to be even more adaptable. 
However while the program is easily changed, a competent programmer must undertake this, as 
it is the source code that has to be changed. The changes could include different modalities of 
treatment, such as surgery and chemotherapy, or different techniques of radiotherapy, such as 
IGRT. From this projects perspective the program is open source. 
 
 
6.2 The Results 
The compilation of the clinical decision trees was by a clinical team at the Addenbrooke's from 
published evidence, information from cancer networks and the Royal College of Radiologists and 
from consensus meetings held with clinical representatives from around the country. These 
clinical decision trees are the basis of the results in this thesis. Any comments made about the 
clinical decisions are speculations based on observations from the project and would require 
input from clinicians for validation. 
6.2.1 Sensitivity Analysis on the Patient Generator 
The first set of results to consider will be the sensitivity analysis on the input data, to evaluate 
what effect this could have on the output. This area is important as it represents the changing 
population or the ageing population for example.  
As this test was completed on the input files by adjusting the number of incidences by a given 
percentage it was only natural that the variation in the number of incidences follows the same 
pattern as the original number of incidences. The larger number of incidences gave rise to the 
largest changes and the smallest number of incidences gave rise to the smallest changes.  
Due to this, every PCT would have to be studied individually to see the changes caused by an 
increase in incidence. For example in breast cancer in Surrey, Chart 5-2, if the over 75's increased 
by 10% then the breast cancer incidence would increase by 2.2% however in Newcastle, Chart 
5-3, the same increase gives rise to a 2.42% increase of incidence. In real terms the Newcastle 
increase accounts for approximately 4.6 new incidences while the Surrey increase accounts for 
23.25 new incidences. While the percentages are similar the increase in radiotherapy demand is 
much higher in Surrey due to the larger initial number of breast cancer incidences that occur in 
Surrey. 
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Depending on cancer type, the different age bands will have more or less of an impact on the 
results. For example, bladder cancer incidence would be increased the most by an increase in 
population aged 65+ whereas the incidences for melanoma are more evenly spread so an 
increase from around ages 40+ leads to larger increases in incidences.  
The results for all cancer sites in Surrey, Newcastle, Hartlepool and Cornwall PCTs are in Appendix 
1 and contain all of the charts and incidence numbers as well as the percentage changes for every 
age band. However, as stated previously each PCT or cancer site would require individual 
evaluation depending on what the user’s area of interest. There is too much information and 
variables to make a generic conclusion summarising the results from the sensitivity analysis on 
the patient generator. 
6.2.2 Sensitivity Analysis on the Decision Trees 
The sensitivity analysis on the decision trees adjusted every decision node individually by 1%, 5% 
and 10%. The actual sensitivity was then calculated using the +/-10% results. The amount the 
output changed is divided by the amount the decision changed. This calculates how much the 
output changes per percentage that the decision changes. By calculating the sensitivity it allows 
for any uneven change in the decision probability, for example when a decision goes to 0% or 
100% the amount the decision changes will be lesser than the change the opposite way due to 
the limiting factor of 0% or 100%. 
A problem with this method of evaluating the results is that it may not show the full sensitivity of 
decisions that start with a very low decision percentage. For example, a 2% decision changed by 
10% only gives a real change of 0.2%. This could mask the true sensitivity if the system is not 
linear. The discussion on the most sensitive nodes will look at this in more detail. This is why in 
Table 5-1 to Table 5-8 the sensitivity have been shown with the original decision percentage and 
information on the actual decision so it can be judged if the most sensitive nodes have room to 
be adjusted or are likely to be changed 
Although the summary sensitivity analysis results only uses the +/-10% perturbation results the 
calculations were completed on all three sets of results and can be seen in the overall sensitivity 
analysis results and tornado diagrams in Appendix 1. This enabled a check for linearity and 
symmetry to be undertaken. As can be observed from the tornado diagrams the results are 
mostly symmetrical. There are a couple of small fluctuations however these tend to be on the 
decisions which have a smaller/larger decision probability and so could be related to the amount 
that the decision changes rather than the clinical decision tree being unsymmetrical. From 
evaluating all of the sensitivity analysis results are mostly linear. Throughout the results there are 
some observable non-linearity, however these either are small differences or are observed when 
comparing the 1% results to the others. There is a greater level of consistency between the 5% 
and 10% results. This suggests that by adjusting the decision probabilities by 1% may not be 
enough of a change to get the true sensitivity of a decision in a decision tree. Also in the trees 
where there is only a single decision, such as Colon or Ovary, the results appear to by 
asymmetrical based on the 10% results. However, this is purely due to the indication for 
radiotherapy being entirely switched off by the decision reaching 0%. When evaluating the overall 
results that contain the 1% and 5% results, where the radiotherapy decision is not completely 
turned off, the results are both symmetrical and linear. 
However, it is quite difficult to make a general conclusion on three sets of sensitivity analysis 
results covering 23 different trees with over 2000 nodes. 
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Because the different cancer groups account for different amounts of incidence and different 
amounts of radiotherapy, the overall results of the tree sensitivity analysis have had the 
radiotherapy burden taken into account. This is to make sure the results are not accidentally 
masked. For example, a node in cancer group A could show a 20% change in outcome and be the 
most sensitive node. However, when the fact that cancer group A only accounts for 1% of all 
radiotherapy burden is applied, the 20% change becomes insignificant in the overall answer. A 1% 
change in outcome in a much more prevalent cancer with a greater burden could affect the 
overall answer by a larger degree than the 20% change in outcome in cancer A. 
Overall, when taking into account the cancer site contribution to the total fraction burden, the 
most sensitive decision is the split between stage 3a and 3b/4 of non-small cell lung cancer. This 
decision has a 13% and 87% probability respectively. For each percentage change the overall 
answer changes approximately 0.17% or -0.174%.  
This decision shows how important the high level of data gathered by the cancer registration 
centres is when it comes to demand prediction. As the staging at presentation of a cancer like 
lung cancer is likely to change region by region, it can have a real effect on the local demands for 
radiotherapy.  
The second most sensitive decision is the split between metastatic and high risk prostate cancer. 
Metastatic prostate cancer has a 33% probability and high risk has a 67% probability. For each 
percentage increase towards metastatic prostate cancer the overall answer changes -0.166%. 
Again, this shows the importance of high level data required when planning for local demand of 
radiotherapy. 
The two most sensitive decision also highlight the possible effect that cancer awareness initiatives 
or screening programmes may have on the radiotherapy burden. If people go to the NHS earlier 
for checking of symptoms this could shift the stage of presentation to earlier stages, then this 
could have a real effect on the overall burden that a region has to cope with. The spread of 
indications for radiotherapy is not necessarily even throughout all of the branches that represent 
different stages of the cancers. This is another key area that MALTHUS can help the NHS plan for. 
If a 1% shift from stage 3b/4 to 3a occurred then it would increase the number of fractions 
required, in England, by approximately 4,300. While this number is not in itself a very large shift, 
if there is a successful awareness campaign and, for example, over five years there is a 10% 
change in stage presentation just to 3a then a 43,000 fraction increase would be required. 
Considering that almost 70% of non-small cell lung cancers are stage 3b or 4 (based on LUCADA 
data from the clinical decision trees) a situation such as this is not beyond the realms of 
possibility. 
For the most prevalent cancers: breast, lung and prostate, the regions in those decision trees that 
are the most sensitive are the expected areas, areas towards the root of the trees. The previous 
paragraphs have discussed lung and prostate cancer. For the breast tree, it is the decision 
between breast conserving surgery or mastectomy. A radiotherapist may not necessarily make 
this decision, but it could still have a significant effect on the radiotherapy demand. 
A degree of care must be taken in using these results because some of the most sensitive, or 
siblings of the most sensitive, are nodes that have been inserted by the Fortran code to bifurcate 
the tree. For example the most sensitive node in lung, as mentioned above, is an inserted node 
splitting up stage 3b or 4 from stage 3a. So the sensitivity is only between 3b/4 and 3a, not taking 
into account the rest of the stages. Whether this actually makes the sensitivity on lung more 
accurate or not needs further evaluation. The argument could be made that if there is a shift in 
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stage of presentation then it is more likely to come from neighbouring stages rather than across 
the whole stage range, so shifting from 3a to 3b and 4 is more likely than stages 3b and 4 
increasing and every other stage decreasing. Although it could also be argued that if the stage of 
presentation is caused by generic factors linked to deprivation, then as a general note the higher 
stages are more likely to be increased with all of the lower stages decreasing. This would have to 
be discussed with clinical experts or cancer registries that have specific data on stage 
presentation in regions. Such work has been touched on already by Lyratzopoulos et al. [55]. The 
analysis only considered the East of England.  A nationwide analysis would be of interest, looking 
for greater differences inter-regional rather than intra-regional level 
The prostate cancer decision tree is equally as sensitive to change as the lung cancer with the 
biggest changes to demand coming from a shift from metastatic disease to high risk T3-4 disease. 
With breast cancer, the decision tree is not as sensitive as the lung cancer tree and the most 
sensitive decisions lay between mastectomy and breast conservation surgery in both stage 1 and 
stage 2. The overall radiotherapy demand would change by less than 0.45% with a 5% change to 
one of the decisions. Even though breast cancer is one of the largest contributors to radiotherapy 
demand, its nodes do not have the largest effects on the overall demand with changes to the 
decision percentages within the tree. 
A patient’s preference may influence the decisions for radiotherapy or no. Patients may opt for 
no radiotherapy if, for example, the nearest radiotherapy centre is not close to them and it could 
be quite a major logistical problem for the patient to receive radiotherapy. Whereas they may 
choose their local hospital, as it may offer a much more preferable option of surgery. Users in a 
hospital would be able to modify the trees in MALTHUS Workbench, to account for patient 
choice, if they knew that their own ratio of radiotherapy to surgery is different to other hospitals, 
thus changing their overall demand to represent their own region and facilities. This is where the 
fact that the clinical decision trees are user modifiable helps MALTHUS provide local simulations 
with a greater accuracy. 
Overall, with the sensitivity analysis of the decision trees it is the major cancer groups that will 
cause the greatest changes to overall radiotherapy demand, as expected, with more sensitive 
areas laying towards the root of the trees.   
6.2.3 Coefficient of Variation 
The coefficient of variation (CV) is a useful tool for comparing the precision of different data sets. 
For this reason, it has been looked at for inclusion within MALTHUS to make sure that all general 
sets of results are produced with the same precision as each other. It would achieve this by 
automatically adjusting the number of walkthroughs that MALTHUS completes, based on a 
number of parameters: the number of Virtual Patients generated, the desired CV and the number 
of nodes within the clinical decision tree. The generation of the formula was by deriving 
relationships between the aforementioned parameters, the explanation of the methodology is in 
section 3.3.6 and 5.2. 
Despite the generation of a formula, it has not been included in MALTHUS yet because there are 
no strict guidelines on what a good coefficient of variation is. There are numerous examples of 
the usage of coefficient of variation in industry [56] [57] or University labs [58] and two sources 
do quote that a CV of below 0.05 is a valid target [56] [58].  
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However, further research needs to be undertaken to identify what would be a suitable 
coefficient of variation for MALTHUS to target. Setting an excessively low CV could unnecessarily 
increase the computational workload, while not setting the CV low enough could lead to 
imprecise results. Nonetheless, even though MALTHUS does not use the optimal number of 
walkthroughs formula, the CV calculations are still useful when compare the precision of different 
datasets. 
6.2.4 Overall Results 
The fast Monte Carlo has provided  large tables of results, in Appendix 1, that enables comparison 
between all PCTs and CNs, summarising the incidences within the PCT/CN, the cancer site 
contribution to total incidences, the total fractions in a given cancer site and the ARR for the 
PCT/CN. These tables show the differences that occur between PCTs and CNs again highlighting 
why loco regional models are important.  
A comparison between MALTHUS Pro and MALTHUS Workbench can verify the results from the 
fast Monte Carlo. Workbench generated a number of results using a different number of 
walkthroughs for comparison against the fast Monte Carlo results. In Workbench 2,000, 10,000, 
100,000 and 1,000,000 walkthroughs were selected. The repetition of the 2000 walkthroughs trial 
was to demonstrate how the results could vary when not enough walkthroughs are used. 
Table 6-1 presents the results, along with the number of nodes in each tree. The inclusion of the 
number of nodes is to see if the size of the decision tree is a contributing factor to any variations 
between the results. 
From Table 6-1 it is clear that there are minor differences between MALTHUS Pro and Workbench 
in bladder and prostate. The prostate tree has the largest difference, comparing 16.39 average 
fractions per person from MALTHUS Pro to 16.52 average fractions per person from Workbench 
on 1 million walkthroughs.  
The number of nodes within a tree is not contributing to the two main differences as the lung 
tree has more nodes than bladder and head and neck has more nodes than any other tree, with 
over three times the number of branches than in the bladder tree. If the number of nodes were a 
major factor then the expectation would be that head and neck and lung would show greater 
differences with head and neck showing the largest difference out of all trees.  
On close detailed inspection of node summaries after completing runs on both bladder and 
prostate the differences in number of fractions given appear to be fractions of a percent over the 
whole tree, totalling up to the 0.11 and 0.13 average number of fractions different respectively. 
The cause of this could be minor differences in how the random number generator works in both 
programming languages (Fortran vs Delphi). As with most programming languages Fortran 2008 
specifies that there shall be a uniform random number generator, however the standard does not 
specify the implemented algorithm. The Fortran 2008 random number generator has been put 
through the ‘Diehard tests’ by George Marsaglia, which test for randomness, and it passed well 
[59]. It is currently unknown how well the Delphi random number generator performs under the 
same suite of tests. In addition, minor differences between a bifurcated and non-bifurcate tree 
could contribute to the differences.  
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Cancer Site 
Number 
of 
Nodes 
Fast MC WB2k WB2k(2) WB10k WB100k WB1M 
Av.Fracs Av.Fracs Av.Fracs Av.Fracs Av.Fracs Av.Fracs 
Bladder 162 3.36 3.47 3.55 3.46 3.49 3.47 
Breast 165 14.41 14.50 14.43 14.40 14.44 14.39 
Cervix 75 11.51 11.63 11.40 11.48 11.50 11.48 
CNS 45 10.82 10.88 10.86 10.83 10.83 10.86 
Colon 3 0.5 0.52 0.50 0.51 0.50 0.50 
Endometrium 51 6.52 6.42 6.60 6.45 6.50 6.48 
H&N 530 22.62 22.75 22.66 22.67 22.60 22.61 
HL 39 8.33 8.43 8.35 8.32 8.30 8.30 
Kidney 3 0.80 0.82 0.80 0.80 0.80 0.81 
Leukaemia 3 0.25 0.24 0.25 0.25 0.25 0.25 
Lung 203 8.19 8.06 8.29 8.24 8.19 8.19 
Melanoma 35 0.52 0.54 0.50 0.52 0.52 0.51 
Myeloma 3 0.75 0.74 0.75 0.75 0.75 0.74 
NHL 45 2.68 2.70 2.72 2.68 2.65 2.69 
Oseophagus 73 4.75 4.67 4.73 4.77 4.78 4.74 
Others 3 2.20 2.20 2.20 2.20 2.19 2.18 
Ovary 3 0.48 0.49 0.48 0.48 0.48 0.48 
Pancreas 45 2.63 2.62 2.67 2.62 2.65 2.62 
Prostate 346 16.39 16.46 16.70 16.56 16.53 16.52 
Rectum 83 10.34 10.17 10.37 10.38 10.39 10.40 
Sarcoma 29 12.39 12.47 12.51 12.45 12.45 12.46 
Stomach 35 0.30 0.32 0.29 0.29 0.30 0.31 
Testis 31 0.75 0.74 0.72 0.74 0.72 0.74 
 
Table 6-1 Comparison between increasing number of runs in a MALTHUS workbench simulation 
and a MALTHUS Pro simulation, for all cancer sites. 
When comparing the total number of fractions over the whole of England, MALTHUS Pro predicts 
2073555 and Workbench predicts 2077994. That amounts to a 0.21% difference, which is an 
acceptable difference when considering they are calculating radiotherapy demand for 51.5 
million people over 23 different cancer groups, along with the fact that rounding to the nearest 
percentage occurs in the clinical decisions and stage distributions. 
6.2.5 Monte Carlo Results 
The full Monte Carlo results offer a higher level of information over the fast Monte Carlo results. 
Due to the current un-reactive nature of the decision trees, the full Monte Carlo runs predict the 
same average number of fractions per person, which is the expectation, because the fast Monte 
Carlo uses the same code. However, the full Monte Carlo also has information about the number 
of Virtual Patients generated, the spread of results and statistics based on the results, which the 
fast Monte Carlo does not calculate. 
 89 
In addition, because the tree nodes are un-reactive, the kurtosis is coming out at around three 
and the skewness is very low for the distribution of total fractions. This shows that they are 
normally distributed and are not skewed to one side. The expectation is that this would change 
between PCTs if factors such as age or stage presentation change some decision percentages.  
However, the coefficient of variation, which enables a comparison of precision between datasets, 
is quite different for the four PCTs. For bladder cancer, the CV ranges from 0.08 for Surrey, the 2nd 
largest PCT, to 0.23 for Hartlepool, the smallest PCT. This would indicate that for the smaller PCTs 
2,000 runs of 2,000 walkthroughs is not enough. The smaller PCTs, which have a lower number of 
incidences, would need to increase the number of walkthroughs that each Virtual Patient 
completes to compensate for the fewer Virtual Patients. Due to the difference in the number of 
incidences Surrey is undertaking almost 10 times the total number of walkthroughs that 
Hartlepool is. The difference in the total number of walkthroughs is driving the difference 
between the CVs, as the more iterations of a model that is completed, the more accurate the 
answer will be. This is demonstrated in Section 5.2 and, with further validation, the formula 
generated could be applied to MALTHUS to reduce the difference in precision between the 
different datasets.  
Tailored decisions on the amount of radiotherapy demand to be planned for, for regions within 
England, can be made by using the information generated in the full Monte Carlo runs. Just taking 
an average figure for the whole of England could under-estimate, or even over estimate in some 
cases, the actual demand if more or less than the average number of incidences of a certain 
cancer occur within a region.  
 
6.3 General 
6.3.1 Variations across England and Deprivation 
Table 5-11 summarises the largest differences between PCTs for each cancer site. The largest 
difference between PCTs occurs in lung cancer, where in Newcastle lung cancer accounts for 
19.57% of cancers, while in Wiltshire it only accounts for 8.69% of cancers. Prostate cancer also 
shows a large variation with it accounting for 16.43% of cancers in Dorset, but only 7.4% of 
cancers in Hartlepool. Breast cancer shows the third largest difference with it accounting for 
21.08% of cancers in Richmond and Twickenham but only 13.07% in Tower Hamlets.  
As expected, it is very clear to see from Table 5-11 that differences do occur between different 
regions, backing up the need for a regional model instead of just a national average. The regional 
variations could be due to a number of factors; age profile within region, life styles, smoking 
habits, drinking habits and deprivation to name a few. MALTHUS provides the ability to run 
simulations at local level as well as nationally which makes the results it produces unique 
compared to Australian and Canadian demand predictions.  
Table 5-11 also contains information on the deprivation ranking of the PCTs to investigate if there 
is any correlation between deprivation and the major differences in site contribution to overall 
incidences within a PCT. This is only a very limited and preliminary study as it only looks at the 
largest differences in the cancer groups and does not look at the profile of deprivation 
throughout each cancer group.  
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Further studies into the data to link the deprivation index for every PCT to the ranking of PCTs 
within a cancer group should be undertaken for a complete guide for across England on modern 
incidences and will require a collaboration with a deprivation expert. 
There are similarities between the preliminary study and a report completed by NCIN evaluating 
cancer incidence by deprivation over the period 1995-2004 [8]. Head and neck, stomach and lung 
are all in the deprived category, for MALTHUS, the classification of liver is under others, which is 
in the deprived category as is liver in the NCIN report. Breast, melanoma and prostate appear in 
the affluent category for both. The similarities that occur between the two sets of data are 
expected. Stomach, lung and head and neck show links to diet, smoking and drinking, which is 
more common amongst the deprived areas [8] [60]. 
6.3.2 MALTHUS Vs Other Models 
In comparing MALTHUS against CCORE's work in Australia and QCRI's work in Canada, it must be 
remembered that MALTHUS is aimed at a different output compared to CCORE and QCRI. The 
latter two have looked at the proportion of cancer patients requiring radiotherapy, i.e. the ARR. 
That is only one part of MALTHUS, while it does give that answer it also gives a lot more. 
MALTHUS also gives fractions given, patient age ranges of the fractions given, local variations in 
the model, a more rigorous of sensitivity analysis and future prediction of radiotherapy demand. 
 
Table 6-2 shows the difference in ARR between the three models and the contribution to total 
radiotherapy between CCORE and MALTHUS. A comparison of certain cancer groups is not 
possible, due to the different grouping of the cancers in the different models. In addition, QCRI 
modelled only a small number of cancers, which is why there are only three results for them. 
  Model ARR 
Contribution to Total 
Radiotherapy 
Cancer Site 
QCRI 
Canada 
CCORE 
Australia  
MALTHUS 
England 
CCORE 
Australia 
MALTHUS 
England 
Bladder   58.00% 23.43% 1.70% 0.78% 
Breast 66.0% 83.00% 76.09% 10.80% 12.82% 
CNS   92.00% 45.50% 1.80% 0.71% 
H&N   78.00% 80.85% 3.10% 2.33% 
Leukaemia   4.00% 5.00% 0.10% 0.13% 
Lung 61.0% 75.00% 61.24% 7.60% 7.66% 
Melanoma   23.00% 2.63% 2.50% 0.09% 
Oseophagus   80.00% 29.67% 0.80% 0.75% 
Pancreas   57.00% 14.85% 1.10% 0.38% 
Prostate 61.0% 60.00% 53.54% 7.20% 6.60% 
Stomach   68.00% 48.14% 1.40% 0.11% 
Testis   49.00% 4.89% 0.50% 0.03% 
 
Table 6-2. Comparison of modelled ARRs from MALTHUS Pro, CCORE, and QCRI, with 
information on cancer prevalence from CCORE and MALTHUS. 
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There are some significant differences between the models. The treatment for breast cancer 
appears to be very different in each model, while lung is almost identical between MALTHUS and 
QCRI’s model.  
Section 2.7 offers a comparison of the modelling techniques used by CCORE, QCRI and the initial 
MALTHUS plans.  
6.3.3 MALTHUS Vs the Original NRAG Report 
The original NRAG report was the seminal work that showed that there was a gap between the 
number of fractions currently delivered in England and the number recommended [27]. However, 
variations in incidence and treatment in different regions were noticed and linked to deprivation 
by the original NRAG writers [61]. Therefore, the need arose to build on from the original NRAG 
models and develop new methodology and clinical decision trees to be able to look into this. 
From this, the idea of MALTHUS was both generated and funded.  
Table 6-3 shows the difference in output from MALTHUS (working on the 2007-2009 average) to 
the original NRAG results and it shows the 2007 access rates from the NRAG study. As shown in 
the table, the appropriate rate of radiotherapy has actually decreased from the original NRAG 
estimate of 50.7% to around 40% from MALTHUS. Some of the updated, more complex trees in 
MALTHUS are predicting quite a different ARR from NRAG, as can be seen from the following 
examples. The largest difference lies with testicular cancer. NRAG originally estimated 46% ARR 
while MALTHUS estimates 4.89%. The results for rectum also showed a large difference with a 
decrease from 88.7% to 48.4%.  
A reason for the differences between MALTHUS and NRAG is the complexities of the clinical 
decision trees are different, there are approximately 260 decisions in NRAG and 2000 in 
MALTHUS. This creates a better-defined model for demand, which leads to possibility of more, or 
fewer, indications for radiotherapy in areas where NRAG did or did not have an indication for RT 
due to more treatment options considered or disease classifications taken into account. 
Additionally, the basis of the NRAG model was Scottish research and adjustments made for 
application to England. A newer evidence base, data from English registries and larger clinical 
consensus was utilised to create the clinical decision tress for Malthus from scratch. The larger 
clinical consensus came from the MALTHUS user group meetings that occurred, gathering the 
knowledge of over 70 different clinicians, radiotherapists and radiation physicists from across the 
country.  
Where there have been substantial changes between NRAG and MALTHUS, the MALTHUS 
estimates are actually closer to the measured 2007 access rate, showing that the MALTHUS 
decision trees could potentially more accurately represent the clinical practice in England.  
Another factor to take into account is that both NRAG and the 2007 figures include re-treatment 
and MALTHUS does not. Therefore, the difference would be smaller between NRAG and 
MALTHUS if re-treatment was be applied to MALTHUS. The gap between MALTHUS and the 2007 
figures would increase if MALTHUS were to include retreatments, as the ARR for MALTHUS would 
increase. 
For an in-depth analysis on where the differences are actually arising from within the clinical 
decision trees, and why, a clinician would be required to provide the analysis between the NRAG 
and the MALTHUS trees. The original NRAG clinical decision tree also do no state the source of 
information used. 
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In addition, MALTHUS can evaluate the regional variations that NRAG could not, as shown in 
Table 5-11 and the overall results generated by the fast Monte Carlo shown in Appendix 1. 
MALTHUS itself can be considered a success as it was mandated to be used by the NHS in future 
planning for radiotherapy demand [62]. This shows that the NHS is sufficiently confident in the 
model and its outputs. The creation of the program was in such a way that it is very easy to insert 
additional clinical decision trees, or update them, and use up to date data on population and 
incidences so when newer data becomes available it is the basis of MALTHUS radiotherapy 
demand predictions. This combined with MALTHUS’s ability to work with adaptive nodes, if a 
decision tree requires it, means that the core program is a highly flexible “shell” designed to be 
adapted to suit various requirements. Additionally the program is not fixed and so updates are 
possible in the future for any new requirements that arise, such as multimodal treatment, new 
treatments like proton beams or more complex self adjustment criteria.  
  NRAG MALTHUS 2007 Access Rate 
Bladder 31.00% 23.43% 31.00% 
Breast 71.70% 76.09% 62.70% 
Cervix 56.40% 47.32% 53.50% 
CNS 61.30% 45.50% 63.70% 
Colon 0.70% 5.00% 5.20% 
Corpus Uteri 46.20% n/a 58.10% 
Endometrium n/a  28.72% n/a  
H&N 78.60% 80.85% 65.40% 
HL 70.60% 58.67% 38.70% 
Kidney 24.10% 10.00% 8.20% 
Leukaemia 4.00% 5.00% 4.90% 
Lung 65.90% 61.24% 49.70% 
Melanoma 15.70% 2.60% 9.70% 
Myeloma 33.10% 25.00% 24.40% 
NHL 54.30% 19.83% 29.30% 
Oesophagus 53.70% 29.67% 51.20% 
Others 50.20% 20.00% 19.80% 
Ovary 4.00% 6.04% 6.10% 
Pancreas 49.80% 14.85% 3.50% 
Prostate 61.40% 53.56% 46.60% 
Rectum 88.70% 48.37% 40.30% 
Sarcoma  n/a 48.14% n/a 
Stomach 13.40% 4.74% 6.40% 
Testis 46.00% 4.89% 8.00% 
Total 50.70% 39.63% 36.80% 
 
Table 6-3. Comparison between the modelled ARRs from MALTHUS and NRAG with the 2007 
audited access rates. 
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6.4 Summary 
This section has discussed the different aspects of MALTHUS, from the input data, through the 
different assumptions and features of the model and to the results it outputs. The various 
sections of the model were discussed with reasons given as to why certain things where chosen 
for their purpose.  The discussion of the results was to analyse both the expected and unexpected 
results and validations and to then compare them to other models. The overall results showed 
the variations in incidences across different PCTs in England and started to link deprivation to the 
differences.  
The next section will address the conclusions and recommendations from the project. 
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7 Conclusions and Recommendations 
7.1 General Conclusions 
The healthcare community has established the need for an accurate radiotherapy tool to predict 
demand in, driven by an increase in cancer burden associated with an ageing population, and a 
shortfall in treatment services. From this unmet need, our team has developed the idea of 
creating custom decision tree software for predicting radiotherapy demand. The research version 
of the tool that forms the core of my dissertation, MALTHUS, was written ab initio in the 
computationally efficient Fortran language and has utilised both custom code and our 
departmental Fortran common library for statistical calculations.  
A few areas of novelty have emerged from the development of MALTHUS. The first is the concept 
of a Virtual Patient that traverses the clinical decision trees and collects a Virtual Patient record of 
treatment data rather than a standard decision tree that bases its result on the terminal branch 
of a random walkthrough.  
Another area of novelty links in with the Virtual Patients, namely the Virtual Patient reactive 
node. The nodes within MALTHUS have the option of changing one of its underlying variables in 
reaction to a variable encountered with specific parameters within a Virtual Patient. This gives 
MALTHUS the ability to simulate the differences in regions accurately. Even without the reactive 
nodes, MALTHUS still operates on a regional level covering the whole of England, which no other 
model worldwide does so far. This enables MALTHUS to offer a far more accurate simulation of 
radiotherapy demand. 
A critical review of literature from other research groups, that have published their work 
evaluating decision trees for radiotherapy demand prediction, shows that the design of their 
models does not operate at a regional level of radiotherapy demand. They have been based 
around a basic decision tree structure/operating model and they only consider the ARR and not 
the number of fractions to be delivered. 
The detailed methodology of MALTHUS has been described and it has been explained how the 
different sections operate, providing knowledge of the program, so it can be understood where 
the results came from and how they were generated. The explanation of the creation of the 
external XML clinical tree reader and bifurcator shows how the clinical decision trees are 
converted for use within MALTHUS, along with an explanation of the .Tom files that will be the 
basis for the Delphi/Fortran link that join the research and open access version of the model. 
The creation of the area of the program that deals with the population data and cancer incidence 
data was in such a way that the data files are not constricted to specific age band structure for 
input, the program automatically sorts them out into individual age bands and matches the 
correct incidence to population data. This enables more flexibility when it comes to using new 
data, potentially from difference sources. 
The description of the operating modes shows the different simulations, tests and verification 
tests that MALTHUS can currently complete. These expansion of, and addition to, these modes is 
possible as it is our own program, so there is access to the complete source code.  
The Verification tests on the population and Virtual Patient generator, tree walkthrough and the 
node modifier all demonstrated consistent results showing that MALTHUS is able to generate 
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valid cohorts of patients, walk them through the tree and produce viable results. This adds 
validation to the general results the program outputs, as it can be said that the core components 
work correctly, and increases the credibility of the results of the application 
The sensitivity analysis results show how changes within age bands affects the incidences and 
how changing the decisions within the tree can affect the overall radiotherapy demand. The 
program adjusted every single node in all trees by +/- 1%, 5% and 10% to measure the change in 
output, with the actual tree sensitivity analysis using the 10% results. For the patient generator an 
adjustment to the number of incidences by +/- 10% in each age band highlights the effect each 
age band has on the overall number of incidences. Both of these sensitivity analysis tests are 
important, as it is known that the population age profile is changing and that clinical decisions are 
not going to be the same in every region. The tree sensitivity analysis also has the extra benefit of 
showing which clinical decision do have the greatest effect on the number of fractions, highlight 
where extra research should be completed on the accuracy of the clinical decisions.  
The full Monte Carlo results show the full capabilities of the program, running the Virtual Patient 
generator and tree walkthrough 2,000 times each, giving a full range of output results and 
statistics. The fast Monte Carlo provides a large quantity of information about the different PCTs 
within England by walking a single generic patient through each clinical decision tree 4,000,000 
times and then applying the results to the number of incidences of any population group. This 
computational shortcut only holds true for non-reactive clinical decision trees but with the 
current non-reactive clinical decision trees, the fast Monte Carlo can highlight the differences in 
fractions, incidence and ARR between the PCTs.   
Discussion and evaluations occurred for all aspects of MALTHUS, from the input data, through the 
model and to the results it outputs. The various sections of the model have been discussed with 
reasons given as to why certain things where chosen for their purpose.  The discussion of the 
results looked at both the expected and unexpected along with validations and comparisons to 
other models. The overall results, based on the fast Monte Carlo output, showed the variations in 
incidences across different PCTs in England, which also highlights the need for regional models 
over a single country wide average model. 
MALTHUS is able to operate at the regional level because of the high level of input data the NCIN 
provided. The data came from the UK Cancer Information System, which is the data collected by 
the cancer registries. The clinical decision trees compiled by Dr Raj Jena, Dr Michael Williams and 
Dr Caroline Round are also more complex than other clinical decision trees published for 
radiotherapy demand prediction. Those two combined, enable MALTHUS to complete Monte 
Carlo method simulations and provide a high level of information on output. 
Even though the current clinical decision trees in MALTHUS do not contain information that 
utilises reactive nodes, results showed them working. Due to this, the full Monte Carlo was 
underutilised. Nonetheless, results proved that full Monte Carlo works, but it would be a lot more 
effective with reactive trees so the outputs do depend on the population input data.  
With the fast Monte Carlo completed and applied to every single PCT in England and the indices 
of deprivation applied to the results table, a brief look into possible deprivation links to cancer 
incidence was undertaken. The identification of few associations, such as breast and stomach 
cancer incidence, follows the pattern suggested by the current literature. However, this was only 
a brief investigation and the results that MALTHUS outputs are applicable to more investigation 
work into incidence patterns. 
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MALTHUS has successfully achieved the original objectives of creating a robust, local radiotherapy 
utilisation model, using actual population and incidence data to be able to build a true 
representative cohort of patients and then be able to walk them through a clinical decision tree 
to predict the number of required fractions. MALTHUS not only works on a regional level and 
country level, but on any level for which input population and incidence data is available. 
Additionally the fast Monte Carlo results are applicable to any population/incidence data, 
including any future predictions in the data. 
7.2 Recommendations for Further Work 
While MALTHUS has been successful in generating valid results and setting up a platform for 
future work, a few areas of further investigation have arisen. 
A major area of potential interest is the effect of socioeconomic factors such as deprivation on 
radiotherapy demand. This has been evaluated briefly within the project and externally to a 
greater extent, however, there is plenty of scope to do an in depth analysis of incidence profiles 
versus PCT deprivation, and then if the data is available, extend the analysis to consider stage 
distribution. The encoding of any proven relationship into the clinical decision trees in MALTHUS 
to provide ‘deprivation aware’ decision trees is entirely possible. Other factors should also be 
looked at in conjunction with deprivation, for example while a cancer may tend to be prevalent in 
more deprived regions it could be that other factors are driving this prevalence over deprivation, 
such as an older age profile, environmental or occupational factors. This potentially could benefit 
patients as it could allow the NHS to plan the local resources more effectively and undertake 
things such as targeted cancer screening and surveillance for regions depending on their 
deprivation level. When examining a combination of factors such as deprivation, age and 
incidence this could also help the NHS by highlighting areas where deprivation has a smaller 
effect than previously imagined and could save research money and time from looking at 
deprivation links that are not necessarily there. 
While the input data into MALTHUS is of the highest quality available, the population and 
incidence data should both have an analysis of errors attempted. There is a chance that the 
incidence data has not been recorded correctly, multiple counts for some incidences or no counts 
for others. Therefore, error analysis would then include any uncertainties in the results cause by 
possible errors in the incidence data. The same is applicable to the population data, especially 
with any population prediction data or models. This would only serve to strengthen the outputs 
that MALTHUS produces, benefiting all users of MALTHUS. 
The sensitivity analysis of the decision trees show a number of sensitive decisions have the 
possibility of a factor that is not directly related to cancer incidence influencing them. It could be 
based on resources within a hospital, what treatments the clinician has been trained to give or 
even that a clinician may choose to use a newer style of treatment based on a study that others 
have yet to evaluate (perhaps in the context of a clinical trial). Hence, thorough investigation with 
clinicians is required on the areas that the sensitivity analysis has highlighted, to assess the 
probability that they could change. This thorough investigation work will only stand to make 
MALTHUS a more accurate tool for the NHS to use, providing better results to act as basis for 
commissioning policy. 
Another important area that remains under-investigated is the effect of patient choice. Just 
because the best option in terms of treatment outcome is treatment A does not mean that the 
patient will necessarily choose it. They could possibly choose treatment B due to time or distance 
factors. Thus, an area of study is patient choice and distance to treatment centre, as well as the 
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reaction of Drs to treatment pathways and resources. A study of patient choice and the factors 
contributing that choice would benefit commissioners as it could help them plan for new satellite 
radiotherapy centres to ensure that the maximum amount of the population has reasonable 
access to the best treatment, if that treatment is radiotherapy.  
Leading on to hospital resources, a logical step for MALTHUS would be to look at other treatment 
modalities beyond radiotherapy. There already are a few surgical decision nodes in the clinical 
decision trees but and expansion to a ‘surgical node’ could include their own surgical factors built 
in, radiotherapy has fractions so surgery could have complexity or length of surgery for example. 
Chemotherapy is another area of study, it could lead to the generation of a new set of decision 
trees. Or even built alongside the radiotherapy trees with surgery too, to generate a program to 
calculate all common treatment modalities in an integrated fashion. A tool that combines all of 
the common treatment modalities can only benefit everyone. The NHS would be able to plan the 
best mix of treatments in a region, the commissioners to be able to future plan for all cancer 
services within their region and the patients, to give them access to the best possible and optimal 
treatment that they require. 
As well as common treatment modalities, the investigation of new treatment modalities is 
possible, such as proton therapy to coincide with the building of the brand new proton treatment 
centres in England. Treatment indications for proton beam therapy will not be the same as 
conventional x-ray treatment, and so the current clinical decision trees may not be applicable for 
new proton therapy planning. The help of clinicians working with protons and possibly a proton 
therapy solution provider could assist in the adaptation of MALTHUS, to produce what possibly 
could be the world’s first demand prediction program for proton therapy. The flexibility of 
MALTHUS would especially help this, as a brand new proton centre would not just replace an 
existing radiotherapy centre, it would work alongside the current radiotherapy centres and would 
therefore only be getting select patients. This is where MALTHUS could produce the region 
specific demand predictions for treatment indications for a new proton therapy centre.  
Aside from building new things into MALTHUS, it could potentially utilise results from other 
models to give additional value. For example the Workforce Integrated Planning Tool (also 
commissioned by NCAT) calculates the number of workforce required for a given radiotherapy 
service. Simple estimates from this are easy to add into MALTHUS to provide basic information on 
the workforce required for the radiotherapy demand predicted. So a generic “radiotherapy” tool 
could be produced that enables commissioners or planners to look at the whole picture for their 
region, something that goes beyond a crude fraction burden or ARR, but rather a prediction of 
treatment demand, machine requirements and lifecycle management, work force and skill mix. 
Such an analysis could be sense checked against the Radiotherapy Equipment Survey, enabling 
the highlighting of areas where there is in fact overcapacity next to a region with under capacity. 
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7.3 Concluding Comments 
To summarise the MALTHUS program is a Fortran based tool that utilises a novel method of 
decision tree walk through by using a Virtual Patient structure and Monte Carlo methods to 
predict radiotherapy demand. As specified in the original aims it not only calculates appropriate 
rates of radiotherapy but also calculates the number of fractions required. Another project 
requirement is to be able to calculate demand down to regional level, something that has 
remained unachieved prior to this work.  MALTHUS achieved this enabling a more accurate 
prediction for the NHS to use to address the current shortfall in radiotherapy provision. It also has 
the ability to work with self-adjusting, reactive decision trees to allow the undertaking of more 
complex simulations. Further developments on MALTHUS could unlock its full potential and to 
provide a much more comprehensive set of results on top of the radiotherapy demand results it 
already achieves. 
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8 Publications and Presentations Arising from this Research  
Out of the MALTHUS Project there have been a number of new Linacs and radiotherapy satellite 
centres commissioned. The Norfolk and Norwich have an additional new machine after Tom 
Roques used MALTHUS to provide justification for his hospital. Sheffield Hospital did similar.  
Swindon have recently had a satellite radiotherapy centre approved on the justification of needs 
presented by output of MALTHUS [63].  
 
There have been three papers and an editorial that have arisen from the MALTHUS project and 
they can be found, printed, in Appendix 2: 
Quantifying Uncertainty in Radiotherapy Demand at the Local and National Level using the 
MALTHUS Model. R. Jena, T.Mee, N.F.Kirkby, M.V.Williams. Clinical Oncology 27 , January 2015, 
92-98 
The MALTHUS Programme: Developing Radiotherapy Demand Models for Breast and Prostate 
Cancer at the local, Regional and National Level. C.Round, T.Mee, N.F.Kirkby, T.Cooper, 
M.V.Williams, R.Jena. Clinical Oncology, 2013, September, 25(9):538-45 
Radiotherapy Demand and Activity in England 2006-2020. C.Round, M.V.Williams, T.Mee, 
N.F.Kirkby, T.Cooper, P.Hoskin, R.Jena. Clinical Oncology, 2013, September, 25(9):522-530 
Editorial: The MALTHUS Programme – A New Tool for Estimating Radiotherapy Demand at a Local 
Level. R.Jena, C.Round, T.Mee, N.Kirkby, P.Hoskin, M.Williams. Clinical Oncology, 2012, 24:1-3 
 
Dr R. Jena gave a presentation at the 2nd ESTRO Forum in Geneva in April 2013 on Needs Vs 
Provision: how does the UK tackle this problem.   
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10 Appendix 1 – Files on CD  
All the files below should be on the attach CD to this thesis (or be provided with an electronic 
copy of the thesis). They are all standard files and should be able to be opened with Microsoft 
word & excel, Notepad or an internet browser. The .csv files should be opened with Excel. 
Each excel (.xlsx file has a ‘Read Me’ tab as the first tab in the file, this should explain bits of the 
file to the reader. 
Chapter 3: 
3.3.1 Example XML tree file:    XML Endometrium.XML  
           Example Fortran tree file:   FORTRAN Endometrium.txt 
3.3.4 Optimal number of walkthroughs: OptimalNumberOfWalkthroughs.xlsx 
3.4.6 Monte Carlo example output:  MC Cancer Summary.csv 
Chapter 4: 
4.2 100,000 walkthrough justification 100000Justification.xlsx 
Chapter 5: 
5.1.1 Patient generator sensitivity analysis Sensitivity Analysis – PatGenCORN.xlsx 
      Sensitivity Analysis – PatGenHART.xlsx 
      Sensitivity Analysis – PatGenNEWC.xlsx 
      Sensitivity Analysis – PatGenSURR.xlsx 
5.1.2 Decision tree sensitivity analysis Sensitivity Analysis – Tree.xlsx 
5.2 Full Monte Carlo results   Results in organised folders in the chapter 5  
      folder 
5.3 Fast Monte Carlo results for Cancer Networks  Overall CN.xlsm 
 Fast Monte Carlo results for PCT’s   Overall PCT.xlsm 
Chapter 6: 
6.2.1 See files for 5.1.1 
6.2.2 See files for 5.1.2 
6.2.3 See files for 5.3 
6.2.4 See files for 5.2 
6.3.3 See files for 5.3 
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Abstract
The Malthus programme produces a model for the local and national level of radiotherapy demand for use by commissioners and radiotherapy service leads in
England. The accuracy of simulation is dependent on the population cancer incidence, stage distribution and clinical decision data used by the model. In order to
quantify uncertainty in the model, a global sensitivity analysis of the Malthus model was undertaken. As predicted, key decision points in the model relating to
stage distribution and indications for surgical or non-surgical initial management of disease were observed to yield the strongest effect on simulated radio-
therapy demand. The proportion of non-small cell lung cancer patients presenting with stage IIIB/IV disease had the largest effect on fraction burden in the four
most common cancer types treated with radiotherapy, where a 1% change in stage IIIb/IV disease yielded a 1.3% change in fraction burden for lung cancer
patients. A 1% change in mastectomy rate yielded a 0.37% change in fraction burden for breast cancer patients. The model is also highly sensitive to changes in
the radiotherapy indications in colon and gastric cancer. Broadly, the ﬁndings of the sensitivity analysis mirror those previously published by other groups.
Sensitivity analysis of the local-level population and cancer incidence data revealed that the cancer registration rate in the 50e64 year female population had
the highest effect on simulation results. The analysis reveals where additional effort should be undertaken to provide accurate estimates of important pa-
rameters used in radiotherapy demand models.
 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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Statement of Search Strategies Used and
Sources of Information
This paper reﬂects expert opinion and current literature
accessed by the authors; no formal search strategy has been
deﬁned.
Introduction
The Malthus programme is a radiotherapy demand
model commissioned by NHS England in 2011 to provide
estimates of radiotherapy demand at both the local and
national level. The previous model from the National
Radiotherapy Advisory Group predicted a nationwide
annual radiotherapy demand of 54 000 attendances per
million of population by 2016, with an access rate (per-
centage of cancer patients requiring radiotherapy at some
stage in their illness) of around 50% [1]. The National
Radiotherapy Advisory Group model was instrumental to
the infrastructure investment for cancer services in En-
gland. However, the model was not always observed to
provide a good ﬁt with local-level simulations, due to sig-
niﬁcant regional variation in population demographics and
cancer burden within England. The aim of Malthus was to
use local-level population and cancer incidence data to
provide ﬁne-grained estimates of radiotherapy demand at
the local level [2,3]. For the year 2016, the Malthus model
simulations at the national level predicted a higher annual
radiotherapy demand at 55 200 attendances per million of
population, even though the predicted access rate for
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radiotherapy had dropped to 40.6%. However, local-level
simulations carried out in the Malthus model reveal the
heterogeneity of radiotherapy demand. Annual radio-
therapy demand in Haringey Primary Care Trust (PCT), a
North London city commuter area, is predicted to reach
38 800 attendances per million in 2016. For the same time
period, demand in Torbay PCT, a coastal retirement area, is
predicted to reach 71 900 attendances per million.
Malthus joins a cohort of models that have been created
to estimate appropriate rates of radiotherapy utilisation in a
range of healthcare systems [1e5]. A common feature of
these models is the use of data relating to new cancer
incidence, cancer stage distribution and appropriate in-
dications of radiotherapy treatment in order to provide an
estimate of appropriate radiotherapy utilisation. Previously
published models utilise MonteeCarlo simulation tech-
niques to produce a continuous simulation, which tracks
the dynamics of the usage of radiotherapy treatment over
time, yielding a ﬁnal estimate of the appropriate use of
radiotherapy treatment for each clinical indication. Malthus
differs slightly in design from other models in using discrete
event simulation. Instead of modelling radiotherapy de-
mand continuously, patients pass through a series of
discrete ‘events’ where they may or may not accumulate an
indication for radiotherapy treatment and a number of
treatment attendances. These events may represent staging,
decisions around initial surgery, nodal status or patient
factors such as age or comorbidity. In modelling terms, each
discrete event that is associated with radiotherapy treat-
ment attendance marks a change in the state of the virtual
cancer patient. These events are encoded in a single docu-
ment or structure, known as a decision tree. As each virtual
cancer patient is passed through the appropriate decision
tree, the treatment statistics are summated to produce the
ﬁnal result of the simulation. The ﬁnal result is therefore
probabilistic in nature and each time the application is set
to run a given simulation, there will be a small difference in
the predicted number of treatment attendances.
All of the radiotherapy demand models are subject to
uncertainty. Despite tremendous advances in electronic
data capture for cancer registration by the UK cancer reg-
istries, ascertainment for cancer diagnosis and stage are not
available in full for all tumour types. As such, estimates for
stage distribution are encoded into the model, utilising data
from national audits and local cancer registries. Further-
more, although the model tries to encode best clinical
practice based on clinical trial data, uncertainty exists in
determining appropriate values for decision events down-
stream of cancer diagnosis, such as trying to determine an
appropriate rate of mastectomy for postmenopausal
women with stage II breast cancer. For such events, the
model relies on estimated data, established from clinical
consensus and review of evidence in the literature.
Although discrete event simulation is a powerful modelling
technique, it remains prone to such uncertainties in esti-
mated data that are used to construct the model. In other
models of this type, the effect of uncertainty in individual
estimates in the clinical decision tree have been evaluated
via univariate and multivariate sensitivity analysis [4,6]. In
such an analysis, parameter values for each individual es-
timate utilised in the model are varied in a systematic
manner, in order to determine the effect on the ﬁnal output
of the model. In the published models of radiotherapy uti-
lisation, the analysis is typically only carried out on the
decision trees that encode treatment decisions.
The Malthus model encodes population and cancer
incidence data for local populations. At the time the model
was commissioned, healthcare services in England were
divided into 152 local PCTs and 28 regional cancer networks.
The accuracy of local-level simulations will depend both on
the accuracy of estimates encoded in clinical decision
trees and on the accuracy of estimates of cancer incidence in
the local population. In this manuscript, we describe the
extension of the Malthus model to include a global sensi-
tivity analysis. This analysis extends not only to clinical
events described in the decision trees, but also evaluates
uncertainty in population and cancer incidence data both at
the local and national level. The results of the sensitivity
analysis reveal where additional effort should be directed in
order to reduce uncertainty in the output of the model.
Materials and Methods
Design of the Model and Data Inputs
The design of the Malthus model has previously been
described [2,3]. In brief, the model application simulates
radiotherapy demand to follow the organisational structure
of the NHS before April 2013. Population demographic data
and cancer registration data are available for each of the 152
PCTs that made up NHS England from 1 April 2007 to 31
March 2009. The population was also divided up into 28
cancer networks, although it should be noted that one PCT
may belong to more than one cancer network. For each of
these population areas, the model calculates the radio-
therapy demand for 23 tumour sites and provides summary
statistics (see Figure 1). Furthermore, the model uses pop-
ulation growth models from the Ofﬁce of National Statistics
and cancer incidence models from Cancer Research UK to
predict radiotherapy demand into the future. Factors
inﬂuencing clinical decision making around surgery,
radiotherapy and chemotherapy were encoded into deci-
sion trees (see Figure 2). For each cancer type and stage,
appropriate rates of radiotherapy utilisation and fraction-
ation schedules were established from evidence-based
studies in the literature. For some treatment indications,
robust evidence was not available and for these estimates
we obtained estimates via clinical consensus after consul-
tation with a group of over 100 oncologists from across the
UK. This version of the model was coded as a Microsoft
Windows application, which was made freely available to
the radiotherapy community, allowing users to run and
customise their own simulations (Malthus Workbench).
A second version of the model was developed in the
Fortran language, capable of reading the same population
data and decision tree data ﬁles used in the public version of
the model (Malthus Pro). The decision trees were converted
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Fig 1. Overview of operation of the Malthus model. Local-level data are used to generate a population of virtual cancer patients with an age,
gender and frequency distribution that matches that of the underlying population. The patient is allocated a cancer type and passed into the
appropriate decision tree. As the patient traverses the tree, radiotherapy treatment attendances are accrued according to evidence-based in-
dications. Statistics are summated across all virtual patients to yield the ﬁnal estimate of radiotherapy demand.
Fig 2. Excerpt from lung cancer decision tree. Stage distribution, initial management, radiotherapy indications and fractionation regimens are
included in the decision tree. Percentage values indicate the proportion of patients passing to a speciﬁc node of the decision tree, which are
subjected to sensitivity analysis.
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into a binary tree structure, to allow simulation of individ-
ual cancer patients to be carried out at high speed. This
greatly facilitated the sensitivity analysis, allowing every
single parameter in themodel to be varied and the results to
be collected within a reasonable timeframe.
Implementation of Sensitivity Analysis
The sensitivity analysis consisted of two key compo-
nents. The ﬁrst was a sensitivity analysis of the 23 decision
trees that encode appropriate rates of radiotherapy usage
and fractionation data. The analysis was carried out on each
decision tree in isolation and the results were then com-
bined to produce the overall sensitivity analysis. To carry
out the sensitivity analysis, a single virtual patient was
generated and passed through the decision tree 1 000 000
times to obtain results on predicted fractionation. The
probability associated with each node in the tree was then
changed by 1%, 5% and 10% and the analysis repeated. The
process was repeated for every node in the decision tree to
determine the effect of each given node on the predicted
fraction burden for a patient.
The second component was a sensitivity analysis of the
virtual patient generator. This was used to determine how
the model is sensitive to population demographic data and
cancer registration data at the level of the local population.
It was observed during the design of the sensitivity analysis
that variation of the base population values, while main-
taining the same cancer registration ﬁgures, has the same
effect as modifying the cancer incidence rate. Similarly,
variation of both the base population values and cancer
registration ﬁgures by the same amount would yield exactly
the same cancer incidence rate. This would have a con-
founding effect on the sensitivity analysis. It was therefore
decided to carry out the sensitivity analysis by modifying
the cancer incidence directly. This was performed by
modifying the incidence for each age band in each PCT by
10% and observing the result on predicted radiotherapy
fraction burden.
The analysis was carried out for all 23 cancer types on
four representative PCTs (Hartlepool, Newcastle, Cornwall
and Surrey). These PCTs were chosen to give a spread of PCT
size, geographical location and population age distribution.
Veriﬁcation of the model against base data was carried out
to ensure that no systematic errors were introduced into the
model through the addition of the sensitivity analysis code.
Analyses were carried out for a 3 year period and the results
were annualised.
Fig 3. Results of sensitivity analysis of virtual patient generator. The effect of 10% variation in cancer incidence for each age cohort on overall
breast cancer incidence is shown for the four representative primary care trusts (PCTs).
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Results
Due to the volume of data generated by the sensitivity
analysis, representative sections of the analysis will be
shown.
Sensitivity Analysis for Cancer Incidence Data
Breast cancer incidence was observed to have the largest
effect on the model and the strongest effect was observed
by variation of the breast cancer incidence in the 60e64-
year-old patient cohort in Cornwall PCT. A 10% increase for
this value yielded a 1.59% increase in overall breast cancer
incidence. For Surrey and Newcastle, the same 60e64-year-
old cohort was found to have the greatest effect, such that a
10% change in the value yielded changes in the overall
breast cancer incidence of 1.41 and 1.34%, respectively. For
Hartlepool, the largest effect was observed in the 55e59
year age group (1.4% increase). The results across all age
bands are shown in Figure 3.
Sensitivity Analysis for Clinical Decision Trees
The results of varying values in the clinical decision trees
are shown for 1% perturbations. The effect is the percentage
change in predicted fraction burden, both for the individual
tumour type and for the model as a whole. Note that in
some cases, increasing the proportion of patients entering a
speciﬁc node of the decision tree can have the effect of
decreasing the total fraction burden, by diverting patients
away from a treatment regimen with a large fraction
burden. Considering ﬁrst the four most common indications
for radiotherapy (breast, prostate, lung and head and neck
cancer) we observed that the most sensitive nodes inﬂu-
encing simulated fraction burden lay early in the decision
tree. For the breast cancer tree, the choice of mastectomy or
breast-conserving surgery for ductal carcinoma in situ, stage
I and stage II breast cancer had the greatest inﬂuence on
fraction burden. In the prostate cancer tree, the incidence of
high-risk stage T3-4 disease and patients presenting with
metastatic disease had the greatest inﬂuence. In the lung
cancer tree, the split between stage IIIa and stage IIIb/IV
disease had the greatest inﬂuence; in head and neck cancer,
the proportion of patients presenting with nasopharyngeal
cancer had the greatest inﬂuence. Details of the most sen-
sitive nodes for each of these four sites are summarised in
Table 1.
Extending the analysis beyond the four most common
cancers, we observed key decision steps in other trees that
had a signiﬁcant effect on the model output. Two of the
most signiﬁcant steps relate to radiotherapy treatment
Table 1
Results of the sensitivity analysis showing the ﬁve nodes having the greatest effect on fraction burden for the four most common tumour
types treated with radiotherapy. The ﬁrst percentage change column relates to the effect of the node within their given decision tree,
whereas the second percentage column relates to the effect of the node on the model as a whole
Site Node description Sibling node description % Change in
attendance
given 1%
change
% Overall change
in number of
attendances
given 1% change
Breast S1 e Mastectomy BCS 0.37 0.106
S1 e BCS Mastectomy 0.37 0.106
S2 e BCS Mastectomy 0.34 0.098
S2 e Mastectomy BCS 0.34 0.098
DCIS e Mastectomy BCS 0.17 0.049
Prostate Metastatic disease High risk T3e4 0.60 0.166
High risk T3e4 Metastatic disease 0.60 0.166
High risk T3e4 e unﬁt for radical treatments Fit for radical treatments 0.53 0.147
High risk T3e4 e ﬁt for radical treatments Unﬁt for radical treatments 0.53 0.147
High risk T3e4 e ﬁt for radical treatments e hormones
alone/surgery e found to be T3 with positive margins
Hormones and radiotherapy 0.41 0.114
Lung NSCLC e stage IIIa NSCLC e stage IIIb or IV 1.28 0.170
NSCLC e stage IIIb or IV NSCLC e stage IIIa 1.31 0.174
NSCLC e stage IIIb Stage IV 0.98 0.130
NSCLC e stage IV Stage IIIb 1.00 0.133
NSCLC e stage IIIb e good performance status Poor performance status 0.59 0.078
Head and
neck
Oropharynx/unknown primary HNC e stage IVc Stage IIIeIVb 0.27 0.024
Oropharynx/unknown primary HNC e stage IIIeIVB Stage IVc 0.27 0.023
Oropharynx/unknown primary HNC e stage III/IVb e not ﬁt
for curative therapy
Fit for curative therapy 0.26 0.023
Oropharynx/unknown primary HNC e stage IIIeIVb e ﬁt for
curative therapy e disease unsuitable for curative therapy
Disease suitable for curative
therapy
0.26 0.023
Oropharynx/unknown primary HNC e stage III/IVb e ﬁt for
curative therapy
Not ﬁt 0.25 0.022
BCS, breast-conserving surgery; NSCLC, non-small cell lung cancer; HNC, head and neck cancer; DCIS, ductal carcinoma in situ.
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indications for melanoma, stomach cancer, and the decision
tree encoding treatment options for other cancers beyond
the 22 tumour sites considered explicitly by the model (see
Table 2).
Comparison with Sensitivity Analysis from Other Groups
The varying structure of the decision trees used by each
of the research groups precludes a direct comparison of
sensitivity analysis. The Canadian and Australianmodels are
designed to simulate an optimal utilisation rate for radio-
therapy, deﬁned as the proportion of cancer patients ex-
pected to receive radiotherapy treatment. Our model
simulates radiotherapy demand in terms of fraction burden.
However, it is interesting to note that our sensitivity anal-
ysis resembles ﬁndings published by Barton et al. [7] in the
Cancer Care Australia 2003 report, inwhich themost critical
decision points established by the sensitivity analysis match
very closely to our own analysis (see Table 3).
Discussion
The formal sensitivity analysis is helpful in determining
the sources of uncertainty in a radiotherapy demand
simulation. We have shown in the analysis of population
demographics and cancer incidence that there are locale-
speciﬁc effects that need to be considered when collecting
data, because a national-level simulation will have the ef-
fect of smoothing out differences between local pop-
ulations. Breast cancer incidence for women between the
ages of 50 and 64 years has themost signiﬁcant effect on the
model. This is no great surprise, as this corresponds to the
screening age for women in the UK and cancer registrations
from screening programmes will probably have high levels
of case ascertainment. Bladder cancer incidence shows a
peak sensitivity in the model in males over 65 years and
ascertainment rates may be lower for this tumour type.
Understanding changing population demographics will
therefore be important for modelling radiotherapy demand
for bladder tumours. Population projections for the next 20
years show clearly that the greatest increase will be in the
proportion of the population aged 65e80 years, but there is
a lack of data evaluating projected changes at the local level
[8]. In counterpoint, we observe from the model that the
age stratiﬁed incidence of melanoma is relatively uniform,
with incidence changes in the 40e44 year age group having
the greatest effect on incidence.
The sensitivity analysis of the decision trees is not
dependent on locale-speciﬁc population data and therefore
applies equally to local- and national-level simulations. Our
observations are qualitatively similar to those published by
Table 2
Results of the sensitivity analysis. Nodes from other decision trees that have a signiﬁcant effect on fraction burden. The ﬁrst two percentage
change columns relate to the effect of the node within their given decision tree, whereas the ﬁnal two percentage columns relate to the
effect of the node on the model as a whole
Site Node description Sibling node description % Change in attendance
given 1% change
% Overall change in
number of attendances
given 1% change
Colon No radiotherapy Palliative radiotherapy 19.00 0.101
Palliative radiotherapy No radiotherapy 19.89 0.105
Leukaemia No radiotherapy Radiotherapy 19.00 0.015
Radiotherapy No radiotherapy 19.89 0.016
Melanoma Stage I e surgery Medically inoperable 7.03 0.088
Stage I e medically inoperable Surgery 7.01 0.088
Stage I Stage II/III/IV e2.71 e0.034
Stomach Local disease e surgery e adjuvant
radiotherapy
No radiotherapy 23.19 0.021
Local e surgery e no radiotherapy Adjuvant radiotherapy e22.56 e0.020
Other No radiotherapy Radiotherapy e5.16 e0.141
Radiotherapy No radiotherapy 5.31 0.145
Table 3
Comparison of top ﬁve critical nodes from the CCORE 2003 sensitivity analysis and equivalent nodes from the Malthus sensitivity analysis
Top ﬁve critical nodes in the CCORE sensitivity analysis Corresponding critical nodes in Malthus sensitivity analysis
Radiotherapy versus surgery for localised prostate cancer Radical treatment indications for T3 prostate cancer
Radiotherapy in T4 colon cancer Radiotherapy indications in colon cancer
Adjuvant radiotherapy in node-positive melanoma Surgery versus medically inoperable melanoma
Radiotherapy post-prostatectomy with positive margins High risk T3e4 e ﬁt for radical treatments e hormones alone/
surgery e found to be T3 with positive margins
Surgery versus radiotherapy for localised bladder cancer Stage II bladder cancer, good performance status, cystectomy
and neoadjuvant chemotherapy
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the CCORE group. We observed that across the four tumour
sites that drive demand for radiotherapy, the output of the
model is drivenby factors upstreamof decisions to treatwith
radiotherapyand choices of fractionation schedule. This is an
important observation, particularly in light of current de-
velopments in hypofractionated radiotherapy schedules for
prostate [9] and lung cancer [10]. The key factors in the
clinical decision trees relate tostagedistributionand surgical
practice. With enhanced data collection from multidisci-
plinary team outcomes being fed into the cancer registries,
ascertainment for tumour stage and operative status are
increasingly becoming available from cancer registry data
feeds. Decisions relating to the use of surgery against
radiotherapy as primary treatment are complex and multi-
factorial, relating to local expertise, organisation of local
cancer services and multidisciplinary team meetings, travel
time for radiotherapy and patient preference. The sensitivity
analysis helps users of the model to determine where effort
shouldbedirected inobtainingestimates for appropriateuse
of surgery and radiotherapy at the locale-speciﬁc level.
The sensitivity analysis of all 23 decision trees reveals
some important observations beyond the four main tumour
types. In particular, we observed that the model is sensitive
to estimates of appropriate radiotherapy usage in the
treatment of colon and stomach cancer. Availability of new
evidence either promoting or reducing the uptake of
radiotherapy for this indication would therefore have a
signiﬁcant effect on predictions of fraction burden for these
two conditions. In conclusion, we show that the availability
of a sensitivity analysis for local-level radiotherapy simula-
tions has signiﬁcant utility in obtaining accurate projections
of radiotherapy demand.We continue to reﬁne ourmodel to
offer this facility to users in a fast and intuitive manner.
Acknowledgements
The Malthus programme was funded by the National
Cancer Action Team. TM is in receipt of funding from the
Engineering and Physical Sciences Research Council
(G0200663).
References
[1] Department of Health. Radiotherapy: developing a world class
service for England. Available at: http://www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPolicyAnd
Guidance/DH_074575 [accessed 30.09.14].
[2] Round C, Mee T, Kirkby N, Cooper T, Williams MV, Jena R.
The Malthus programme: developing radiotherapy demand
models for breast and prostate cancer at the local, regional
and national level. Clin Oncol 2013;25(9):538e545.
[3] Round CE, Williams MV, Mee T, et al. Radiotherapy demand
and activity in England 2006e2020. Clin Oncol 2013;25(9):
522e530.
[4] Delaney GP, Jacob S, Featherstone C, Barton MB. The role of
radiotherapy in cancer treatment: estimating optimal uti-
lisation from a review of evidence-based clinical guidelines.
Cancer 2005;104:1129e1137.
[5] Zhang-Salomons J, Mackillop WJ. Estimating the lifetime
utilization rate of radiotherapy in cancer patients: the mul-
ticohort current utilization table (MCUT) method. Comput
Methods Programs Biomed 2008;92:99e108.
[6] 2013 CCORE Review of optimal radiotherapy utilisation rates
prepared for Department of Health and Ageing, Australian
Government. Available at: http://inghaminstitute.org.au/sites/
default/ﬁles/RTU_Review_Final_v3_02042013.pdf [accessed
30.09.14].
[7] Radiotherapy in cancer care: estimating the optimal uti-
lisation from a review of evidence-based clinical guidelines,
Cancer Care Australia. Available at: http://canceraustralia.gov.
au/sites/default/ﬁles/publications/radiotherapyreport1_
504af01e8daf0.pdf [accessed 30.09.14].
[8] National Population Projections. Population projections by
age and sex for the United Kingdom, Great Britain and con-
stituent countries. Series PP2 No 26. Ofﬁce for National
Statistics.
[9] Pollack A, Walker G, Horwitz EM, et al. Randomized trial of
hypofractionated external-beam radiotherapy for prostate
cancer. J Clin Oncol 2013;31(31):3860e3868.
[10] Lagerwaard FJ, Haasbeek CJA, Smit EF, Slotman BJ, Senan S.
Outcomes of risk-adapted fractionated stereotactic radio-
therapy for stage I non-small-cell lung cancer. Int J Radiat
Oncol Biol Phys 2008;70:685e692.
R. Jena et al. / Clinical Oncology 27 (2015) 92e9898
Original Article
The Malthus Programme: Developing Radiotherapy Demand
Models for Breast and Prostate Cancer at the Local,
Regional and National Level
C. Round *, T. Mee y, N.F. Kirkby y, T. Cooper z, M.V. Williams *, R. Jena *
*Oncology Centre, Addenbrooke’s Hospital, Cambridge University Hospital NHS Trust, Cambridge, UK
y Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, Surrey, UK
zRadiotherapy National Cancer Action Team, London, UK
Received 5 February 2013; received in revised form 11 April 2013; accepted 16 April 2013
Abstract
Aims: The Malthus Programme has delivered a tool for modelling radiotherapy demand in England. The model is capable of simulating demand at the local level.
This article investigates the local and regional level variation in predicted demand with respect to Breast and Prostate cancer, the two tumour types responsible
for the majority of radiotherapy treatment workload in England.
Materials and methods: Simulations were performed using the Malthus model, using base population incidence data for the period from 2007e2009. Simu-
lations were carried out at the level of Primary Care Trusts, Cancer Networks, and nationwide, with annual projections for 2012, 2016 and 2020. Benchmarking
was undertaken against previously published models from the UK, Canada and Australia.
Results: For breast cancer, the fraction burden for 2012 varied from 5537 fractions per million in Tower Hamlets PCT to 18 896 fractions per million in Devon PCT
(national mean - 13 592 fractions per million). For prostate cancer, the fraction burden for 2012 varied from 4874 fractions per million in Tower Hamlets PCT to
23 181 fractions per million in Lincolnshire PCT (national mean - 15 087 fractions per million). Predictions of population growth by age cohort for 2016 and 2020
result in the regional differences in radiotherapy demand becoming greater over time. Similar effects were also observed at the level of the cancer network.
Conclusions: Our model shows the importance of local population demographics and cancer incidence rates when commissioning radiotherapy services.
 2013 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
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Introduction
The Malthus Programme was commissioned by the
National Cancer Action Team to provide tools for modelling
radiotherapy demand at both local and national levels in
England [1]. The tools are targeted at healthcare commis-
sioners, radiotherapy service leads and all staff involved in the
provision of radiotherapy. No previous knowledge of model-
ling is required to run the application. We know that signiﬁ-
cant local variation exists in cancer incidence and subsequent
radiotherapy demand is driven by differences in stage, age,
geography, performance status, comorbidities and the uti-
lisation of other treatment modalities in the cancer pathway.
Such differences mean that a national best ﬁt model is
unlikely to ﬁt the requirements of every individual treatment
centre.
Previous models of radiotherapy demand have been
published from Canada, Australia, Scotland and England
[2e5]. A difﬁculty encountered in any radiotherapy de-
mand model is the curating of appropriate cancer inci-
dence data and, where population data from their
countries were unavailable, authors have used other
retrospective sources of data, such as the American Na-
tional Cancer Institute Surveillance, Epidemiology and End
Results (SEER) database. The Malthus model uses high-
quality incidence data from the National Cancer Intelli-
gence Network, which tracks cancer registrations to the
level of the Primary Care Trust (PCT) (population range
from 91 500 to 1 282 384) and regional Cancer Network
(population range from 710 174 to 4 024 508) in England.
For details of stage and the use of surgery, we obtained
data from the Eastern Cancer Registry and Information
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Centre (ECRIC). These data enabled us to use the Malthus
model to test the hypothesis that a single radiotherapy
demandmodel at the national level is not representative of
radiotherapy demand at more granular levels.
This article reviews the local- and regional-level models
for breast and prostate cancer. These two sites were
selected because they make up about 55% of the national
radiotherapy workload and, thus, have important conse-
quences for radiotherapy commissioning.
Materials and Methods
Model Conﬁguration
The Malthus Workbench discrete event simulation tool
was used for this analysis [1].We used themodel to produce
both radiotherapy treatment fraction and access rate data
for patients with breast and prostate cancer. Access rate is
deﬁned as is the proportion of all cancer patients who
require radiotherapy at least once during the course of their
illness [3].
The model was run using evidence-based decision trees
and set to consider primary treatment episodes with either
radical or palliative intent (to facilitate comparison with
other studies). We used base population and cancer inci-
dence data for the period from 2007 to 2009. Simulations
were carried out at the PCT level and the Cancer Network
level, as well as at the national level. Simulations were run
for years 2012, 2016 and 2020.
Evidence Base and Decision Trees
Data for the discrete event simulation were encoded in a
clinical decision tree. The highest level of evidence available
for the role of radiotherapy and evidence for fractionation
were established for breast and prostate cancer. This was
based on the ranking of levels of evidence and incorporated
into the decision tree branches [6]. These were ratiﬁed by a
representative group of clinical oncologists. In addition to
encoding information about treatment options, the decision
trees also include information about the stage distribution of
patients with a given tumour type (e.g. the proportion of
breast cancer patientswith stage II disease). This information
was derived from national audits and the ECRIC. The trees
also encode information regarding the proportions of pa-
tients considered for different treatment options on the basis
of both tumour factors and patient factors (e.g. proportion of
stage II breast cancer patients undergoingwide local excision
versus mastectomy). These estimates were derived from
ECRIC data and from peer review. The decision trees and
underlying evidence are available for download at the proj-
ect web site [7]. Key factors in the design of the decision trees
for breast and prostate cancer, speciﬁcally where they differ
from previous models, are outlined below:
Breast cancer decision tree
 Radiotherapy for ductal carcinoma in situ (DCIS) after
breast-conserving surgery was included in the decision
tree, on the basis of the Cochrane review and the
Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) [8,9]. Conventional 2 Gy fractionation has
been modelled as there is no current high-level evi-
dence to support the use of hypofractionation in DCIS.
 Fractionation for radiotherapy in early stage invasive
breast cancer is based on the Cochrane review and the
EBCTCG [10e12].
 Stage data were acquired from ECRIC, whose estimates
for breast cancer staging are 93% complete.
 Mastectomy rates were obtained from ECRIC.
Prostate cancer decision tree
 Clinical risk group stratiﬁcation [13] was obtained from
ECRIC, whose estimates for clinical risk grouping are
87% complete.
 Prostatectomy rates were obtained from ECRIC, and
validated at a national meeting of 70 oncologists held in
June 2011.
It should be noted that there is no evidence for low-risk
prostate cancer that any of the options of active surveil-
lance, surgery or radiotherapy (external beam or implant) is
better than any other. It has been argued in a consensus
statement that this stage of disease has been overtreated
and that it should be reclassiﬁed as a premalignant condi-
tion [14]. This means that our decision tree is descriptive as
there is no evidence on which to base management de-
cisions and patient choice, inﬂuenced by clinician advice is
dominant. Similar arguments regarding treatment choice
apply to some degree for patients with higher risk prostate
cancer.
Benchmarking
Our model of radiotherapy demand is calculated in
treatment fractions rather than an access rate. The access
rate does not directly reﬂect the radiotherapy workload in
terms of radical and palliative treatment fractionation. Ac-
cess rates were calculated to act as comparators against the
previous studies. Here we have used the conventional term
fraction, which for this purpose is equivalent to an atten-
dance as recorded in the English radiotherapy data set [15].
Results
Breast Cancer
The overall access rate for breast cancer was simulated at
75.2%. Our simulations demonstrate marked variation in
fraction burden at both the local and the regional level (see
Table 1). The highest incidence of breast cancer in England
was 0.36% annually (averaged over 3 years) in Devon PCT
because of a higher proportion of older people. This results
in a predicted demand of 18 896 fractions per million in
2012, rising to 19 744 fractions per million for 2016 and
20 827 fractions per million for 2020. The predicted de-
mand for Devon PCT in 2012 was 139% of the national mean
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in the same year and is projected to rise in 2016 and 2020.
Conversely, the lowest burden was observed in Tower
Hamlets PCT and the annual incidence was 0.11% (being an
inner London suburb with a younger population). The
fractions per million estimated were 5537 in 2012, 5773 in
2016 and 6007 in 2020. The variation in radiotherapy de-
mand mirrors the observed variation in breast cancer inci-
dence (0.11% in Tower Hamlets compared with 0.36% in
Devon).
At the network level, the breast cancer incidence was
highest in the Peninsula Cancer Network at 0.34%, with an
estimated fraction burden of 17 615 fractions per million in
2012, rising to 18 345 and 19 296 fractions per million in
2016 and 2020, respectively. The North East London Cancer
Network had the lowest cancer prevalence of 0.18%, with a
fraction burden of 9495 fraction in 2012, rising to 9908 and
10 302 fractions per million in 2016 and 2020, respectively.
Prostate Cancer
The overall access rate for prostate cancer was simulated
at 54.4%. Again our simulations demonstrate marked local
and regional variation in fraction burden (see Table 2). The
national simulated fraction burden in 2012 was 15 087 per
million, rising to 18 191 and 21 026 fractions per million in
2016 and 2020, respectively. The national incidence of
prostate cancer was 0.19%. The results of the modelling at
the PCT level show the highest incidence of prostate cancer
to be 0.29% in Lincolnshire PCT and the lowest incidence in
Tower Hamlets PCT 0.061%.
Modelling for radiotherapy requirements in Lincolnshire
PCT shows that in 2012, 23 181 fractions per million would
be expected to be delivered, rising to 27 589 in 2016 and
30 957 in 2020.
The same simulation for Tower Hamlets PCT, which has
the lowest incidence of prostate cancer, yielded an expected
fraction burden of 4874 fractions in 2012, rising to 5915 in
2016 and 6777 in 2020.
At the Cancer Network level, similar effects were
observed: North East London Cancer Network has the
lowest prostate cancer incidence. This would result in an
excess provision of fractions of the order of 10 213 fractions
per million in 2012, 12 276 fractions per million in 2016 and
14 249 fractions per million in 2020. At Cancer Network
level similar effects are observed. North East London CN has
the lowest prostate cancer prevalence at 0.13%, with a
predicted fraction burden of 10 562 fractions per million in
2012, rising to 12 850 and 14 369 fractions per million in
2016 and 2020, respectively. The Dorset Cancer Network
has the highest prostate cancer incidence at 0.32%. The
predicted fractions per million in 2012, 2016 and 2020 were
25 824, 30 415 and 35 428, respectively.
Discussion
Variation Between Model Simulations
Our model demonstrates marked variation in both
radiotherapy demand at the local level compared with a
national-level simulation. The differences arise due to
geographical variation in the age distribution and reported
cancer registrations. Figure 1 illustrates the difference in
age distribution for the three PCTs discussed in the analysis.
In Tower Hamlets PCT, 83% of the population is below the
age of 50 years and therefore carry a low cancer burden. In
contrast, for Devon PCT, the percentage of the population
over the ages of 50 and 70 years are 43 and 17%, respec-
tively. The older population carries an increased cancer
burden.
The model uses a national-level simulation of population
growth by age cohort and the greatest expansion in popu-
lation is expected in the over 70s and 80s age cohorts. The
effect of the ageing population will be felt most in areas
with a larger population of retirement age, as these cohorts
also have the highest rates of expansion of the over 70s
Table 1
Model-based simulations of breast cancer radiotherapy demand (fractions per million and percentage of national average) for Primary Care
Trusts and Cancer Networks with the lowest and highest cancer incidence
England Primary Care Trust Cancer Network
Devon Tower Hamlets Peninsula North East London
2012 13 592 18 896 (139%) 5537 (41%) 17 615 (130%) 9495 (70%)
2016 14 412 19 744 (137%) 5773 (40%) 18 345 (127%) 9908 (69%)
2020 14 971 20 827 (139%) 6007 (40%) 19 296 (129%) 10 302 (69%)
Table 2
Model-based simulations of prostate cancer radiotherapy demand (fractions per million and percentage of national average) for Primary
Care Trusts and Cancer Networks with the lowest and highest cancer incidence
England (per million) Primary Care Trust Cancer Network
Lincolnshire Tower Hamlets Dorset North East London
2012 15 087 23 181 (154%) 4874 (32%) 25 824 (171%) 10 562 (70%)
2016 18 191 27 589 (152%) 5915 (33%) 30 415 (167%) 12 850 (71%)
2020 21 026 30 957 (147%) 6777 (32%) 35 428 (168%) 14 369 (68%)
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population cohort (see Figure 2). Our model assumes that
these patients will be ﬁt for and will receive the same
treatment as younger patients. For breast cancer, there is
evidence that this is not the case in the surgical treatment of
older patients and that this then results in higher death
rates from cancer [16]. Radiotherapy in low-risk breast
cancer in the elderly has a smaller beneﬁt in reducing the
local recurrence rate than in younger patients [17]. This is
currently neither incorporated nor reﬂected in our model.
Active treatment may not be appropriate in prostate cancer
patients with a life expectancy of less than 10 years. English
data on how this consideration is applied in practice are not
available, so estimates were obtained at the Malthus Forum
from clinicians involved in the treatment of prostate cancer.
This could lead to a disparity between modelled and actual
demand [18]. There is some evidence that clinicians un-
derestimate a patient’s life expectancy, which can result in
fewer patients being offered active treatment [18], with
a consequent reduction in radiotherapy requirements.
Conversely, overestimation of life expectancy can lead to
overtreatment of prostate cancer [19,20]. Our model does
not explicitly include comorbidity and performance status
in the management of breast and prostate cancer. These are
important factors in clinicians’ treatment decisions and
there is a paucity of data.
Geographic factors and travel times are known to inﬂu-
ence treatment decisions [21]. Criterion-based bench-
marking is designed to estimate actual practice [22e24] and
uses urban-based populations with minimal travel times to
minimise the effect of a patient’s location on radiotherapy
uptake.
Commissioning of radiotherapy services in England
needs to respond to population demands at the PCT and
Cancer Network level because of the marked differences in
population need. In the worst case, this could result in the
under-provision of radiotherapy equipment in certain areas
of the country and increased waiting times for radiotherapy
treatment. Breast and prostate cancer make up 55% of the
radiotherapy burden, but the local variation in cancer inci-
dence and consequent radiotherapy demand is also marked
for smoking- and occupational-related cancers, such as
head and neck cancer in the North West and lung cancer in
the industrialised cities.
Benchmarking against Previous Models
Comparison of the Malthus model with previous models
is complicated by the fact that previous models have pro-
duced an access rate for radiotherapy rather than radio-
therapy demand expressed in treatment fractions.
Therefore, the Malthus model was set to run national-level
simulations and access rates for the population were
calculated. For breast cancer, our estimated access rate of
76% is higher than previous models that included radio-
therapy treatment for DCIS (see Table 3) [5,7,22,23,25] and
lower than the value given by Delaney et al. [26], who did
not include this indication (see Table 3). The decision trees
underlying the model show variation in the mastectomy
rates cited for each disease stage (See Table 4). Speciﬁcally,
mastectomy rates for stage I and stage III disease are lower
in both the National Radiotherapy Advisory Group and
Malthus model than in the Mackillop model [25]. Compa-
rable data are not provided in the Delaney et al. paper [26].
For prostate cancer, our 54% estimated access rate is
lower than observed in previous models [5,7,22,24,27,28]
(see Table 5). Our estimate is close to that of the criterion-
based benchmarking model of Tyldesley et al. [22], in
which access rates were compared with a community for
whom there were no barriers to the use of radiotherapy
and no ﬁnancial incentives to overtreatment [22,24] (see
Table 5).
Fig 1. Age distribution of Tower Hamlets, Devon and Lincolnshire
Primary Care Trusts.
Fig 2. Changes in proportion of the population over 70 years old in
Tower Hamlets, Devon and Lincolnshire Primary Care Trusts.
Table 3
Comparison of breast cancer radiotherapy access rate estimates
between the Malthus model and other models
[26] (excludes
DCIS indications)
[25] [5] [23] (criterion-
based
benchmarking)
[22]
(EBEST)
[7]
83% 57% 72% 61% 66% 76%
DCIS, ductal carcinoma in situ; EBEST, epidemiologically based
estimates.
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Although the Malthus model was not speciﬁcally
designed to provide national-level simulation, this is useful
for comparison and benchmarking against previously pub-
lishedmodels. Themodels show variation in access rates for
radiotherapy. For the breast cancer simulation, the Malthus
model predicted a higher access rate than any of the pre-
vious models that include radiotherapy treatment for DCIS.
This was due to different estimates of appropriate rates of
mastectomy in different stages of the disease.
For prostate cancer, the Malthus model yielded a signif-
icantly lower access rate due to a combination of higher
rates of surveillance in early stage disease, and increased
use of bisphosphonate therapy for palliation of bony me-
tastases in place of single fraction radiotherapy treatments.
The latter will have a large impact on access rate, as fewer
patients with metastatic prostate cancer will receive palli-
ative radiotherapy, but a small impact on fraction burden as
the change in the number of treatment fractions will be
small.
The detected incidence of prostate cancer is dramatically
inﬂuenced by prostate-speciﬁc antigen (PSA) screening and
this makes modelling of cancer incidence particularly
difﬁcult [29]. Table 6 shows cancer incidence per million
and its variation in respect to PSA ascertainment [30e33]. In
the USA, 60e70% of the male population over 50 years old
has had a PSA test [30], but this ﬁgure is only 6% in the UK
[31]. This inﬂuences both cancer incidence and stage. The
decision to embrace PSA screening (which is presently
limited and opportunistic) could double the radiotherapy
requirement for this disease and increase the overall
requirement across all cancers by 10%.
Analysis of the prostate cancer decision tree reveals that
the model is sensitive to the effects of stage distribution and
patient choice. In the current decision tree, 20% of patients
are considered to have low-risk disease and 35% of patients
to have high-risk disease. Repeating the simulation for a
scenario in which 40% of patients have low-risk disease and
15% have high-risk disease lowers the predicted average
fraction burden for 2016 from 18 191 fractions per million to
16 047 fractions per million. Using the current tree, the
choice of radiotherapy treatment in patients with low and
intermediate disease who are ﬁt for treatment is 45 and
70%, respectively. If 50% of patients choosing primary
radiotherapy for these disease stages were to choose active
surveillance, the predicted average fraction burden for 2016
would fall from 18 191 fractions per million to 15 220
fractions per million. Modelling for both prostate and breast
cancer is inﬂuenced by surgical options and by patient
choice. It is very difﬁcult to acquire detailed data on patient
choice.
In order to simulate accurately local-level demand for
radiotherapy of breast and prostate cancer using Malthus,
additional data regarding local surgical treatment rates
should be included in the model. This would also offer the
Table 4
Breast cancer radiotherapy access rates and mastectomy rates cited in current and previous models
[26] [41] (estimated appropriate
mastectomy rate)
[5] [7]
Optimal radiotherapy utilisation rate 83% (excludes DCIS) N/A 72% 76%
Mastectomy rate (DCIS) 33% 27% 43% (based on SRAG) 31% (ECRIC)
Mastectomy rate (stage I) 19% (includes T2) 43% 25% 23%
Mastectomy rate (stage II) N/A 48% 52% 47%
Mastectomy rate (stage III) N/A 73% N/A 38%
DCIS, ductal carcinoma in situ; SRAG, Scottish Radiotherapy Advisory Group; ECRIC, Eastern Cancer Registry and Information Centre; N/A,
data not available in manuscript.
Table 5
Comparison of prostate cancer access rate estimates between the Malthus model and other models and actual radiotherapy usage. Kerba
[24] used criterion-based benchmarking where ‘best practice’ prevails e patients discussed by the multidisciplinary team, no short or
prolonged radiotherapy waits driving radiotherapy demand or utilisation, patients had access to all appropriate and timely modalities of
cancer treatment and no ﬁnancial barriers to care
Group Overall lifetime estimate Actual radiotherapy usage
[27] [28] [5] [24] [7] [24] [24] [22]
Geographical
region
Australia Canada England Ontario England Ontario USA Surveillance,
Epidemiology and
End Results (SEER)
British Columbia
Year of
assessment
2003 2003 2007 2010 2012 2010 2010 2011
Initial delivery
28%
Initial
estimate 37%
Access rate 61% 61% 61% 59% 54% 59% Lifetime estimate
43%
Lifetime 43%
C. Round et al. / Clinical Oncology xxx (2013) 1e8 5
Please cite this article in press as: Round C, et al., The Malthus Programme: Developing Radiotherapy Demand Models for Breast and Prostate
Cancer at the Local, Regional and National Level, Clinical Oncology (2013), http://dx.doi.org/10.1016/j.clon.2013.05.006
opportunity to use the model for comprehensive planning
of cancer services, including surgery as well as radiotherapy.
There are opportunities for using reduced fractionation
in both breast and prostate cancers, both of which, as high
volume sites, place a high demand on radiotherapy services.
Trials, both on-going and planned, are exploring these
possibilities, examining hypofractionation [34e40] and as
few as ﬁve fractions for both breast [37] and prostate cancer
[41]. In breast cancer, there is interest in intra-operative
treatment [39], simultaneous integrated boost [40] and
partial breast irradiation, including the use of MammoSite
[42]. Early results have been reported, but for both these
malignancies, mature results at 10 years will be required
before any recommendations about implementation can be
made [35,36].
Conversely, increasingly aggressive treatment of patients
with oligometastatic disease is being observed with both
stereotactic ablative radiotherapy and fractionated therapy.
For example, in the STAMPEDE study of treatment options
in advancing or metastatic prostate cancer, ﬁt patients with
metastatic disease may be offered 20 fractions of radio-
therapy to the primary site [43]. Trials in the use of imme-
diate or salvage radiotherapy in post-prostatectomy cancer
[44,45] could add to the radiotherapy burden if found to be
beneﬁcial as a quarter of intermediate-risk and all high-
risk patients might require postoperative radiotherapy or
deﬁnitive radiotherapy [46].
Radiotherapy Re-treatment
In order to facilitate comparison with previous models
from other groups, re-treatments of the primary tumour
with more than 10 treatment fractions have been excluded
from these simulations. In the Malthus model, re-treatments
are calculated as a ﬁxed percentage of the fraction burden for
each decision tree and are added to the total fraction burden
at the end of the simulation. The percentages are drawn from
an audit of national practice carried out in 2007 [47]. Re-
treatment rates from the audit for breast and prostate can-
cer are 4.9 and 3.7% of the primary fraction burden. These
rates are signiﬁcantly lower than those fromDelaney et al [3]
who cited re-treatment rates as 27 and 30% for breast and
prostate cancer, respectively. These differences may reﬂect
increased use of surgical and systemic therapies for locally
recurrent disease.
Conclusions
The Malthus model shows a signiﬁcant variation in
radiotherapy demand at the local level, which must be
considered when planning radiotherapy services. Services
need to be tailored to regional population demographic
differences and the cancer incidence associated with that
locality. A calculation based on national generic cancer
incidence could result in a disparity in radiotherapy ca-
pacity and demand, potentially resulting in a surplus or
deﬁcit in many regions.
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Abstract
Aims: This paper compares the predictions of radiotherapy demand for England from the Malthus model with those from the earlier National Radiotherapy
Advisory Group (NRAG) model, from the international literature and also with observed radiotherapy usage in England as a whole as recorded in the English
radiotherapy dataset (RTDS).
Materials and methods: We reviewed the evidence base for radiotherapy for each type and stage of cancer using national and international guidelines, meta-
analyses, systematic reviews and key clinical trials. Twenty-two decision trees were constructed and radiotherapy demand was calculated using English cancer
incidence data for 2007, 2008 and 2009, accurate to the Primary Care Trust (PCT) level (population 91 500e1 282 384). The stage at presentation was obtained
from English cancer registry data. In predictive mode, the model can take account of changes in cancer incidence as the population grows and ages.
Results: The Malthus model indicates reduced indications for radiotherapy, principally for lung cancer and rarer tumours. Our estimate of the proportion of
patients who should receive radiotherapy at some stage of their illness is 40.6%. This is lower than previous estimates of about 50%. Nevertheless, the overall
estimate of demand in terms of attendances is similar for the NRAG and Malthus models. The latter models that 48 827 attendances should have been delivered
per million population in 2011. National data from RTDS show 32 071 attendances per million in 2011. A 50% increase in activity would be required to match
estimated demand. This underprovision extends across all cancers and represents reduced access and the use of dose fractionation at odds with international
norms of evidence-based practice. By 2016, demand is predicted to grow to about 55 206 attendances per million and by 2020 to 60 057.
Discussion: Services have increased their activity by 14% between 2006 and 2011, but estimated demand has increased by 11%. Access remains low and English
radiotherapy dose fractionation still does not comply with international evidence-based practice.
 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Key words: Access; capacity; demand; fractionation; modelling; radiotherapy
Introduction
One in three people will develop cancer, and radio-
therapy is used in the treatment of 40% of those who are
cured of their disease. Services in England have been
perceived to lag behind the rest of Europe in terms of
radiotherapy provision [1]: in 2003, 70% of patients waited
longer than a month to start treatment [2]. In response, the
National Radiotherapy Advisory Group (NRAG) was estab-
lished and its report recommended substantial expansion of
services [3]. It included a model of radiotherapy demand,
but it did not take into account the three-fold local variation
in cancer incidence in England [4]. The National Cancer
Action Team therefore commissioned a new modelling tool
for radiotherapy demand, called Malthus (Monte-Carlo
Application for Local Treatment and Healthcare Usage
Simulation). Our aim was to produce the most accurate
model that we could for England and to design one that
accounted for local differences in cancer incidence.
The proportion of patients who require radiotherapy at
least once during the course of their illness has been termed
the access rate and estimated at 52% for an Australian
population [5]. Accurate determination at an individual
level requires follow-up out to 20 years and is then affected
by changes in practice [6]. An alternative cross-sectional
method compares cancer incidence with radiotherapy
treatment given for the ﬁrst time to ‘new’ patients [7,8]. This
includes patients treated initially with radiotherapy and
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also those with late recurrences receiving radiotherapy for
the ﬁrst time, having been diagnosed and treated (without
radiotherapy) in earlier years [7,8]. From the access rate,
radiotherapy demand can be estimated in terms of courses
of radiotherapy required after an adjustment for re-
treatment [5,8e10]. We have used a more direct approach
and constructed 22 treatment trees that include the radio-
therapy attendance requirement as a direct measure of
workload [3,8,11,12]. To estimate re-treatment we used
English audit data [8] and applied a multiplication factor at
the completion of each treatment tree.
Malthus is a decision aid for planning and commis-
sioning radiotherapy services at a local or regional level.
Malthus can be used to estimate demand and therefore
linear accelerator requirements, but does not model
brachytherapy, nor does it include benign indications, non-
melanoma skin cancer or paediatric cancer. In England,
radiotherapy services were commissioned at the level of the
Primary Care Trust (PCT). This was a body commissioning
National Health Service (NHS) medical services for its local
population. PCTs have now been abolished and radio-
therapy services will be commissioned nationally by the
NHS Commissioning Board through specialised commis-
sioning. Private patients are treated on NHS machines, but
in addition there were 12 (4%) private linear accelerators in
2011 (personal communication, H Forbes and C Ball, Nat-
CanSAT, 2012).
Malthus is driven by differences in cancer incidence that
vary by a factor of three and largely depend on the age
structure of the population [4]. For example, the highest
incidence of breast cancer in England was 0.36% annually in
the Devon PCT because of a higher proportion of older
people in this retirement centre. By contrast, the lowest
burden was observed in Tower Hamlets PCT, where the
annual incidence was 0.11% (being an inner London suburb
with a younger population) [4].
This paper compares the predictions of radiotherapy
demand derived from the Malthus model with those from
the previous NRAG model [3], from the international liter-
ature and also with observed rates of use of radiotherapy in
England as a whole as recorded in the radiotherapy dataset
(RTDS) [13].
Materials and Methods
We reviewed the evidence base for radiotherapy for each
type and stage of cancer using national and international
guidelines, meta-analyses, systematic reviews and key clin-
ical trials [4,14].Weconstructedevidence-based radiotherapy
decision trees based on English local cancer incidence data
from the National Cancer Intelligence Network. Cancer inci-
dence data for the 3 years 2007, 2008 and 2009, accurate to
the PCT level were curated and used to populate the model.
The population served by PCTs ranged in size from 91 500 to
1 282 384. A 3 year dataset was used to provide an adequate
incidence of cancer for even the smallest PCT [4,14]. We ob-
tained details of stage and the use of surgery from the Eastern
Cancer Registry and Information Centre [4,14].
Malthus is a discrete event simulation model of radio-
therapy utilisation. It is available as a downloadable applica-
tion; registration is required before it will run [15]. Age-
stratiﬁed cancer registration data for each PCT or Cancer
Network are used to establish a virtual population of cancer
patients. Treatmentevents foreachpatient are encoded in the
form of 22 tumour-speciﬁc decision trees, which can be
downloaded with the supporting evidence base [16]. The
treesencodeevidence-based radiotherapy treatmentpractice
accounting for both tumour factors (tumour type, stage and
grade) and patient factors (type of surgery, ﬁtness level). Each
node in the decision tree stores the probability of transition
from their parent node, a radiotherapy fraction burden andan
evidence base reference (see Figure 1). Each virtual patient
accumulates radiotherapy treatment fractions as they tra-
verse the decision tree. In the proximal stages of the decision
tree, the transition probabilities relate to the stage distribu-
tion of the tumour, values forwhich have been obtained from
regional cancer registry data. The distal nodes encode treat-
ment alternatives for a given tumour type and stage, together
with the associated fraction burden. For some nodes the
proportion of patients entering each of the alternative treat-
mentarmsdependson theperformance status, patient choice
and the role of surgery: appropriate values were established
from national audits and expert peer-review [4,14].
To account for the stochastic nature of the simulation,
2000 iterations of the decision tree are carried out for each
virtual patient identiﬁed in the curated incidence data.
Summary statistics are collected for each tree for the ﬁnal
report. Re-treatment of patients for recurrent or metastatic
disease increases radiotherapy workload, accounting for
18% of patients and 5% of fractions [8]. To take account of
this we used audit data indicating the additional workload
for each cancer site [8] and applied the appropriate ﬁgure as
a multiplier after the calculation of radiotherapy demand
for the ﬁrst treatment for that cancer.
The output of Malthus is attendances, each deﬁned as a
visit for one or more fractions of radiotherapy, including
multiple treatments to different parts of the body. It is an
objective, consistent measure and is the same unit of
measurement as that used by NRAG and by the RTDS
[3,13,17]. A series of attendances is termed an episode:
detailed deﬁnitions of this and other terms are provided in
the Appendix [17].
To allow for future changes in the population size, and in
tumour incidence through to the year 2031, the base cancer
registration data can be modiﬁed. Malthus uses the Ofﬁce of
National Statistics 2008 population growth model [18] to
produce age-stratiﬁed estimates of population growth, and
the Cancer Research UK/Association of Cancer Registries
model for changes in cancer incidence [19]. However, the
model describes change for England as a whole and may not
be correct for a particular locality if there are substantial dif-
ferences in, for example,migrationpatterns ordemographics.
Details of all radiotherapy administered in England over
the three ﬁnancial years 2009e2012 are now held in the
English RTDS and some of these data have been published
[13].We have beenprovidedwith a summary of attendances
and episodes by cancer diagnosis for the ﬁnancial year
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2011e2012 (personal communication, H Forbes and C Ball,
NatCanSAT, 2012). This includes all treatment delivered on
NHS machines, including that to private patients. However,
in England,12 (4%) linacs are purely in the private sector and
do not submit data into the RTDS.
Results
Comparison of the National Radiotherapy Advisory Group
and Malthus Models
Table 1 shows summary results for the whole of England.
The Malthus and NRAG models give results that are broadly
similar in terms of attendances per million, although the
Malthus estimate is 9% lower for 2006, but then increases to
exceed the NRAG estimate by 3% in 2016. Activity as a
percentage of modelled demand is similar at 63% in 2006/
2007 and 66% in 2011 for Malthus and 58 and 63% for NRAG.
This indicates that about a 50% increase in activity would be
required to match estimated demand [1,8]. Estimated de-
mand increases by 5.6% between 2011 and 2016 in the
NRAG model. Malthus shows a 13.1% increase because the
underlying population [18] and cancer incidence models
[19] indicate a more rapid increase than the earlier work
that underpinned the NRAG model [20].
Table 2 shows a detailed comparison between the NRAG
and Malthus models for 2006, including the workload
generated by re-treatment. Data for cancers of the breast
(28%), head and neck (9%), lung (13%) and prostate (29%)
are highlighted as together they account for 79% of atten-
dances: theyare the focusof thispaperbecausechanges in the
indications for radiotherapy for rarer tumours will have a
much smaller impact on the overall demand for radiotherapy.
In the NRAG model, the access rate is described as the
appropriate rate of radiotherapy and is 50.4% for the English
population [3]. TheMalthus model gives a lower estimate of
40.6%, reﬂecting lower values for most tumours (Table 2).
Estimates of access rate are similar for breast and head and
neck cancer, but lower for lung and prostate cancer. The
overall access rate predicted by Malthus is 80.4% of that in
the NRAGmodel. The application and the decision trees that
underpin these changes, together with the supporting evi-
dence base, are available to download [15,16].
The evidence-based fractionation modelled for all those
who are treated (including re-treatment) increases from
15.2 attendances per episode in the NRAG model to 17.4 in
the Malthus model. Breast fractionation is little changed,
but more attendances per episode are recommended for
prostate and rectal cancer; there is a reduction for cancer of
the lung and head and neck. For rectal cancer there is a
three-fold increase in the predicted number of attendances
per episode because the use of preoperative magnetic
resonance imaging has reduced the use of short-course
preoperative radiotherapy [21]. Dose fractionation for
head and neck cancer is lower in the Malthus model than in
NRAG because the latter uses a single ﬁgure of 35 fractions
for all indications and ignores the use of fewer fractions for
postoperative or palliative treatment.
Radiotherapy demand can be modelled by combining
estimates of access and fractionation, together with an
adjustment for re-treatment. Table 2 shows that overall
predicted radiotherapy workload in attendances per million
for 2006 was lower for Malthus (44 320) than NRAG
(48 545), a difference of 9%. The workload modelled for
breast cancer was little changed; it was lower for lung and
head and neck cancer and substantially increased for
prostate cancer, increasing from 8866 attendances per
million in NRAG to 11 759 in Malthus.
Comparison with Current Radiotherapy Activity
Table 3 compares activity data for 2011e2012 from RTDS
with the Malthus model for 2011. It is not possible to identify
new patients having their ﬁrst course of radiotherapy in
RTDS, so the recorded episodes include patients being re-
treated. To account for this, estimates of re-treatment have
been added when running the Malthus model. RTDS epi-
sodes are lower than predicted for breast, head and neck,
lung, prostate and pancreatic cancer; overall episodes are
79% of the modelled estimate. Dose fractionation, expressed
Fig 1. Schematic of the decision tree structure. The central node ascribes a 15 fraction course of radiotherapy to 90% of young high-risk patients
undergoing breast-conserving surgery for stage I breast cancer. Treatment details and a reference to the evidence base (the Early Breast Cancer
Trialists Collaborative Group) are carried in the node. The node has three subnodes, which encode details of the distribution of patients receiving
a radiotherapy boost. The total radiotherapy treatment burden is accumulated for each iteration through the tree.
Table 1
Radiotherapy demand in attendances per million modelled by
Malthus and the National Radiotherapy Advisory Group (NRAG) [3]
compared with activity data for the whole of England as deter-
mined in a national audit (2007) [7] and from the English radio-
therapy dataset (2011)
Activity NRAG Malthus
2006 e 48 253 44 320
2007 28 089 e e
2011 32 071 50 900 48 827
2016 e 53 771 55 206
2020 e e 60 057
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as attendances per episode, is reduced in RTDS compared
with Malthus and overall is only 83% of expected. Total at-
tendances are substantially reduced for breast, head and
neck, lung and prostate cancer and the overall ﬁgure in RTDS
is only 66% of that predicted by Malthus. Underactivity is a
combination of fewer patients than expected being treated
(79%) and their receiving fewer fractions per course (83%).
Overall, a 50% increase in attendances would be required to
match estimated demand.
Table 4 shows modelled workload and activity for 2011
in terms of episodes and attendances per incident cancer as
well as per million population.
Sensitivity Analysis
A one-way sensitivity analysis of the decision tree pa-
rameters was carried out manually, adjusting the proba-
bility associated with key nodes in the trees by 10%, and
observing the effect on simulated attendances for the
given decision tree and overall. The 10 most sensitive
nodes across all 22 decision trees and their effects on the
simulation output are summarised in Table 5. The total
increase in demand if all these changes were applied is
2410 attendances per million, representing a 4.8% increase
overall.
Table 2
Comparison of radiotherapy demand for 2006 estimated by theMalthus and the National Radiotherapy Advisory Group (NRAG)models. The
data include both new patients and those attending for re-treatment and are grouped into access rate (for new patients only), dose frac-
tionation and total attendances. Data for cancers of the breast (30%), prostate (27%), head and neck (9%) and lung (8%) are highlighted as
together they account for 75% of attendances
Cancer site Access rate Fractionation Attendances
NRAG
access
rate
Malthus
access
rate
Malthus
access as
% NRAG
NRAG
attendances
per episode
Malthus
attendances
per episode
Malthus
fractionation
as % NRAG
NRAG
attendances
per million
Malthus
attendances
per million
Malthus
as %
NRAG
Malthus
as %
total
Bladder
cancer
31.0 26.0 83.8 16.9 12.2 72.3 1268 641 50.5 1.4
Central
nervous
system
tumours
61.3 45.4 74.0 24.3 23.4 96.2 1454 892 61.3 2.0
Breast cancer 71.7 76.4 106.5 16.1 15.5 96.3 12 821 12 990 101.3 29.3
Cervical
cancer
56.4 52.2 92.5 24.3 22.0 90.5 749 649 86.6 1.5
Colon cancer 0.7 5.4 769.0 3.6 8.5 235.6 12 302 2618.0 0.7
Corpus uteri 46.2 31.7 68.6 23.2 21.4 92.1 1484 879 59.2 2.0
Head and
neck
78.6 81.1 103.1 35.0 28.0 80.1 4534 3769 83.1 8.5
Hodgkin
lymphoma
70.6 58.7 83.2 15.0 14.2 94.6 350 239 68.4 0.5
Kidney 24.1 10.4 43.3 3.5 6.6 188.6 112 111 99.1 0.3
Leukaemia 4.0 4.8 118.8 10.0 5.0 50.0 59 32 53.1 0.1
Lung cancer 65.9 60.8 92.3 17.0 12.5 73.8 8315 6158 74.0 13.9
Melanoma 15.7 13.9 88.3 24.4 19.2 78.8 722 609 84.2 1.4
Myeloma 33.1 25.3 76.6 5.0 3.0 60.9 149 106 71.4 0.2
Non-Hodgkin
lymphoma
54.3 26.7 49.2 14.1 12.6 89.3 1766 720 40.8 1.6
Oesophageal
cancer
53.7 29.6 55.0 24.9 15.4 61.7 2242 653 29.1 1.5
Ovarian
cancer
4.0 6.1 152.3 5.0 7.5 149.9 30 59 198.2 0.1
Pancreatic
cancer
49.8 14.8 29.7 19.5 12.7 65.4 1508 335 22.2 0.8
Prostate
cancer
61.4 54.0 88.0 21.4 27.3 127.8 8866 11 759 132.6 26.5
Rectal cancer 88.7 48.6 54.8 6.6 19.9 301.3 1753 1885 107.5 4.3
Stomach
cancer
13.4 4.6 34.6 25.0 7.6 30.5 575 52 9.1 0.1
Testicular
cancer
6.2 4.6 73.6 10.0 15.6 156.4 28 38 132.6 0.1
Other and
sarcoma
50.2 21.3 42.5 15.7 11.1 71.0 5093 1571 30.9 3.5
Total 50.4 40.6 80.4 15.2 17.4 114.3 48 545 44 320 91.3 100.0
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Discussion
The ESTRO QUARTS1 report highlighted variation in
radiotherapy demand between countries with different
cancer incidence, driven by the age structure of the popu-
lation and other risk factors [1]. The Malthus model uses
only English data both for cancer incidence and for stage at
presentation to allow local predictions, taking into account
the three-fold variation in cancer incidence between PCTs
[4]. It is intended as a decision aid for planning and
commissioning radiotherapy services in England at a local
or regional level.
Access to radiotherapy provides one indicator of radio-
therapydemand.Conversion intoworkload requiresdetails of
attendances per episode and linac productivity [5]. Access is
Table 3
Comparison of radiotherapy activity modelled by Malthus for 2011 and that recorded in the English radiotherapy dataset (RTDS) for
2011e2012. Data include both newpatients and those attending for re-treatment and are grouped into episodes, dose fractionation and total
attendances. Data for cancers of the breast (30%), prostate (27%), head and neck (9%) and lung (8%) are highlighted as together they account
for 75% of attendances
Cancer site Episodes Fractionation Attendances
Malthus
2011
episodes per
million
RTDS
2011e2012
episodes
per million
RTDS
episodes
as %
Malthus
Malthus
attends
per
patient
RTDS
attends
per
episode
RTDS
as %
Malthus
Malthus
2011
attends per
million
RTDS
2011e2012
attends per
million
RTDS
attends
as %
Malthus
RTDS
attendances
as % total
Bladder
cancer
51 54 106.2 12.0 12.1 100.9 609 653 107.2 2.0
Central
nervous
system
tumours
39 64 166.2 23.3 22.5 96.7 898 1442 160.6 4.5
Breast cancer 880 709 80.6 15.5 13.7 88.5 13 606 9704 71.3 30.3
Cervical
cancer
28 33 118.6 22.0 19.1 87.0 615 635 103.2 2.0
Colon cancer 35 23 67.3 8.1 7.0 87.0 282 165 58.5 0.5
Corpus uteri 49 35 71.5 21.4 15.3 71.6 1041 534 51.3 1.7
Head and
neck
151 123 81.6 28.0 23.6 84.4 4212 2903 68.9 9.1
Hodgkin
lymphoma
18 11 61.4 14.2 13.7 96.4 249 148 59.2 0.5
Kidney 18 30 165.8 6.5 4.7 72.1 119 143 119.6 0.4
Leukaemia 7 9 130.4 5.0 6.4 128.2 34 57 167.1 0.2
Lung cancer 511 338 66.2 12.7 8.0 63.1 6476 2702 41.7 8.4
Melanoma 43 25 58.6 18.6 8.2 44.2 797 206 25.9 0.6
Myeloma 37 40 106.9 2.4 3.9 161.9 88 153 173.1 0.5
Non-
Hodgkin
lymphoma
62 67 109.3 12.6 10.0 79.1 776 671 86.4 2.1
Oesophageal
cancer
45 61 133.8 15.1 11.4 75.9 682 693 101.6 2.2
Ovarian
cancer
8 9 121.9 7.4 7.9 106.3 56 72 129.6 0.2
Pancreatic
cancer
29 8 26.2 14.0 13.5 96.3 412 104 25.3 0.3
Prostate
cancer
517 395 76.3 27.4 22.2 80.8 14 187 8747 61.7 27.3
Rectal cancer 99 109 109.5 19.9 15.7 78.7 1977 1704 86.2 5.3
Stomach
cancer
7 10 159.2 6.1 7.2 118.7 40 75 189.0 0.2
Testicular
cancer
3 2 86.1 13.9 13.1 94.6 35 28 81.5 0.1
Other and
sarcoma
148 31 21.0 11.1 17.2 155.1 1636 532 32.5 1.7
Total 2782 2186 78.6 17.7 14.7 82.7 48 827 32 071 65.7 100.0
1 The ESTRO QUARTS project ‘Radiation Therapy for Cancer: QUAntiﬁca-
tion of Radiation Therapy Infrastructure and Stafﬁng Needs (QUARTS)’
was supported by the EUROPEAN COMMISSION, Directorate General
Research-Quality of Life and Management of Living Resources under con-
tract: QLG4-CT-2002-30583.
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Table 4
Comparison of radiotherapy activity modelled by Malthus for 2011 and that recorded in the English radiotherapy dataset (RTDS) for
2011e2012. The population of England was 52.785 million; episodes and attendances per incident cancer have been calculated using cancer
incidence data
Cancer site Cancer
incidence
2011
Episodes Attendances
Malthus
2011
episodes
per million
RTDS
2011e2012
episodes per
million
Malthus
2011
episodes
per cancer
RTDS
2011e2012
episodes
per cancer
Malthus
2011
attends per
million
RTDS
2011e2012
attends per
million
Malthus
2011
attends per
cancer
RTDS
2011e2012
attends per
cancer
Bladder cancer 8671 51 54 0.31 0.33 609 653 3.71 3.98
Brain,
meninges
and central
nervous
system
4364 39 64 0.47 0.77 898 1442 10.86 17.45
Breast cancer 48 220 880 709 0.96 0.78 13 606 9704 14.90 10.62
Cervical cancer 2504 28 33 0.59 0.70 615 635 12.96 13.38
Colon cancer 25 196 35 23 0.07 0.05 282 165 0.59 0.35
Corpus uteri 7134 49 35 0.36 0.26 1041 534 7.71 3.95
Head and neck 8691 151 123 0.91 0.75 4212 2903 25.59 17.63
Hodgkin
lymphoma
1592 18 11 0.58 0.36 249 148 8.27 4.90
Kidney 7318 18 30 0.13 0.22 119 143 0.86 1.03
Leukaemia 7161 7 9 0.05 0.07 34 57 0.25 0.42
Lung cancer 35 481 511 338 0.76 0.50 6476 2702 9.64 4.02
Melanoma 12 257 43 25 0.18 0.11 797 206 3.43 0.89
Myeloma 4294 37 40 0.45 0.49 88 153 1.09 1.88
Non-Hodgkin
lymphoma
10 846 62 67 0.30 0.33 776 671 3.78 3.27
Oesophageal
cancer
7266 45 61 0.33 0.44 682 693 4.96 5.03
Ovarian cancer 5582 8 9 0.07 0.09 56 72 0.53 0.68
Pancreatic
cancer
7546 29 8 0.21 0.05 412 104 2.88 0.73
Prostate cancer 39 685 517 395 0.69 0.53 14 187 8747 18.87 11.64
Rectal cancer 9611 99 109 0.54 0.60 1977 1704 10.86 9.36
Stomach cancer 6141 7 10 0.06 0.09 40 75 0.34 0.65
Testicular
cancer
1870 3 2 0.07 0.06 35 28 0.98 0.80
Other and
sarcoma
30 758 148 31 0.25 0.05 1636 532 2.81 0.91
Total 292 187 2782 2186 0.50 0.39 48 827 32 071 8.82 5.79
Table 5
Sensitivity analysis of the 10 nodes having the largest effect on simulated fraction burden in the Malthus model. Effect of a 10% change in
node probability on attendances and consequent percentage change in individual tree and overall
Node Extra attendances per million % Change in tree % Change overall
Breast cancer stage II (breast conservation) 290 2.1 0.58
Breast stage I (breast conservation) 478 3.5 0.96
Prostate high risk 452 3.0 0.90
Prostate, high risk, ﬁt for radical therapy 657 4.3 1.32
Prostate intermediate risk 141 0.9 0.28
Lung stage IIIb, good performance status 232 3.6 0.46
Lung stage IIIa, no surgery, deﬁnitive radiotherapy 82 1.3 0.16
Head and neck: oropharynx 47 1.1 0.09
Head and neck Oral cavity 31 0.7 0.06
Total 2410 4.83
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substantially lower in the Malthus model at 40.6% than the
ﬁgureof52%estimatedonthebasisofAustraliandata [5]. That
estimate underpinned the Scottish [11,12] and NRAG models
[3]. TheMalthusmodel uses data from English sources rather
than the global literature [5] and uses English stage distri-
bution data available for a range of tumours from cancer
registries and national audits [4,14]. The construction of the
decision trees also reﬂects changes in evidence-based prac-
tice and the indications for radiotherapy [16].
Compared with the NRAG model, the Malthus model
predicts lower access rates for lung and pancreatic cancer
with increased use of chemotherapy and changes in case
selection (Table 3). Reduced use of radiotherapy is also
modelled for cancers of the oesophagus, stomach, rectum
and most of the rarer cancers. For breast and head and neck
cancer, access rates were little changed. For endometrial
cancer, clinical trial results have reduced the role of radio-
therapy. For prostate cancer, the Malthus model predicts
that fewer patients should receive radiotherapy, but models
more attendances per episode so that attendances increase
by 32% compared with NRAG (Table 3).
In Table 6 the Malthus model is compared with previous
evidence-based estimates of radiotherapy demand [5,22].
For the four cancers that dominate radiotherapy workload,
the values of access rate show a range of up to 16% between
models: this is much larger than the quoted 95% conﬁdence
limits. The Australian estimates are higher for breast and
lung cancer and the methodological differences (which
include the source of epidemiological and stage data, the
allowance for patient choice and whether autopsy-only
cases are included) have been discussed elsewhere [5,22].
The reliability of models has been investigated in
a comparison of estimated need and radiotherapy uti-
lisation in British Columbia [22]. Radiotherapy activity was
compared with evidence-based modelling and with
criterion-based benchmarking in which treatment data
from regions with a radiotherapy centre with short waiting
lists and with salaried radiation oncologists were identiﬁed
as a reference [22,23]. This comparative study concluded
that, for Canadian patients, activity matched models based
on Canadian data and Canadian criterion-based bench-
marking estimates [22]. This emphasises the importance of
using locality-speciﬁc data and modelling [1] as we have
done for the English population. Utilisation varied by
geographical area and may have been affected by the long
travel times in some regions [22]. Travel time as a factor
affecting the uptake of radiotherapy has been studied in
England [24] and large differences in access rates were
found between different geographical regions and linked to
deprivation scores [25]. To date, this observation has not
been investigated using individual patient data.
Our sensitivity analysis shows that the most critical de-
terminants of radiotherapy fraction burden relate to the
stage distribution of the four most common cancer types,
and patient performance status, because they determine
ﬁtness for radical radiotherapy (Table 5). However, model-
ling of radiotherapy demand is critically inﬂuenced by some
factors on which information is limited. Fitness for radical
treatment will be inﬂuenced by stage at presentation, per-
formance status and comorbidity. Socioeconomic status and
travel time [24] may also have an effect on treatment
choices, as may age, which is often ignored as a factor,
despite being very inﬂuential in practice [9,26,27]; these
factors and comorbidity are not included in the Malthus
model and their inﬂuence in determining the gap between
modelled demand and observed activity is unclear.
The modelling of patient choice is difﬁcult, particularly
where surgery has an important competing role as in breast
and prostate cancer. Indeed in low-risk prostate cancer, a
recent consensus statement endorsed the role of active
surveillance [28] and it has been argued that this tumour
does not have the hallmarks of malignancy [29]. We have
used English data on surgery rates and have thus modelled
current practice, which we have tested for accuracy at a
consensus conference. This descriptive approach has been
applied because there is no deﬁnitive evidence to guide
clinician advice and patient choice.
In terms of attendances, complete revision of radio-
therapy demand modelling for England has resulted in
an estimate of overall demand and the gap in provision,
which is little changed from that of NRAG [3] (Table 1). In
the 5 years after the NRAG report, there has been some
improvement in radiotherapy provision in England. Table 1
shows that Malthus and NRAG gave similar predictions for
evidence-based radiotherapy demand and that the increase
in activity required to meet modelled demand remains at
Table 6
Comparison of Malthus with published models from Australia and Canada, showing overall radiotherapy access rates
Model RORU CCORE NRAG Malthus
Reference [25] [4] [3] This paper
Country Canada Australia England England
Breast cancer 66% (61.6e71.2%) 83% (82.5e84.6%) 72% 76%
Head and neck e 78% 79% 81%
Lung cancer 61% (57.1e64.9%) 75% (69.7e80.5%) 66% 61%
Prostate cancer 61% (55.6e66.8%) 60% (57e67%) 61% 54%
Total e 52% 50% 41%
RORU, Radiation Oncology Research Unit, Vancouver, Canada.
CCORE, Collaboration for Cancer Outcomes Research and Evaluation, Sydney, Australia.
NRAG, National Radiotherapy Advisory Group.
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about 50% [1,3,8]. The 14% increase in NHS activity between
2006 and 2011 slightly exceeds the 11% increase in
modelled demand over the same period. These calculations
ignore the contribution of the 4% of linear accelerators used
solely in the private sector.
Dose fractionation is an important determinant of
radiotherapy activity and is directly controlled by the pre-
scriber. Details of radiotherapy administered in England
over the three ﬁnancial years 2009e2012 are held in the
RTDS and summary analyses of dose fractionation have
been published [13]. These show that for prostate cancer,
the most frequent dose fractionation (67%) was 74 Gy in 37
fractions; 19 or 20 fraction regimens were also used as in
the CHHiP study [30]. For breast cancer, 40 Gy in 15 frac-
tions was prescribed for 87%, reﬂecting the inﬂuence of the
START trials [31,32]. For lung cancer, radical treatment was
dominated by 20 fraction regimens [33], which have a poor
evidence base [34]. Few patients receive treatment using 30
or more fractions, which would be standard in most of
Europe and North America for many indications and some
oncologists have reported that their practice is constrained
by lack of resources [33]. For head and neck cancer, radical
treatment with 30e35 fractions is internationally accepted
as standard [34]. Again, in England, 20 fraction regimens are
common, but have a poor evidence base [34].
In England there is extensive use of hypofractionated
regimens: these have been established by clinical trials in
breast cancer [31,32] and have been the subject of the
CHHiP trial in prostate cancer, which so far has only re-
ported on short-term toxicity [30]. For other indications, the
evidence base is weak [34].
Conclusions
Compared with the earlier NRAG model, Malthus models
some reduction in indications for radiotherapy, principally in
respect of lung cancer and rarer tumours. Hence, our estimate
of 40.6% for the proportion of patients who should receive
radiotherapy at some stage of their illness is lower than pre-
vious estimates of about 50%. Nevertheless, the overall esti-
mate of demand in terms of attendances is similar. Services
have increased their activity by 14% between 2006 and 2011,
but estimated demand has increased by 11%. Access remains
lowand English radiotherapy dose fractionation still does not
comply with international evidence-based practice.
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Appendix
Glossary [17]
Access e the percentage of incident cancer patients who
receive at least one course of radiotherapy in their lifetime
[5].
Activity e the number of radiation treatments delivered
in unit time, for example attendances per hour or atten-
dances per year.
Attendance e all the radiation treatments to one or
more targets that occur as consecutive or concurrent events
for a patient. For example, if a patient is receiving palliative
irradiation to their right arm (prescription 1) and to their
spine (prescription 2), each of ﬁve fractions over 1 week
given concurrently, then each daily treatment is one
attendance. This patient will have had one episode of
treatment, the fractions per episode will be ﬁve for
both prescriptions and the total number of attendances will
be ﬁve. However, if prescriptions 1 and 2 had been
given at separate times, then the total attendances
would have been 10. In addition, those rare patients
receiving two or more fractions a day with a planned in-
terval: hyperfractionation to the same target would be
recorded as having two attendances per day.
Capacity e available attendances per hour or per year.
This should exceed calculated demand by 10% to take ac-
count of random variation in referral patterns. The National
Radiotherapy Advisory Group report recommended an
additional 3% for educational and developmental re-
quirements [3].
Demand e the number of attendances per year required
to deliver the radiotherapy requirement of the catchment
population.
Episode e a course of radiation given during the entire
pre-planned period of care as covered in the original
treatment intent. Such episodes may be delivered in one
attendance or multiple attendances over many weeks (e.g.
multiple phases of treatment, treatment to multiple sites
given concurrently or consecutively or split courses of
radiotherapy).
Fractionation e the number of attendances per episode.
Prescription e a prescription speciﬁes a dose and frac-
tionation for a series of identical treatments to an ‘ICRU-
like’ reference point (this is akin to a medical prescription).
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Background
The radiotherapy delivery service in England is
emerging from a 25 year blight on strategic planning and
forecasting of radiotherapy demand. Two of the most
inﬂuential documents used as evidence for renovation and
expansion in radiotherapy services are the Royal College of
Radiologists (RCR) equipment, workload and stafﬁng
survey [1] and the National Radiotherapy Advisory Group
(NRAG) report [2]. Where the RCR survey quantiﬁed
signiﬁcant variation in allocation and consumption of
radiotherapy resources across England and Wales, the
NRAG 2007 report generated national targets for radio-
therapy service provision in terms of fraction burden
(40,000 fractions per million of population by 2010 and up
to 54,000 fractions per million by 2016) and the proportion
of cancer patients receiving radiotherapy at some point in
their cancer journey (access rate), which was estimated at
52% [3]. Although the NRAG model has been instrumental
in providing evidence of radiotherapy under provision, it
has proven difﬁcult for clinicians and local commissioning
groups to apply the model at a regional level, just as the
RCR report would have predicted. Independent of any
differences in clinical practice among radiation oncologists
across the country, local variation in radiotherapy demand
is driven by differences in population demographics and
age distribution, co-morbidity, disease incidence and
variation in the diagnostic and surgical pathways leading
to radiotherapy treatment. It clear that a national ‘best ﬁt’
model cannot provide a good ﬁt for commissioning and
service provision at the local level.
The Malthus Programme
The Malthus programme delivers a tool for simulation of
radiotherapy demand that provides a local model, as well as
providing a comprehensive review of appropriate radio-
therapy fractionation schedules. It is an academically led
collaboration between the Faculty of Engineering and Phys-
ical Sciences at the University of Surrey and the Department
of Oncology and Cambridge University Hospitals NHS Foun-
dation Trust, commissioned by the National Cancer Action
Team. The clinical armof the project has carried out a detailed
reviewof the literature in order to establish the evidencebase
for radiotherapy treatment regimens across 23 disease sites.
However, there are many areas where the evidence base for
radiotherapy treatment fractionation is lacking, and here we
obtain information by clinical consensus. The modelling arm
of the project has developed a fast and easy to use software
tool based on discrete event simulation techniques.
Encoding Clinical Practice into Decision
Trees
In our simulations, the rate of appropriate radiotherapy
treatment is established by creating decision trees for 23
disease sites. The approach is the same as that adopted by
other groups [3,4], whereby all common treatment scenarios
for a patient with a speciﬁc cancer type are described in the
form of a branching tree structure. As the patient moves
through the tree, a treatment history is constructed that
captures the total number of treatment fractions received by
the patient. Our approach has been to try and establish the
correct ﬁgure for the proportion of patients entering each
branch of each decision tree via evidence base or by
consensus, and to provide a reference for the source of the
estimate (See Figure 1). In the proximal branches of our
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decision trees, we encode information about stage distribu-
tion and surgical management of disease from the Eastern
Cancer Registration and Information Centre, national audits
and surveys of local practice. As we move towards the distal
branches, we encode details of radiotherapy treatment
regimens. The model simulates radiotherapy demand by
generating a ‘virtual’ cancer patient who is then passed
through the appropriate decision tree many times (typically
2000 passes in one simulation). The treatment details are
collected for these iterations and the process is repeated for
every virtual cancer patient in the population being
investigated.
Fractionation schedules with a deﬁned evidence base are
identiﬁed in our decision trees, with references to published
work. For non-evidence-based fractionations, we have
established a consensus that encapsulates the common
treatment practices across the country. In June 2011 a clinical
forum was held in London where oncologists worked to
establish consensus documents for the four major disease
types treated with radiotherapy (i.e. breast cancer, lung
cancer, head and neck cancer, and prostate cancer). Subse-
quently, decision trees have been disseminated and
reviewed by over 100 clinical oncologists nationally, in an
attempt to ensure that common treatment protocols have
been captured. The decision trees represent a summary of
evidence-based and consensus practice across England, but
there may be situations where the trees need to be altered in
order to match local practice, or to consider potential
scenarios (e.g. changes in clinical practice due to evidence
from a new study). The software provides the tools necessary
to permit these alterations to be made quickly and easily by
the user. The model can also take into account radiotherapy
retreatments, using the data obtained in an RCR audit [5].
Encoding Local Population Data in
Local-level Simulations
Through close collaboration with the National Cancer
Intelligence Network, Malthus uses an electronic data feed
providing population size and cancer registrations by age
band, gender and primary care trust (PCT). This allows
simulations to be carried out with a high degree of gran-
ularity. For example, running a simulation of breast cancer
radiotherapy demand for Haringey and Torbay PCTs with
the same clinical decision trees yields different results.
Haringey PCT has a predicted annual fraction burden of
2032 for breast cancer, similar to the 2286 fractions for
Torbay. However, the population of Haringey is signiﬁ-
cantly higher than Torbay (2,225,138 versus 133,749
persons) and, hence, the fraction burden per million of
population changes from 9026 in Haringey to 17,092 in
Torbay. Drilling down into the simulation results reveals
that the difference is driven by a marked increase in breast
cancer radiotherapy demand in the over 60s in Torbay
(Figure 2).
Forecasting Radiotherapy Demand
Population growth (especially in the over 70s) and the
rising incidence of cancer mean that the demand for
radiotherapy is set to rise in the future. The software also
provides tools to aid in the projection of radiotherapy
demand into the future. Malthus is able to forecast radio-
therapy up to 2031, using a population growth model
derived from the latest Ofﬁce of National Statistics report
[6], and a cancer incidence model from Cancer Research UK
and the Association of Cancer Registries [7]. Although
a range of incidence models is reported in the literature, we
believe these models to be the most appropriate when
applied to the English population.
Project Launch and Availability of the
Software
TheMalthus programmewas launched at the NRAG 2011
conference, and is available for download free of charge to
Fig 1. Excerpt from the breast cancer decision tree. Note that citations are given for evidence-based fractionation, and data sources are cited for
the proportions of patients entering each branch of the tree.
Fig 2. Radiotherapy demand simulation for Haringey and Torbay
primary care trusts using the breast cancer decision tree.
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healthcare users in England from the project website
(http://www.camradiotherapy.org.uk/malthus). Malthus
runs on any modern PC running Microsoft Windows XP,
Vista or Windows 7, with at least 2 Gb of RAM. Regular
updates to the programme and decision trees will be made
available to registered users, and a user group meeting is
scheduled for 9 March 2012.
Looking to the Future
Currently, Malthus offers an easy to use simulation tool
for radiotherapy demand simulation, which can be cus-
tomised to reﬂect local patient factors and clinical practice.
In the next year of the project, our group will focus on
curating high-quality information on tumour stage distri-
bution and non-radiotherapy-based treatment, and
including these data into revised decision trees. The model
will also be expanded to include treatment complexity
using the Basic Treatment Equivalent algorithm, and
include simulation of intensity-modulated and image-
guided radiotherapy demand. Finally, a research-focussed
version of the model is also under development, which
will offer detailed sensitivity and error analysis.
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